



USE OF BAYESIAN METHODS FOR THE 
DESIGN, ANALYSIS AND SYNTHESIS OF 
CLINICAL TRIALS 
By 
DANIELLE LISA BURKE 
A thesis submitted to 
The University of Birmingham 
for the Degree of 
DOCTOR OF PHILOSOPHY 
School of Health and Population Sciences 
















This unpublished thesis/dissertation is copyright of the author and/or third 
parties. The intellectual property rights of the author or third parties in respect 
of this work are as defined by The Copyright Designs and Patents Act 1988 or 
as modified by any successor legislation.   
 
Any use made of information contained in this thesis/dissertation must be in 
accordance with that legislation and must be properly acknowledged.  Further 
distribution or reproduction in any format is prohibited without the permission 







This thesis explores Bayesian methods for the statistical design, analysis and synthesis of 
clinical trials, and compares these with a frequentist approach in several settings to 
determine key differences, advantages and limitations. 
A review of randomised trials indicates that Bayesian methods are rarely applied, but useful 
for making probability statements and incorporating prior evidence, especially in trials with 
small sample sizes. These advantages are illustrated in a trial in congenital lower urinary 
tract obstruction, which has few events but elicited prior distributions about treatment effect. 
Bayesian methods are then developed for meta-analysis of phase II trials and multiple 
outcomes, with an emphasis on informing phase III trial decisions. A Bayesian random-
effects logistic regression is advocated for meta-analysis of a binary outcome to account for 
all parameter uncertainty, and to derive prediction intervals for the treatment effect in a new 
phase III trial. Bayesian multivariate meta-analysis methods are then encouraged to make 
joint inferences across multiple outcomes and incorporate prior distributions for missing 
correlations. However, a simulation study identifies that external evidence or clinical 
guidance is needed to ensure appropriate prior distributions for between-study variances and 
correlations to avoid misleading results. 
Researchers should thus consider Bayesian methods for clinical trials, but recognise 
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CHAPTER 1:  INTRODUCTION 
1.1 Overview of the thesis 
A fundamental component of medical research is the evaluation of new treatments and 
interventions using randomised clinical trials. Such trials enrol patients with a particular 
disease or condition, and typically randomise each patient to receive either a new treatment 
or an existing treatment (a control). Outcomes are then recorded for each individual over 
time, and the hope is that patients receiving the new treatment have improved outcomes 
compared to those in the control group. Medical statistics is a key part of randomised trials, 
and statisticians play a crucial role in their implementation: from the design and sample size, 
to the collection and analysis of data, and to the interpretation of results. Traditionally, the 
analysis of randomised trials has been undertaken in a so-called frequentist framework, 
which produces results (such as p-values and confidence intervals for the treatment effect) 
by viewing the trial data as from an experiment that can theoretically be repeated identically 
many times. However, an alternative approach is a Bayesian analysis framework, which 
takes a more subjective view by combining the trial data with any prior information, and does 
not require inferences to depend on long-run, repeated sampling theory. The Bayesian 
approach thereby allows direct probabilistic inferences about the treatment effect (such as 
the probability the treatment is effective), and - by combining prior evidence with the new 
data - many consider it to be more relevant to clinical decision making. 
The primary aim for this thesis is to apply and develop Bayesian methods for the design, 
analysis, and synthesis of randomised clinical trials, and to compare their potential benefit to 
standard frequentist methods. In particular, this thesis focuses on the application of Bayesian 
methods in trials with small numbers of events, or the synthesis of small numbers of trials. 
This includes trials in rare diseases, where it may be difficult to recruit large sample sizes, or 
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early phase trials, which typically have small numbers of patients. Furthermore, in terms of 
the development of Bayesian methods, this thesis proposes and evaluates novel Bayesian 
approaches for meta-analysis in the context of phase II trials and multiple outcomes, 
especially for obtaining results that inform subsequent phase III decisions. An underlying 
theme throughout all the projects is how the results of interest depend on the choice of prior 
distributions for unknown parameters, and an extensive simulation study is undertaken to 
evaluate this issue. 
The remainder of this chapter introduces in detail the key topics of this thesis, and 
summarises the core statistical methods and concepts that form the foundation of the work 
undertaken. The aims of the thesis are then listed and the remaining chapters are 
signposted. 
1.2 Clinical trials 
Medical research often occurs within a clinical trial (or an intervention study), which is a study 
in which participants receive specific interventions according to a research plan or protocol 
that was created by the study investigators.1 The intervention may be a medical product, 
such as a drug or device or changes to a participants’ behaviour, for example their diet. The 
new intervention must be compared to a control group, which might be the standard 
intervention that is already available, or a placebo that contains no active ingredients, or a 
historical control. At the first stage of development of a new intervention, it is often not known 
whether it will be beneficial, harmful, or no different to the interventions that are already 
available. Therefore, a clinical trial is able to determine the safety and efficacy of the 
intervention by measuring certain outcomes in the participants. 
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1.2.1 Phases of trials 
In pharmaceutical development of a new drug, it is common to divide the trials into four 
phases, although there is commonly an overlap of intentions in practice. The earliest stage of 
drug development in humans occurs in phase I (or phase 1) trials. These trials may be 
randomised or uncontrolled, and they aim to assess the safety and determine appropriate 
doses of a drug.2 They are commonly conducted with few subjects and may be done on 
healthy individuals, or patients with the target disease. For example, Desfrere et al.3 
conducted a dose-finding phase I trial to determine the dose regimen of intravenous 
ibuprofen for the treatment of patent ductus arteriosus in preterm infants. 
Phase II (or phase 2) trials continue to assess the dose level and safety of the new drug, but 
these trials are usually small with the intention of obtaining some early indication of a 
possible treatment benefit. Phase II trials may be uncontrolled and the results are compared 
to historical controls. For example, Foss et al. conducted a single-arm phase II trial to 
determine the safety and efficacy of a combination therapy in patients with newly diagnosed 
peripheral T-cell lymphoma.4 There are however advantages of conducting a randomised 
phase II trial, rather than a single arm trial, such as a reduction in selection bias.5,6 Also, a 
primary analysis may identify a statistically significant difference and, although this result 
should always be interpreted with caution because the sample size is small, it may help to 
identify the treatments that are more likely to show a benefit in a later trial. For example, Byrd 
et al. conducted a randomised phase II study of fludarabine with concurrent versus 
sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic 
lymphocytic leukemia.7 The findings of this study were in favour of the new therapy and the 
authors were able to recommend further studies. 
4 
 
The next stage of drug development is a phase III (or phase 3) trial, which is typically a large 
randomised trial with either a standard therapy arm or a placebo arm that aims to obtain an 
estimate of treatment effect. If there is evidence of a clinically and significantly important 
benefit of the new therapy at this stage (and evidence of its safety and cost-effectiveness 
have also been obtained) then this new drug may be licensed for use. An example of a large 
phase III trial is the ISIS-2 trial that assessed the long-term survival of patients with 
suspected acute myocardial infarction, and compared intravenous streptokinase, oral aspirin, 
both, or neither.8 This trial randomised 17,187 patients in 417 hospitals in 16 countries and 
concluded that there are survival benefits produced by intravenous therapy for at least 10 
years. The first three stages of drug development can take up to 10 years for a successful 
new therapy.9 
Phase IV (or phase 4) trials are usually post-marketing surveillance studies that continue to 
monitor the safety of the drug, which can be removed from the market if there are adverse 
events. For example, Aprotinin has been shown to have anti-inflammatory responses. 
However, Schmartz et al. assessed the effect of Aprotinin on the inflammatory reaction to 
cardiopulmonary bypass in a randomised phase IV trial.10 
1.2.2 The importance of randomisation 
This thesis focuses primarily on phase II and III randomised trials, where the aim is to 
quantify the treatment effect for either informing subsequent phase III research, or for 
determining whether the treatment should be recommended for clinical practice. 
Randomisation is fundamental for the quantification of treatment effects because it reduces 
selection bias by ensuring that there are no systematic differences between the treatment 
groups in factors, which are known or unknown that may affect the outcome.11 In other 
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words, randomisation theoretically removes the potential for comparisons of treatment 
groups to be affected by confounding factors. 
1.3 Bayesian statistical methods 
In all phases of clinical trials there is a need for robust statistical methods. For example, 
statistical methods are required to determine the appropriate dose-level of a drug, to 
estimate a sample size for a new study that is large enough to detect the clinically-important 
difference between therapies, or to estimate the treatment effects and account for all 
uncertainty. Another important aspect is the synthesis of clinical trial results when there are 
multiple trials in a similar disease area, or that compared a similar therapy, and meta-
analysis is required to produce evidence-based summary results. 
In this thesis, the focus of the statistical methods to analyse and synthesise clinical trials is 
largely within a Bayesian framework. Methods within the Bayesian framework have been 
extensively developed12 in several areas including dose-finding trials with methods such as 
the continual reassessment method,13,14 interim analysis of clinical trials,15,16 and meta-
analysis.17-20 Chapter 2 of this thesis will explore where Bayesian statistical methods are 
currently being used in practice and determine where there may be some benefit of the 
Bayesian approach in specific settings, which then stimulates work in Chapters 3 to 6. 
The following sections describe the essential elements of the Bayesian framework. These 
include a fundamental introduction to Bayesian inference, a discussion of the types of prior 
distribution, and estimation of parameters using Markov chain Monte Carlo methods. These 




1.3.1 Bayesian versus frequentist paradigm 
When given a set of data for analysis, a key difference between Bayesian and frequentist 
approaches to statistical inference is the view of probability. The Bayesian approach 
assumes that an unknown parameter (for example, a treatment effect) of interest, θ, is fixed 
but our beliefs about it are expressed as a subjective probability distribution, which allows 
subjective, direct probabilistic inferences to be made about the magnitude of θ from the data 
at hand and other external information. In contrast, the frequentist approach considers θ to 
be a fixed, unvarying quantity, and probabilistic inferences about θ arise by observing the 
observed frequency of events in the data at hand, and assuming that it was obtained from a 
process that could be infinitely and identically repeated.21 Another important difference is that 
the Bayesian approach acknowledges prior probability information about the unknown 
parameter of interest, which is incorporated as a prior distribution.22 This prior distribution can 
be derived in numerous different ways, such as from evidence in previous clinical trials or 
from clinical opinion. The prior distribution is a topic of much controversy and is therefore 
discussed in detail in section 1.3.3. 
1.3.2 Bayesian inference derived from Bayes theorem 
Bayesian inference is based on a paper that was published posthumously by Thomas 
Bayes,23 which introduced Bayes’ theorem, and this is expressed mathematically in equation 






In this equation, p(θ|y) is called the posterior probability distribution of θ having observed the 
data y; p(y|θ) is the likelihood function (which summarises the observed data, and is the 
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focus of the frequentist approach); and p(θ) is the prior probability distribution for θ. P(y) is 
known as the normalising factor and its value is not usually of interest since it does not 
contain θ. Therefore, equation (1.1) is often written as: 
 p(θ|y)∝p(y|θ)p(θ) (1.2) 
When making inferences from the posterior distribution, this usually involves estimating 
features such as the mean and variance. These can be expressed in terms of posterior 
























Unlike frequentist statistics, within the Bayesian framework it is possible to make direct 
probability statements about the posterior probability of θ, relative to some value of clinical 














Similar to confidence intervals in a frequentist framework, the Bayesian posterior distribution 
can be used to derive a 100(1-α)% (often α=0.05) credible interval (CrI), which gives an 
interval in which θ lies with probability (1-α). If the credible interval is a two-sided interval with 
equal probability in each tail, then the lower and upper bounds of the interval (θL,θU) can be 
estimated such that: 
 
p(θ<θL|y)=� p(y|θ)p(θ)p(y) dθθL-∞ = α2 
p(θ>θU|y)=� p(y|θ)p(θ)p(y) dθ∞θU = α2 
(1.7) 
Often, rather than reporting the equal-tail credible interval, instead the highest posterior 
density (HPD) interval is used. The HPD interval is the interval within which the values 
contained have the highest posterior densities.25 In this thesis, however, only equal-tailed 
credible intervals will be reported. 
1.3.3 The prior distribution 
In a Bayesian framework, in order to obtain posterior distributions of parameters of interest, 
prior distributions must be specified for all unknown parameters. One advantage of this 
framework is that it allows for all external prior information to be incorporated into the 
analysis alongside the data. In terms of specifying a prior distribution, for convenience in the 
calculations, it is often preferable to choose a prior distribution that is ‘conjugate’ to the 
likelihood function. This means that when the prior distribution is combined with the likelihood 
using Bayes theorem the resulting posterior distribution will be from the same family as the 
prior distribution.21 The most common conjugate models are shown below in Table 1.1. 
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Table 1.1: Bayesian conjugate models. 
Prior Likelihood Posterior 
Normal Normal Normal 
Beta Binomial Beta 
Dirichlet Multinomial Dirichlet 
Gamma Poisson Gamma 
 
An aspect of the Bayesian framework that causes concern for frequentist statisticians is that 
there is no ‘correct’ prior distribution for an unknown parameter. There may be a range of 
sources from which the prior distribution can be derived and varying levels of uncertainty that 
could be considered. The sources of elicitation may include subjective belief, or evidence 
from previous objective studies, such as previous trials in a similar disease area, earlier 
phase trials, observational studies, or meta-analyses.22 Prior distributions that are derived 
from subjective belief are frequently gained from experienced individuals, such as specialist 
clinicians in the area of research.26 These priors are often heavily criticised by frequentist 
statisticians because they may be biased by the individuals’ opinion, the choice of individual 
and the timing of the elicitation.22 If multiple subjective beliefs have been derived from several 
specialists then the prior distributions may be combined to form one subjective prior 
distribution. This may be fairly straightforward if the specialists have similar opinions, but 
perhaps it would not be sensible to combine the distributions if there are opposing views 
because the resulting prior distribution may not represent any one of the individual opinions. 
A particular range of prior distributions are sometimes called ‘default’ or ‘off-the-shelf’ priors, 
which include ‘sceptical’ and ‘enthusiastic’ priors. If, for example, the analysis is of a 
randomised clinical trial, a sceptical prior that does not allow for large treatment differences 
may be used to limit the potential optimism. The derivation of this prior distribution must be 
guided by clinical expertise or evidence from external trials so that a plausible sceptical prior 
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distribution is obtained.27 The external information may be a trial where a similar treatment 
(such as a drug from the same class) was evaluated, but perhaps in a different disease area. 
Often these prior distributions are centred on the value of no difference between treatments 
such that there is only a small probability (for example, 5%) that the treatment effect is as 
large as the alternative hypothesis θA. In practice, this means that there will need to be fairly 
strong evidence in the data to recommend action because the posterior distribution may be 
drawn closer to the value of no difference. If there is a sensitivity analysis for the choice of 
prior distribution, this sceptical prior may not always be necessary; it may depend on whether 
the researchers think that the results may be optimistic for reasons such as publication 
bias.27 Sceptical priors are considered in real examples in Chapters 3 and 4. 
An enthusiastic prior distribution can be used if it is considered likely that the trial may stop 
early if there are results in favour of the standard treatment or control. The prior distribution 
may be centred on a value that represents a difference in favour of the new treatment, for 
example the alternative hypothesis, and variance derived such that there is only a small 
chance (for example, 5%) that the true treatment effect is negative.28 In large sample 
settings, these prior distributions are not likely to be adopted because if the results are 
positive in favour of the new treatment and this is only due to the enthusiastic prior (i.e. the 
results without the prior distribution are inconclusive) then the findings are less likely to be 
accepted by the clinical community. However, in settings such as rare diseases or paediatric 
trials, the sample sizes are small and often end with non-conclusive results. However, if 
existing evidence can be incorporated this can effectively increase the sample size of the 
trial. The use and acceptance of prior evidence in these settings depends largely on the 
relevance of the prior information and how likely it may be to obtain further data rather than 




Due to the tension involved in using informative (and possibly subjective) prior distributions, 
there are ‘vague’ prior distributions, which are also referred to as ‘reference’ or ‘non-
informative’ priors. The intention of using vague priors is to represent almost no information 
about the unknown parameters of interest in order to be the least subjective. As a result, if 
the data is sufficiently large, the amount of information in the prior distribution is small relative 
to the likelihood, and thus the posterior distribution is similar to the likelihood function. This 
approach is useful if there is no prior information available to derive an informative prior 
distribution. Furthermore, the Bayesian framework can be adopted because it can handle far 
more complex scenarios than a frequentist framework, but perhaps the user does not want to 
include informative prior evidence. However, these prior distributions must be selected with 
caution because no prior distribution is truly non-informative. In particular, variance 
parameters in multilevel models tend to be highly sensitive to the choice of ‘vague’ prior 
distribution.29 Regardless of the prior distribution that is selected, it is important to do a 
sensitivity analysis for the prior distributions to examine how the conclusions depend on the 
choice of prior. This issue will be an underlying theme in all projects in this thesis, and 
motivates a simulation study in Chapter 6. 
1.3.4 Schools of Bayesians 
Due to the different prior distributions, there are various different Bayesian schools of 
thought. Three broad schools may be identified and these are the ‘reference’, the ‘proper’, 
and the ‘decision-theoretic’. Briefly, the ‘reference’ approach adopts reference priors (defined 
in section 1.3.3) and uses a Bayesian interpretation for the results using the posterior 
distribution. This essentially means that the results are very similar to those that arise from a 
frequentist analysis; however the interpretation is in Bayesian terms. The ‘proper’ Bayesian 
adopts informative prior distributions based on previous evidence and conclusions are based 
on the posterior distribution. Lastly, the ‘decision-theoretic’ school (sometimes referred to as 
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the ‘full’ Bayes approach) uses utility functions to make decisions based on maximising the 
expected utility. In this thesis, the reference and proper Bayes approaches are used, 
depending on the extent of prior information available; however sensitivity to the choice of 
prior distribution is explored in all analyses. The reporting of results is derived from the 
posterior distributions. 
1.3.5 Markov chain Monte Carlo estimation method 
It is often difficult to derive the posterior distribution of parameter θ, p(θ|y), if there are non-
conjugate distributions or nuisance parameters.21 The Markov chain Monte Carlo (MCMC) 
method is a technique that uses simulation to evaluate integrals as opposed to exact or 
approximate algebraic analysis.21 Suppose there is a p-dimensional parameter vector, θ, and 
the posterior distribution p(θ|y). The Gibbs Sampler is a MCMC method that samples each 
value of θt, for iteration t, from a distribution that depends only on the previously sampled 
values.30 The Markov chain must be started at arbitrary values θ0=(θ1
0,θ2
0,…,θp
0). The Gibbs 
sampler then generates random samples from the full conditional distributions such that, for 




t ) are obtained by the 
sampling method shown below:31 
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 θ1t  is generated from p(θ1|θ2t-1,θ3t-1,θ4t-1…,θpt-1,y) 
θ2



















When the Markov chain has converged, θt are samples from the marginal posterior 
distributions of the parameters of interest, for example p(θ1|y). In this thesis, the posterior 
distributions are obtained using MCMC via the Gibbs Sampler within WinBUGS 1.4.332. 
The initial period of sampling is known as the ‘burn-in’ and these values are discarded. After 
the burn-in period, and the stationary distribution has been reached, the iterations continue to 
obtain a precise sample that forms the posterior distribution. The influence of the initial 
values and the length of the burn-in period can be assessed by sensitivity analyses. The 
posterior distributions must be assessed to confirm convergence has been achieved using 
trace, history and autocorrelation plots. If there is evidence of autocorrelation this suggests 
that the sampling process is not moving around the stationary distribution adequately, and 
consecutively sampled values are correlated. In this case, a larger number of samples may 
be needed to achieve an accurate representation of the posterior distribution. Alternatively, 
the sample can be thinned to reduce the autocorrelation by only retaining every kth sampled 
value. 
1.3.6 Bayesian methods in clinical trials in practice 
In practice, the adoption of Bayesian methods as an alternative to existing frequentist 
methods is still considered relatively low.33 This is likely to be for a number of reasons. 
Firstly, many people feel uneasy about the potentially subjective approach to probability 
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within the Bayesian framework that allows for personal belief or judgement and there is still 
large controversy surrounding the derivation of prior distributions. If there is no prior evidence 
to formulate informative priors then there are issues concerned with how to derive truly non-
informative priors.29 Or, if the prior distribution is derived from subjective belief then the 
results may not be considered as objective evidence. Secondly, Bayesian analyses can be 
computationally complex, and although there has been major development of software to run 
Bayesian analyses, such as WinBUGS, it may be considered unreasonable to write new 
code for each trial when simpler, frequentist routines are already in place. Thirdly, some 
statisticians are unfamiliar with Bayesian techniques, whereas standard methods are 
common and may be easier to adopt rather than learning about new techniques. Finally, it is 
thought that regulatory authorities and journals can be hesitant in accepting new methods, 
and so researchers and pharmaceutical companies may not want to jeopardise their choices 
of a successful publication or drug to market.33 
1.3.7 Simple hypothetical example of a Bayesian analysis of a clinical 
trial 
This section is a simple example of a conjugate analysis of a randomised clinical trial that 
does not require MCMC, but highlights the difference between a frequentist and Bayesian 
analysis. Suppose the primary analysis of the trial is to estimate an unadjusted mean 
difference in blood pressure, μ, which compares a new treatment with control. Assume that 
the likelihood has a normal distribution given by (1.9), where ym is the estimate of mean 
difference from the data and m is the number of patients. It is often mathematically 
convenient to assume that the prior distribution, p(μ), follows a normal distribution as shown 
in (1.10), because then the posterior distribution will be conjugate to the prior distribution. 
Here, µ0 is the mean of the prior distribution and m0 is the ‘implicit’ sample size. The posterior 
distribution is obtained using Bayes theorem and is given by (1.11):21 
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Likelihood: p(ym|μ)~N �μ, σ2m� (1.9) 
Prior distribution: 










The posterior mean, (m0μ0+mym)/(m0+m), is a weighted average of the prior mean and the 
data, rather than just the data within a frequentist framework. Indeed, the frequentist solution 
is simply the maximum likelihood estimate, μ�=ym. 
Assume that from the data μ� is -0.223 (mean difference of -0.233 in favour of the new 
treatment) and σ�2/m is 0.02, where m is 400 and σ�2 is 8. Also, assume an informative prior 
distribution (possibly derived from clinical opinion) that is centred on no difference with 
variance 0.0675. Then, using equations (1.11), the posterior distribution is 
p(μ|ym)~N�-0.169, 0.015�. The distributions are shown below in Figure 1.1. The likelihood is 
drawn closer to the prior distribution with increased precision compared to the likelihood or 
prior distribution alone to produce an updated distribution (posterior). 
Of course, there may be a number of different prior distributions that could have been used 
and the analysis of a clinical trial is unlikely to be so straightforward, but this example shows 





Figure 1.1: Hypothetical example of a conjugate analysis. 
 
1.4 Systematic review and meta-analysis 
Often there are several trials that have attempted to answer a similar research question. For 
example, there may be multiple trials that have compared similar therapies in the same 
population and it is important to synthesise the results from these studies. A systematic 
review is a formal evidence synthesis approach, which collects, critically appraises and 
synthesises the relevant current empirical evidence from published and unpublished 
studies.34 Meta-analysis is the formal statistical method of a systematic review that combines 
quantitative data from several studies to produce pooled overall results that aid evidence-
based clinical decision making.35 For example, for studies that compare a type of new 
therapy to a standard therapy in the same disease area, the estimate of the odds ratio may 
be extracted from each study to produce a pooled estimate of the odds ratio. Several other 
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estimates can be synthesised, such as relative risk, risk difference, or survival outcomes. 
Whilst there has been an explosion of statistical developments in evidence synthesis, in 
particular since the launch of the Cochrane Collaboration in 1993, amongst these methods 
have also been extensive developments of Bayesian methods for meta-analysis. In 
particular, the use of Bayesian methods for multivariate meta-analysis with multiple 
outcomes17,18 and the derivation of prior distributions for the between-study heterogeneity to 
use in a future random-effects meta-analysis.36-38 The Bayesian methods tend to mirror those 
that have been developed within the frequentist framework; however, there may be some key 
advantages of the Bayesian framework. These include the ability to easily account for all 
parameter uncertainty in the model, the ability to include external evidence in the form of 
prior distributions that would otherwise be excluded, and the ability to extend the models to 
complex scenarios, such as combining comparative-arm and single-arm studies in a single 
meta-analysis.20 The next two sections describe different approaches to meta-analysis with a 
description of how to obtain the pooled estimate across studies within Bayesian and 
frequentist frameworks. 
1.4.1 Fixed-effect meta-analysis 
Chapters 4 to 6 of this thesis use Bayesian meta-analysis to pool treatment effect estimates 
from multiple randomised trials. There are various methods that can be applied and the 
simplest approach is a fixed-effect analysis model, which assumes that there is a single 
(fixed) treatment effect across all studies, θ.39 The summary (pooled) estimate, θ�, from a 
meta-analysis gives the best estimate of this single treatment effect, using the evidence from 
all available studies included in the meta-analysis. The fixed-effect model can be written as: 




This model assumes that the estimated treatment effect, Y� i, for study i, follows a normal 
distribution with variance, Si2, which is assumed known. There are various methods, both 
frequentist39,40 and Bayesian, that can be used to estimate θ, which are explored and 
compared in detail in Chapter 4. The most common frequentist method is the inverse-
variance method, which assigns weights to each trial, which are shown in equation (1.13).34 
Here, Si
2 is the variance of the treatment effect estimate from each study, i. The pooled 
treatment effect, θ, can be estimated using maximum likelihood estimation shown in equation 





















Within a Bayesian meta-analysis, a prior distribution must be specified for the unknown 
pooled treatment effect, θ. For example, if there is no external evidence, a ‘vague’ normal 
prior distribution could be selected, such as θ~N(0,10002). 
1.4.2 Random-effects meta-analysis 
In contrast to the fixed-effect approach, a random-effects approach assumes a distribution of 
true treatment effects across studies shown in model (1.16). Now, the estimate of treatment 
effect, Y� i from each study, i, can be estimating a different true treatment effect, θi, and 
therefore the summary (pooled) estimate, β�, from the meta-analysis gives an estimate of the 
average treatment effect, β, across studies.34 Individual studies may therefore have a true 
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treatment effect that varies considerably from this average value, and this between-study 
variance (heterogeneity) in the treatment effect is known as τ2. 
 Yi ~ N(θi, Si
2) 
θi ~ N(β, τ2) 
(1.16) 
Similar to the fixed-effect model, there are numerous methods to estimate the pooled 
treatment effect, β, and between-study variance, τ2, within Bayesian and frequentist 
frameworks. Within a frequentist framework the DerSimonian and Laird ‘method-of-moments’ 
is popular to estimate β and τ2, which is shown in equations (1.17) to (1.20).34,41 In these 
equations, k is the number of studies in the meta-analysis, the weights, wi, are obtained by a 


































Equation (1.18) shows the weight estimation in a random-effects meta-analysis, which 
includes the estimate of τ2. Equation (1.19) is the calculation for the pooled average 
treatment effect estimate (β�), and equation (1.20) is the variance of the pooled average 
treatment effect estimate. 
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Within the Bayesian framework prior distributions must be specified for β and τ2. For 
example, the vague N(0,10002) can be specified for β, however the prior distribution for τ2 is 
more difficult. A previous simulation study by Lambert et al.29 revealed how several ‘vague’ 
prior distributions for this parameter are actually fairly informative and the results can be 
highly sensitive to the choice of prior distribution. This is because often there are few studies 
within a meta-analysis and therefore it is difficult to estimate the extent of between-study 
heterogeneity. Thus, two previous papers modelled a large collection of meta-analysis 
characteristics on τ2 to obtain empirical prior distributions for the between-study 
heterogeneity in a new meta-analysis of continuous outcomes38 and binary outcomes.36 
These prior distributions have been derived for a general meta-analysis setting and various 
areas of healthcare, such as meta-analyses where the outcome is all-cause mortality. 
Consideration of prior distribution in meta-analysis is a key focus of Chapters 4 to 6; in 
particular, Chapter 6 examines the impact of prior distributions for between-study variance 
and correlation parameters when conducting a multivariate meta-analysis of randomised 
trials with multiple outcomes. 
1.4.3 Example of a simple Bayesian and frequentist meta-analysis 
This section is a brief example of a meta-analysis using a fixed-effect and random-effects 
approach, within both frequentist and Bayesian frameworks to highlight any simple 
differences between the approaches. The example is a hypothetical dataset from a paper by 
Riley et al.39. Consider that the estimates of treatment effect are computed and synthesised 
from 10 studies of the same antihypertensive drug, and the mean difference is the estimate 
of the change in systolic blood pressure between the treatment group and the control group. 
Negative estimates suggest that the reduction in blood pressure was greater for those in the 
treatment group compared to the control group. 
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Table 1.2: Example dataset of the estimated mean difference from ten studies. 
Study ID Mean difference (Y� i) S.D(Y� i) 
1 0.0 0.42 
2 0.1 0.22 
3 -0.4 0.03 
4 -0.8 0.20 
5 -0.63 0.30 
6 0.22 0.30 
7 -0.34 0.07 
8 -0.51 0.10 
9 0.03 0.12 
10 -0.81 0.30 
 
The frequentist estimate of the pooled treatment effect within a fixed-effect model is obtained 
using maximum likelihood estimation, as shown in section 1.4.1 and the pooled average 
treatment effect estimate is obtained using the DerSimonian and Laird method described in 
section 1.4.2. The pooled treatment effect estimates in the Bayesian framework are obtained 
using MCMC. A vague prior distribution is specified for the pooled treatment effect in the 
fixed-effect model, so θ~N(0,10002). For the random-effects model, the same vague prior 
distribution is specified for the pooled average treatment effect so β~N(0,10002), and a 
N(0,2) distribution, truncated at zero, is specified for the between-study standard deviation. 
This distribution for the between-study standard deviation is selected as a conservative 




Table 1.3: Pooled summary results of hypothetical meta-analysis. 






Fixed-effect -0.38 (-0.43 to -0.33) - 
Random-effects -0.33 (-0.48 to -0.18) 0.028 
Bayesian 
Fixed-effect -0.38 (-0.43 to -0.34) - 
Random-effects -0.33 (-0.57 to -0.08) 0.084 (0.010 to 0.39)* 
* 95% credible interval for τ̂2 
The pooled results are negative, indicating that hypertensive treatment is, on average, 
beneficial, although the reduction in blood pressure is clinically small. The 95% intervals are 
wider for the random-effects models since there is additional uncertainty by incorporating 
between-study heterogeneity. The frequentist and Bayesian estimates are similar, although 
the estimate of τ2 is larger for the Bayesian analysis and its uncertainty is also accounted for 
in the Bayesian analysis. Therefore, the 95% interval for the pooled average treatment effect 
estimate is wider within the Bayesian framework compared to the frequentist. The results 
from the Bayesian random-effects meta-analysis are shown in the forest plot in Figure 1.2 
below. The visual heterogeneity in results across studies, and the estimate and credible 
interval for τ2 indicate that the random-effects approach is preferable and the true treatment 
effect varies considerably across trials. Thus, in some settings the treatment effect may be 
somewhat different to the average meta-analysis result. This is important if wanting to predict 
the potential treatment effect in a new study or to a new population, and this issue is a key 




Figure 1.2: Example meta-analysis using a Bayesian random-effects meta-analysis. 
 
1.5 Aims and structure for the thesis 
1.5.1 Aims 
There are several key aims of this thesis. 
• To apply Bayesian methods to randomised trials with small numbers of events. 
• To develop novel Bayesian approaches for meta-analysis in the context of phase II 
trials and multiple outcomes, with an emphasis on informing phase III decisions. 
• To examine the impact of prior distributions in these contexts. 






























1.5.2 Structure for the thesis 
Bayesian methods have been extensively developed in many areas of health research, 
however the prevalence of their use in applied medical research is less clear. This thesis 
continues in Chapter 2 by evaluating where and how often Bayesian statistical analysis 
methods are being adopted in applied research. A literature review is undertaken of the 
application of Bayesian methods in published randomised controlled trials in leading medical 
journals in 2012. This identifies the prevalence of Bayesian methods, the type of statistical 
analyses conducted using a Bayesian approach, and whether these were justified over 
frequentist methods. This chapter also evaluates how sample size calculations are informed 
with existing evidence to determine whether the design of randomised trials are informally 
adopting a Bayesian approach by incorporating prior information. The findings of the review 
inform the rationale for the remainder of the thesis. 
Chapter 3 is an application of Bayesian analysis methods to a randomised controlled trial in a 
rare disease called the PLUTO trial (Percutaneous Shunting for Lower Urinary Tract 
Obstruction).42 This chapter investigates the use of Bayesian analysis methods in 
comparison to frequentist methods for a randomised trial with very small sample sizes due to 
failure to recruit its target sample size. Both Bayesian and frequentist survival analysis 
methods are explored with an emphasis on the use of various prior distributions for the 
estimate of treatment effect (both vague and evidence-based), and whether there are 
advantages and limitations of the Bayesian approach in this setting. 
Chapter 4 explores the use of Bayesian and frequentist methods for the univariate meta-
analysis of phase II randomised trials, which tend to be small trials by design. This chapter 
considers the use of meta-analysis methods in the context of phase II trials in order to inform 
the decision to progress to a phase III trial. An example of nine phase II trials in acute 
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myocardial infarction is used for illustration of fixed-effect and random-effects meta-analysis 
methods using frequentist and Bayesian frameworks. Several methodological issues are 
explored including how to assess heterogeneity, deriving prediction intervals, and the impact 
of prior distributions in the Bayesian approach. 
Chapter 5 then extends this work to explore the use of Bayesian methods for multivariate 
meta-analysis of phase II randomised trials with multiple correlated outcomes. The same 
illustrative dataset is used to explore the methodological issues in a bivariate setting, and the 
results are compared to the univariate results of Chapter 4. Several different meta-analysis 
models are applied, and various methods that deal with unknown within-study correlations 
are explored. 
Chapter 6 is a simulation study to assess the choice of prior distribution for the between-
study correlation in a Bayesian bivariate meta-analysis of two correlated outcomes. The work 
extends the bivariate meta-analysis of Chapter 5 by exploring the impact of various vague 
prior distributions for the between-study correlation when there are few studies to estimate 
this parameter. The simulation study also assesses the impact of the prior distributions for 
the between-study correlation on the pooled treatment effect estimates and the between-
study variance. Various possible settings are explored to generalise the results to difference 
scenarios including complete-case and missing data settings. 
Finally, Chapter 7 summarises the key findings from the thesis and discusses the remaining 






CHAPTER 2:  THE USE OF BAYESIAN METHODS IN 
PUBLISHED RANDOMISED CONTROLLED TRIALS: A 
REVIEW OF LEADING MEDICAL JOURNALS 
2.1 Introduction and aims 
An overarching aim of this thesis is to develop Bayesian methods for medical research. 
Bayesian methods for the design and analysis of clinical trials have been promoted for 
general use43 and specifically in relation to data monitoring44 and meta-analysis.45 However, 
promotion and methodological development does not necessarily mean Bayesian methods 
are used in applied research. Therefore, the first aim of this chapter is to review the 
application of Bayesian methods in the design and analysis of randomised clinical trials in the 
published literature, in the leading general medical journals, in 2012. This is to identify: (i) the 
prevalence of Bayesian methods in the published literature compared to frequentist methods, 
and (ii) the type of statistical analyses conducted using a Bayesian approach, and whether or 
not these were justified over frequentist methods. 
Another area of interest for this thesis is how randomised phase III trials are designed in 
terms of accounting for prior evidence of the treatment effect of interest. This evidence most 
likely comes from earlier exploratory phase II trials, or from existing randomised phase III 
trials that were conducted in a different setting, for example a trial in a different population.46 
If there is existing evidence, this could be considered in the design of the phase III trial. 
Later, Chapters 4 and 5 of this thesis will investigate how the results of existing randomised 
phase II trials can inform the design, and potential results, of a randomised phase III trial 
within a Bayesian framework. To facilitate this, the second objective of this review is to 
evaluate how sample size calculations for randomised phase III trials are informed with 
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existing evidence. This will identify: (i) whether the articles describe the sample size 
calculation; (ii) if the description contains justification for the choice of the estimates in the 
sample size calculation by referencing previous evidence or clinical judgement; and (iii) the 
types of research studies from which the supporting material was obtained, in particular 
whether phase II trials were referenced. 
The review will therefore provide a snapshot of the current Bayesian analysis methods of 
randomised controlled trials in the literature and identify appropriate areas for the 
consideration of Bayesian methods in later chapters of the thesis. 
2.2 Methods of the review 
In this section, the aims and methods of the review are described in detail. 
2.2.1 Aims 
This review has the following two key aims. 
Aim 1: Statistical analyses with a Bayesian approach 
• To review the application of Bayesian methods in the design and analysis of 
randomised clinical trials in the published literature, in the leading general medical 
journals, in 2012. This will identify: 
• The prevalence of Bayesian methods in the published literature compared to 
frequentist methods. 
• The statistical analyses that have been conducted using a Bayesian 
approach, and whether or not these analyses have been justified in regard to 
their use over frequentist methods. 
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Aim 2: Sample size in randomised phase III trials 
• To evaluate how sample size calculations for randomised phase III trials are informed 
with existing evidence. This will identify: 
• Whether the articles describe the sample size calculation. 
• If the description contains justification for the choice of the effect size and 
standard deviation estimates in the sample size calculation by referencing 
previous evidence or clinical judgement. 
• The types of research studies from which the supporting material was 
obtained, in particular whether phase II trials were referenced. 
2.2.2 Identifying a set of articles 
A wide search was undertaken to identify articles that reported any type of randomised trial, 
for example phase II, or phase III trials. The initial search of articles was conducted by 
sourcing articles using Web of Science47 that were published in 2012 from seven of the 
leading general medical journals. These journals were: 
• The Lancet 
• PLOS Medicine 
• British Medical Journal (BMJ) 
• New England Journal of Medicine (NEJM) 
• The Journal of American Medical Association (JAMA) 
• Nature 
• Annals of Internal Medicine 
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For example, the search strategy within Web of Science for articles published in the Lancet 
in 2012 was the following: 
TOPIC: (randomi* trial) AND PUBLICATION NAME: (Lancet) AND YEAR 
PUBLISHED: (2012). 
Once the initial search had been completed, the resulting articles were reduced by reading 
the titles and abstracts to remove articles that were not randomised trials, such as meta-
analyses and epidemiological studies. This produced a final set of articles to be evaluated in 
full for the review. 
2.2.3 Evaluation of articles 
Review of articles for Aim 1: Statistical analyses with a Bayesian approach 
It was considered that the use of the Bayesian approach is unlikely to be reported in the 
abstract unless it is the primary analysis of the trial, and therefore the full text of all articles in 
the final set were obtained so that all Bayesian analyses could be identified. Text searches 
were then performed electronically within the full articles obtained, and the text searched was 
any of the following words: 
“Bayes”, “posterior”, “credible”, “MCMC”, “Markov chain”, and “Gibbs”. 
The prevalence of Bayesian methods were summarised by reporting the number of articles 
that contain Bayesian methods out of the total set of articles in the review. The statistical 
analyses that were conducted using a Bayesian approach, and whether these methods were 
justified over frequentist methods, were identified by the following questions: 
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• What was the statistical analysis conducted using a Bayesian approach? 
• Did the authors describe the reason for using the Bayesian approach instead of 
frequentist methods? 
• Was the Bayesian approach used as the primary or secondary analysis of the trial? 
• Was there consideration of the impact of the prior distributions selected in the 
analysis? 
Additional information that was of general interest was also collected. This included an 
overview of the trial context, which detailed the interventions that were compared, the 
disease setting, and the outcome measures being compared. Details of the type of 
randomised trial were summarised, for example, whether the trial was a cluster trial or a 
parallel group trial. An overview of the results presented was given, for example, whether the 
authors presented the means, medians, standard deviations, credible intervals and posterior 
probability estimates. A summary was also given for the software that each article used for 
the Bayesian analyses. 
Review of articles for Aim 2: Sample size in randomised phase III trials 
The articles that were selected for this part of the review were a subset of the full set of 
research articles, with randomised phase III trials being the sole trials of interest for this 
section. It was assumed that all phase III trials would report the sample size calculation in the 
statistical analysis methods; therefore only a subset of trials was deemed sufficient to give an 
overview of the methodology that would be applied in published phase III trials in general. 
Therefore, just the randomised phase III trials from the Lancet were selected to answer the 
aims relating to this part of the review. 
Information was extracted to answer the following questions: 
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• Did the articles detail the sample size calculation? If so: 
• Did the authors justify their choice of the estimates used in the calculation, for 
example by referring to existing data or clinical judgement? 
• What types of research articles or evidence were the estimates in the sample 
size calculation obtained from? 
For the latter question, the types of research articles or evidence referenced were 
summarised into: phase II trials (which may be randomised or non-randomised), randomised 
phase III trials (which may be in various different settings), systematic reviews and meta-
analyses, observational studies (including cohort and case-control studies), clinical 
judgement or other source. 
Also, for all articles detailing a sample size calculation, the elements of the calculation were 
extracted including: the estimate of the primary outcome measure in the control group (i.e. 
the placebo or standard therapy group); the expected value of the primary outcome measure 
in the experimental treatment group; the hypothetical value of treatment effect (for example, 
a relative risk or a hazard ratio estimate); the margins for non-inferiority or equivalence; and 
the intra-class correlation in cluster trials. 
2.3 Results 
In this section the review findings for Aims 1 and 2 are described in detail. A second reviewer 
independently checked a random sample of 10% of the articles to validate the data extraction 
results, and there were no discrepancies. 
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2.3.1 Aim 1: Statistical analyses with a Bayesian approach 
After duplicate records were removed, the literature search in Web of Science identified 696 
potential articles from 1st January 2012 to 31st December 2012. The abstracts were read and 
382 articles were excluded because they were not randomised trials (e.g. meta-analyses, 
letters to editors, observational studies); see Figure 2.1. A final total of 314 articles were 
included in the review (see Appendix A). This included 23 articles in Annals of Internal 
Medicine, 14 articles in PLOS Medicine, one article in Nature, 74 articles in NEJM, 47 articles 
in the BMJ, 69 articles in JAMA, and 86 articles in the Lancet. 
After text search of the full 314 articles, and in-depth reading of these articles, only three 
(1%) were identified that applied a Bayesian approach for one or more of their statistical 
analyses. Of these three, two were in JAMA48,49, and one  was in Annals of Internal 






Web of Science search for randomised trials published in seven leading 
general medical journals in 2012 (n=696) 
Total number of exclusions (n=382) 
Journal articles included in review of Bayesian methods in randomised 
trials for Aim 1 (n=314) 
• 23 articles in Annals of Internal Medicine 
• 14 articles in PLOS Medicine 
• 1 article in Nature 
• 74 articles in NEJM 
• 47 articles in BMJ 
• 69 articles in JAMA 
• 86 articles in the Lancet 
Randomised Phase III trials in the Lancet included in review of sample size 
calculations for Aim 2 (n=74) 
Total number of exclusions (n=240). 
Reasons for exclusion: 
• Not in the Lancet (n=228) 
• Randomised Phase II trial 
(n=10) 
• Randomised Phase I trial 
(n=1) 
• Proof-of-concept trial (n=1) 




Article 1 – Lucas et al.48 (JAMA) 
The article by Lucas et al. in JAMA used a Bayesian analysis and was a cluster randomised 
crossover non-inferiority trial.48 The trial compared the effect of 2- versus 4-week attending-
physician rotations on several outcomes, which include the primary outcome of unplanned 
patient revisit to the same hospital within 30 days, which is a binary response variable. 
Secondary outcomes were length of hospital stay, trainee evaluations of attending-physician 
performance, and attending-physician burnout. 
The primary analysis involved the derivation of a mixed-effects regression model with 
crossed random-effects51 to estimate odds ratios for unplanned patient revisits. The authors 
do not clarify which regression model they used, although the primary outcome is binary and 
the effect measure is an odds ratio, therefore it is likely to be a logistic regression model. 
This analysis adopted a Bayes approach with non-informative priors for model estimation. 
The authors justified the use of the Bayesian estimation by referring to it as equivalent to 
maximum likelihood methods through the use of non-informative prior distributions. Markov 
chain Monte Carlo (MCMC) procedures of estimation were adopted, which the authors 
suggested are superior to maximum likelihood because they are able to handle both crossed 
random-effects and discrete outcomes. 
The model was estimated using MLwiN software, version 2.25, which is run from within 
Stata, version 12, using a command called runmlwin.52 The authors do not state the specific 
choice of prior distributions; however it is likely they were not chosen by the user as MLwiN 
uses in-built ‘non-informative’ prior distributions. Therefore there was no further consideration 
of other prior distributions. 
Although the estimation method is Bayesian, the authors presented the results by 95% 
confidence intervals and p-values. It is unclear why the results were not presented as 
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posterior distributions or credible intervals, and the article did not state how the p-values 
were obtained. However, the authors argued that the use of non-informative prior 
distributions means that the method is “numerically equivalent to…maximum likelihood53” and 
so the authors appear to have presented the Bayesian results as if they are frequentist. 
Article 2 – Newman et al.49 (JAMA) 
The other article in JAMA using a Bayesian analysis reported the results of a randomised, 
double-blind, placebo-controlled, parallel-group trial in patients who have had coronary artery 
bypass graft surgery. The trial investigated the efficacy and safety of acadesine treatment 
that was administered in the peri-operative period and the outcomes were all-cause mortality, 
non-fatal stroke, and severe left ventricular dysfunction through 28 days.49 
The authors used a Bayesian approach to assess futility in two interim analyses. Although 
justification for this Bayesian analysis was not given, it is likely to be for the ease of obtaining 
direct probability estimates. The authors stipulated that the estimated probabilities of 
rejecting the null hypothesis at the end of the study, at 30% and 40% follow-up, must be at 
least 20% and 65%, respectively, to continue with the trial. The method for the interim 
analysis was not detailed in the article, and further details were not given in the 
supplementary material. Also, the authors did not reference any relevant Bayesian 
methodological articles, which may have informed this analysis. Therefore, it is not possible 
to know what analysis was conducted and whether the authors considered sensitivity to the 
prior distribution choices. 
The results revealed that the trial stopped recruiting at the 30% futility analysis “based on the 
recommendation of the DSMB”,49 however the reason for this decision was not documented. 
Thus, it is not possible to know whether this was due to the failure of the criteria for 
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continuation that would have been based on a posterior probability estimate, or another 
reason such as safety. 
Although the interim assessment was Bayesian, the statistical analysis at the end of the trial 
was frequentist. The primary analysis with complete follow-up was a classical Cochran-
Mantel-Haenszel hypothesis test that adjusts for a stratification factor (sex). All statistical 
analyses were performed in SAS version 9. 
Article 3 – Hashkes et al.50 (Annals of Internal Medicine) 
The third article was in Annals of Internal Medicine and was a crossover trial that 
investigated the use of Rilonacept for patients with Familial Mediterranean Fever that are 
resistant to or intolerant of colchicine.50 This trial was a randomised, double-blind, single-
participant alternating treatment study. 
The primary analysis was conducted with a Bayesian approach that compared Rilonacept to 
placebo in terms of the primary outcome of the number of attacks in each treatment group. 
The authors summarised this comparison with a risk ratio and modelled the number of 
attacks in each treatment course given the duration in a treatment group with a Poisson 
distribution. The authors argued for their use of a Bayesian approach by saying that it is, 
“recommended for studies with this design and sample size21”.50 This is because Familial 
Mediterranean Fever is a rare disease resulting in a small trial sample size (n=14). The 
authors showed consideration of the choice of prior distribution for the risk ratio parameter in 
the model by conducting a sensitivity analysis that applied three ‘off-the-shelf’ prior 
distributions for this parameter; a non-informative, an enthusiastic, and a sceptical prior 
distribution.21 The results for the primary analysis were reported for all three prior 
distributions. The impact of the choice of prior distribution was not discussed; however the 
results are consistent for the three prior distributions. 
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A secondary analysis of the odds ratio of “escape” from treatment was also conducted with a 
Bayesian approach. The posterior estimate and 95% credible interval were reported in the 
results. 
The mean, SD and 95% credible interval for the risk ratio were reported, with a risk ratio less 
than one indicating a significant result in favour of Rilonacept. No posterior probability 
estimates were given in the results for the Bayesian analyses. The Bayesian analyses were 
conducted with MCMC methods in WinBUGS Version 1.4, and the WinBUGS code for the 
primary and the secondary analyses were given in an appendix with some details and the 
models. 
Although the authors considered the limitations of statistical analyses with small sample 




Table 2.1: Summary table for articles with Bayesian analysis (Aim 1). 
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deviations and 95% 
credible intervals. 
 
2.3.2 Aim 2: Sample size calculation in phase III randomised trials 
The papers evaluated for their sample size calculation were the 86 articles in the Lancet 
(Figure 2.1). However, twelve of these54-65 were not included because ten were randomised 
phase II trials,54-62,64 one was a randomised phase I trial,65 and one was a proof-of-concept 
trial.63 Thus, 74 relevant articles remained and the evaluation of sample size is summarised 
in Table 2.2 and below. 
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Table 2.2: Summary table for journal articles included in Aim 2 (sample size evaluation 
in randomised phase III trials in the Lancet). 
Journal article Is the sample 
size calculation 
detailed in the 
paper? 
Are the choices of 




What type of research article or 
evidence supports the sample size 
calculation? 
Budde66 Yes No - 
Bolla67 Yes No - 
Laharie68 Yes No - 
Pickard69 Yes Yes Clinical judgement 
Rini70 Yes Yes RCT, non-randomised phase II trial 
Cohen71 Yes Yes RCT, randomised phase II trial 
Coles72 Yes Yes RCT, randomised phase II trial 
Simmons73 No, in trial protocol Yes RCT, observational study 
Lopes74 No, in design and 
rationale paper 
and an original 
trial analysis 
Yes Systematic review/meta-analysis 
Ryan75 Yes Yes Observational study 
Sabate76 Yes Yes Systematic review/meta-analysis 
Camenzind77 No, in design and 
rationale paper 
Yes RCT, systematic review/meta-
analysis, observational study 
Wandt78 Yes Yes Clinical judgement 
Nogueira79 Yes Yes Clinical judgement, non-randomised 
phase II trial 
Scirica80 No, in original trial 
analysis 
No - 
Saver81 Yes Yes Clinical judgement 
Rickard82 Yes Yes RCT 
Crawley83 Yes No - 
Fairall84 Yes Yes RCT 
Zinkstok85 Yes Yes Systematic review/meta-analysis, 
clinical judgement 
Wong86 Yes No - 
Ridker87 No, in original trial Yes RCT 
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Journal article Is the sample 
size calculation 
detailed in the 
paper? 
Are the choices of 




What type of research article or 
evidence supports the sample size 
calculation? 
analysis 
Gallwitz88 Yes No - 
Sandberg89 Yes Yes Clinical judgement 
Davalos90 Yes Yes Systematic review/meta-analysis 
Hauschild91 Yes Yes Clinical judgement 
Kirchhof92 No, in design and 
rationale paper 
No - 
Mees93 Yes Yes Randomised phase II trial 
DeJesus94 Yes Yes RCT 
Sax95 Yes Yes RCT 
Jamieson96 No, in trial protocol Yes Systematic review/meta-analysis 
Sandercock97 Yes No - 
Aschner98 Yes No - 
Gallwitz99 Yes No - 
Bhatnagar100 Yes Yes Survey or audit 
Cima101 Yes Yes Quality of life questionnaire 
Van der Graaf102 Yes Yes Systematic review/meta-analysis, 
non-randomised phase II trial 
Biere103 Yes Yes RCT, systematic review/meta-
analysis, observational study 
Engert104 Yes Yes RCT 
Goya105 Yes No - 
Meirik106 Yes No - 
Van Vollenhoven107 Yes No - 
Guelmezoglu108 Yes Yes RCT, systematic review/meta-
analysis 
Kobayashi109 Yes No - 
Heller110 Yes Yes Regulatory guidelines 
Garber111 Yes Yes Regulatory guidelines 
Castaigne112 Yes No - 
Nijhof113 Yes No - 
Manaseki- Yes Yes Observational study 
Table 2.2: continued. 
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Journal article Is the sample 
size calculation 
detailed in the 
paper? 
Are the choices of 




What type of research article or 
evidence supports the sample size 
calculation? 
Holland114 
Corbacioglu115 Yes Yes Observational study 
Avery116 No, in trial protocol Yes Systematic review/meta-analysis 
Baird117 Yes Yes Survey or audit 
Fleshner118 Yes Yes Observational study 
Garcia119 Yes No - 
El Arifeen120 Yes Yes RCT 
Soofi121 Yes Yes Survey or audit 
Thiele122 No, in design and 
rationale paper 
Yes RCT, pilot trial 
Griffin123 Yes Yes RCT 
Soofi124 Yes No - 
Santolaya125 Yes Yes Phase I study 
Baselga126 Yes No - 
Johnston127 Yes Yes RCT 
Hanney128 Yes No - 
Abraham129 Yes No - 
Glazener130 Yes Yes Systematic review/meta-analysis, 
clinical judgement 
Bang131 Yes No - 
Mitja132 Yes Yes Observational study 
Coovadia133 Yes Yes RCT 
Smith134 Yes Yes RCT, survey or audit 
Mehilli135 Yes Yes Observational study 
Buller136 Yes Yes RCT, regulatory guidelines 
Gebre137 Yes No - 
Enden138 No, a design and 
rationale paper 
Yes Systematic review/meta-analysis 
Smith139 Yes No - 
 
Table 2.2: continued. 
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Did the articles report the sample size calculation? 
Of the 74 articles, all mentioned a sample size calculation (Table 2.2). However, ten of these 
articles (14%) did not discuss the calculation in detail, but instead referenced one of the 
following: a published trial protocol (three articles73,96,116), a published design and rationale 
paper (five articles74,77,92,118,138), or a published original trial analysis (three articles74,80,87 - this 
includes an article that also referenced a rationale paper74). Therefore, the sample size 
calculation for these 10 articles was reviewed from the additional referenced source rather 
than from the article itself. 
Is justification reported for the estimates in the sample size calculation? 
In 25 articles (34% of the total 74 articles, see Table 2.2), the sample size calculation was 
detailed but the authors did not refer to any previous evidence or clinical judgement that 
specifically informed the elements of the sample size calculation.66-68,83,86,88,92,97-99,105-
107,109,112,113,119,124,126,128,129,131,137,139 For example, in the article by Laharie et al., they say: “we 
estimated that randomisation of 100 patients would provide an 80% power to detect a 30% 
difference in failure rate between the ciclosporin and infliximab groups in a two-sided test 
with type I error of 5%. We worked with the initial assumption that the rate of failure would be 
60% in the infliximab group and 30% in the ciclosporin group, corresponding to an OR of 3.5, 
and assumed a loss of 4% due to misdiagnosis.”68 Thus, the authors made assumptions 
about failure rates but do not state prior sources to justify them. 
The remaining 49 articles (66% of the total 74 articles) reported the details of the sample size 
calculation, and justified the choice of some or all of the estimates in the calculation. These 
are now summarised further, but note that the numbers of articles mentioned in the following 
sections do not sum to 49 articles as many of the papers reference more than one source of 
supporting evidence, and so each article may contribute to two or more groups below. 
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What types of research articles are referenced as supporting material? 
Previous phase II trials 
In six out of the 49 articles70-72,79,93,102 (8% of 74 articles, see Table 2.2), earlier phase II trials 
are referenced, in which three were randomised controlled trials70-72 and the remaining three 
phase II trials were non-randomised single arm trials.79,93,102 For example, in the article by 
Cohen et al.,71 the authors reference a randomised phase II trial for the estimate of primary 
outcome in the control group: “On the basis of…the phase 2 study, we expected at least 20% 
of patients in the interferon beta 1a group to meet the disability endpoint by 24 months.” 
Systematic review and meta-analysis 
Twelve articles74,76,77,85,90,96,102,103,108,116,130,138 (16% of 74 articles, see Table 2.2) reference a 
systematic review or meta-analysis in the sample size calculation. For example, in the article 
by Sabate et al.,76 the authors state: “To estimate the rate of events in the BMS group, we 
used…meta-analysis of randomised controlled trials that included patients with STEMI.” 
Randomised controlled trials 
Twenty one papers70-73,77,82,84,85,87,94,95,103,104,108,122,123,127,133,136,140,141 (28% of 74 papers, see 
Table 2.2) reference previous randomised controlled trials in similar settings to the current 
trial, which may be phase II (included in Previous phase II trials above) or phase III trials. 
This includes a setting such as a randomised controlled trial in which one of the drugs of 
interest in the article has previously been compared to placebo; for example the article by 
Rini et al.70 who refer to two previous randomised phase III trials and say, “This study was 
designed to test the hypothesis that treatment would result in an improvement in median PFS 
from 5 months with sorafenib, based on previous clinical data, to 7 months with axitinib.” 
Randomised phase III trials have also been referenced where the same drugs are compared 
in different patient populations; for example, the article by El Arifeen et al.141 describes: “With 
data from the previous study, our estimate of overall neonatal mortality rate in the study 
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population after implementation of the basic neonatal care package was 36 per 1000 
livebirths.” 
Observational studies 
Nine articles73,75,77,103,114,115,118,132,135 (12% of 74 articles, see Table 2.2) reference 
observational studies that contain evidence for the estimates of the sample size calculation. 
These references include different types of observational studies, for example cohort studies 
and case-control studies. In an article by Mitjà et al.132 the authors state that they expect an 
efficacy of 95% on standard therapy based on evidence from two observational studies. 
Clinically relevant differences 
In eight of the articles69,78,79,81,85,89,91,130 (11% of 74 articles, see Table 2.2), some of the 
estimates in the sample size calculation are justified by deeming them to be clinically 
relevant. For example, in the article by Glazener et al.130 the authors justify the assumed true 
difference in primary outcome rates: “We set a difference of 15% in incontinence rates as our 
threshold for clinical importance - derived from discussion by clinicians and the project 
management group”. 
Other sources 
Other sources of evidence are referenced as supporting evidence for elements of the sample 
size in 10 articles85,100,101,110,111,117,121,122,125,136,140 (14% of 74 articles, see Table 2.2). These 
include information from a survey or an audit that has been conducted before the start of the 
trial in four articles.100,117,121,140 For example, the article by Bhatnagar et al.,100 states: “On the 
basis of an audit of the participating hospitals, we estimated that the risk of treatment failure 
in the placebo group would be 25%.” Two articles122,125 reference the results of an earlier 
phase I study or a pilot trial; for example, the authors in the article by Elena et al.125 report 
that: “A planned sample size of 1625 was calculated, which was guided by previous results 
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from a phase 1 study.” The results of a quality of life study questionnaire were referenced in 
one article:101 “We identified only one study about quality of life of tinnitus patients attending 
a specialised tinnitus centre. We used the reported mean change over time of 0.065…to 
calculate our sample size.” Regulatory guidelines were referenced in three articles,110,111,136 
for example the article by Heller et al.110 states that: “Non-inferiority was confirmed if the 
upper limit of the 95% CI of the treatment difference was less than or equal to 0.4% points, 
as recommended by regulatory guidelines.” 
2.4 Discussion 
This review had two aims: first to identify the prevalence and use of Bayesian methods in 
trials within leading medical journals, and second to consider what prior evidence is cited 
when undertaking sample size calculations in phase III trials. The key findings and limitations 
are displayed in Figure 2.2 now discussed. 
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Figure 2.2: Key findings from the review of articles in medical journals. 
Aim 1: Statistical analyses with a Bayesian approach 
• In general medical journals in 2012, very few published randomised trial articles (1%: 3/314) 
applied a Bayesian approach to their analysis. 
• Bayesian methods may be important for trials with small sample sizes (e.g. in rare diseases), 
as this was the justification in one of the trials that applied a Bayesian approach. 
• Bayesian methods are potentially advantageous in interim monitoring of phase III trials, as this 
was highlighted in one of the trials that applied a Bayesian approach. 
• A Bayesian approach with ‘non-informative’ priors is potentially advantageous compared to 
the frequentist approach, especially when the Bayesian approach can more easily handle a 
complex analysis, as was highlighted in one of the trials that applied a Bayesian approach. 
• A Bayesian approach is important to make direct probability statements, as apparent in some 
of the articles using a Bayesian approach. 
Aim 2: Sample size calculation 
• All published randomised trials in the Lancet in 2012 mentioned the sample size calculation, 
either in the published paper or in a referenced source. 
• In a third of the randomised trials in the Lancet in 2012, the paper made no reference to 
previous evidence or clinical judgement that supported the calculation of the sample size 
estimate. 
• In 21 of the articles (28%) in the Lancet in 2012, values in the sample size calculations were 
supported by previous randomised controlled trials, which include phase II and phase III trials. 
• In six articles (8%) in the Lancet, the sample size calculations were supported by evidence 
from previous phase II trials. Of these, three were randomised phase II trials. 
• Other sources of evidence for the sample size estimates include systematic reviews or meta-
analyses (16%), observational studies (12%), clinically relevant values (11%), and other 




2.4.1 Overview of key findings 
Analysis methods with a Bayesian approach 
The review of 314 articles revealed that there are very few published randomised trials that 
adopted a Bayesian analysis approach within leading general medical journals in 2012 (1%). 
Thus, even though Bayesian methodology has been well-developed in the literature, these 
methods are not being commonly adopted for the analysis of randomised trials in these 
journals. This result has also been observed in previous reviews. Chevret conducted a 
review of Bayesian clinical trials between 1982 and 2010 and found only 44 articles that were 
clinical trial reports with a Bayesian analysis out of a total of 331 articles with Bayesian 
methodology.142 The remaining 287 articles were either reviews (67 articles) or biostatistical 
papers (220 articles). Similarly, a review published by Lee and Chu in 2012 found there were 
only 121 papers reporting the Bayesian design and analysis of clinical trials between 1947 
and 2011, and of these 60% (73 articles) were randomised trials.143 Another review in 2009 
looked at published protocols for trials between 2000 and 2005 at the MD Anderson Cancer 
Center (MDACC) in the United States, which is well-known for its adaptive trial designs and 
analyses.144 Of 964 published protocols (not all randomised trials), 195 articles (20%) used a 
Bayesian design or analysis or both, and of these 169 trials were trials run within the MDACC 
only, and 52 trials were Bayesian randomised trials. The most frequent setting that used a 
Bayesian approach was phase II trials (131 articles). 
Thus, in the literature of randomised trial reports, frequentist methods are clearly the 
standard approach and this is likely to be for a number of reasons that have already been 
discussed in Chapter 1.33 Many people may feel uneasy regarding the potential for the 
Bayesian framework to include a subjective approach to probability that is based on personal 
belief or judgement, especially when there is no prior evidence to formulate informative 
priors. Bayesian analyses can be computationally complex, and although there has been 
50 
 
recent development of software to run Bayesian analyses, such as WinBUGS, it may be 
considered unreasonable to write new code for each trial, when simpler existing frequentist 
methods already exist. Some statisticians are unfamiliar with Bayesian techniques, whereas 
standard methods are common and easier to adopt rather than learning about new 
techniques. Finally, it is thought that regulatory authorities and journals can be hesitant in 
accepting new methods, and so researchers and pharmaceutical companies may not want to 
jeopardise their chances of a successful publication or drug to market. 
However, by conducting the review in this chapter, some important insight has been obtained 
from those three articles that did apply Bayesian analysis methods. Bayesian methods have 
been promoted for trials with small sample sizes21,145-148 and the identified article in Annals of 
Internal Medicine used the Bayesian approach specifically for this circumstance as the data 
was from a rare disease.50 Therefore, the use of Bayesian methods in trials with small 
sample sizes may be important and this will be considered in detail in Chapter 3. Another 
identified trial, in the Journal of American Medical Association, highlighted that Bayesian 
methods are advantageous in interim monitoring44 of randomised phase III trials since the 
Bayesian approach can produce probability estimates of interest, whereas this is problematic 
if a frequentist approach was adopted. The advantage and derivation of the probability 
estimates is considered throughout the chapters in this thesis in particular within Chapters 4 
to 6 where direct probability statements about treatment effectiveness are of interest. The 
third identified trial, also in the Journal of American Medical Association, showed that the 
Bayesian framework is adopted if the required analysis is particularly complex as the 
Bayesian framework can be more easily adopted compared to the frequentist approach. This 
trial used non-informative prior distributions so that the results would mimic the results from a 
frequentist equivalent method. The use of non-informative or vague priors is thus explored in 
several chapters in the remainder of this thesis; in particular, Chapter 3 considers a 
sensitivity analysis to the choice of prior distribution in a trial investigating the use of a 
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surgical intervention, and Chapter 6 investigates the choice of several prior distributions for 
the parameters of the between-study covariance matrix in a bivariate meta-analysis model. 
Sample size calculations 
The review of randomised phase III trials in the Lancet showed that a sample size description 
was reported in all trial reports, or in the trial protocol or published rationale and design 
papers. Previous reviews have studied the reporting standards of randomised trials and one 
review, published in 2010, compared the reporting standards of randomised trials in 
December 2000 with the reporting standards of randomised trials in December 2006, which 
was after the publication of the CONSORT statement in 2001.149 There was an increase in 
the number of reports that stated the sample size from 27% (142/519 trials) in December 
2000 to 45% (279/616 trials) in December 2006.149 However, the percentage in 2006 is still 
lower compared to the articles in this review. This may be due to the update to the 
CONSORT statement published in 2010,150 and it may additionally be because not all 
journals require publications to adhere to the CONSORT statement, whereas the Lancet 
does make this requirement. A review of all randomised trials in five leading medical journals 
that endorse the CONSORT statement, between July 2002 and June 2003 show similar 
results to the findings in this review.151 In the Lancet, 95.1% of the trials reported sample size 
justification, which was a higher percentage compared to the other journals such as the BMJ 
with 86.3%, Annals of Internal Medicine with 66.7%, and JAMA with 76.9%.151 
Although the sample size is stated in all articles reviewed in this chapter, the sample size 
calculation was not explicitly supported by any reference to existing evidence in 34% of the 
articles. This observation may be for a number of reasons: 
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i. There may genuinely be no existing prior evidence to inform and support the sample 
size calculation. 
ii. The authors did use prior evidence but did not explicitly state that they had. 
iii. The authors reported references to prior evidence but did not explain them fully in this 
context, and thus the reference was not captured by this review as supporting the use 
of prior evidence (in other words, incomplete reporting may have caused the use of 
prior evidence to be missed). 
The sources of information that were referenced in the other 66% of articles were varied, with 
references from randomised phase III trials, phase II trials, systematic reviews and meta-
analyses, observational studies, clinical judgement, and other sources, such as regulatory 
guidelines. There were six trials that informed the sample size calculation with phase II trials, 
and of those, three were randomised. There were 12 trials that used meta-analyses to inform 
the sample size calculation. The use of phase II trials and meta-analyses to inform sample 
size calculations will be considered in detail in Chapters 4 and 5, in particular, in order to 
better inform the design of phase III trials with the results of multiple earlier trials. 
2.4.2 Limitations 
There are several limitations of this review in terms of reviewing the prevalence of Bayesian 
methodology. These include the restriction of the search criteria to publications in one year 
(2012). If the search was extended to a wider range of publication dates, it is possible that 
more articles with Bayesian methods may be obtained. The review also only focussed on 
seven leading general medical journals, and perhaps these general journals do not tend to 
favour trials with alternative statistical analyses compared to well-known frequentist methods, 
perhaps because the audience may not be familiar with advanced concepts such as 
Bayesian methods. In further research, the review could be extended to include other non-
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general medical journals, such as disease-specific journals (for example, British Journal of 
Cancer), which may more routinely publish trials that use less standard methods. 
A similar limitation is apparent in the review of sample size calculations in randomised 
controlled phase III trials, as this was only conducted for the articles in the Lancet. It is 
possible that the results would differ if the review was conducted in an alternative journal due 
to the varying reporting specifications by different journals. However, this part of the review 
was intended to give an overview of the sample size calculations being used in phase III 
trials and it is unlikely that the key findings would differ in a different journal, especially as the 
Lancet is a leading journal for RCT publication and adheres to CONSORT, which states that 
the sample size and all the quantities in the calculation must be reported. 
Also, this review is limited by reporting standards as it is only possible to review what has 
been reported. For example, authors may have used external evidence toward their sample 
size calculation but not reported this, as mentioned in point iii above. It may also be that the 
sample size is well-reported in the protocols of randomised trials but that this is not replicated 
in the trial reports, possibly due to word count limitations in papers. Further evaluation could 
also investigate the evidence reported in protocols, as in this review the protocols were only 
considered if it was referenced in the article as supporting information. 
2.5 Conclusions and rationale for remainder of thesis 
This review has highlighted that Bayesian methods are not commonly applied in clinical 
trials, which is disappointing. However, the articles that have adopted a Bayesian analysis 
have revealed the settings in which a Bayesian approach may be advantageous and thus 
motivate some of these areas to be explored in the remainder of this thesis. In particular, 
Bayesian methods are promoted in trials of small sample sizes and therefore the next 
chapter will apply Bayesian methods to a trial that failed to recruit its target sample size. 
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Furthermore, the review of sample size calculations in randomised phase III trials has shown 
that previous evidence, such as earlier trials and meta-analyses, is not always incorporated 
into the design of these trials. To address this, Bayesian meta-analysis methods of phase II 
trials will be explored in Chapters 4 and 5 to investigate how they may inform phase III trial 
design and decisions.  
55 
 
CHAPTER 3:  APPLICATION OF BAYESIAN METHODS TO 
A RANDOMISED CONTROLLED TRIAL IN A RARE 
DISEASE: THE PLUTO TRIAL 
3.1 Aims and objectives 
The literature review in the previous chapter highlighted that Bayesian methods may be 
advantageous in trials with small sample sizes because they can formally incorporate 
previous evidence in the analysis. Therefore, this chapter demonstrates the use of existing 
Bayesian analysis methods in a randomised trial with a very small sample size. The analysis 
also incorporates a frequentist approach to illustrate the additional benefits and differences of 
the Bayesian approach, and to highlight any limitations. The analysis has been published as 
part of the trial publication.42 
The PLUTO trial (Percutaneous Shunting for Lower Urinary Tract Obstruction) was a 
randomised controlled trial of a surgical intervention that failed to recruit its target sample 
size. The trial failed to recruit for reasons such as the rare nature of the disease and the 
ethical obligation of the clinician not to randomise patients that they deemed unlikely to 
benefit from the intervention. It is important that the data collected in the PLUTO trial is used 
appropriately to further the understanding of the effectiveness of the intervention since it is 
unlikely that another RCT, in the same population with the same intervention, would be more 
successful in recruiting patients compared to the attempts of the PLUTO trial. 
There were many clinical objectives of the trial but this chapter focuses on determining 
whether the intervention increases the probability of survival up to one year compared to 
those that received standard care. The data also provides a real example of a trial that can 
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be used to explore some statistical questions: what are the differences in the results between 
a Bayesian and frequentist approach if a vague prior distribution is used? Can previous 
evidence be incorporated into the Bayesian analysis appropriately? And, is it possible to 
make a clinical decision for future practice if there are several different prior distributions 
considered to be plausible? 
The chapter is structured as follows: the next section introduces the background to the trial, 
including a description of the condition and the two arms of the trial; section 3.3 outlines the 
statistical methodology that is applied to the trial within a frequentist and Bayesian framework 
and provides a description of the various prior distributions that are applied within the 
Bayesian analysis; section 3.4 provides the results, and compares the two analysis 
approaches; and section 3.5 concludes with some discussion of the findings. 
3.2 Background to the trial 
The PLUTO trial was a multi-centre randomised control trial (RCT) in the UK, Ireland, and the 
Netherlands, that investigated the use of a vesico-amniotic shunt (VAS) compared to 
conservative care in male foetuses for the treatment of congenital lower urinary tract 
obstruction (LUTO).42,152,153 The primary clinical objective was to assess if there is any 
difference in the mortality rates, up to one year, in babies with congenital LUTO between 
those that received the vesico-amniotic shunt compared to those that received conservative 
care. 
3.2.1 Fetal lower urinary tract obstruction 
LUTO is a rare birth defect that occurs in approximately 2.2 out of 10000 births and is most 
commonly developed in male foetuses.153,154 The cause is a partial or complete obstruction of 
the urethra, which is the tube that connects the bladder to the amniotic fluid space around 
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the foetus. The flow of urine is prevented from passing from the bladder into the amniotic 
fluid space, which negatively impacts on the development of the foetus. Urine is an important 
component of amniotic fluid during gestation and contributes to fetal lung development.155 If 
the urethra is completely blocked the urine cannot be released into the amniotic fluid space 
which causes the bladder to enlarge. If the amniotic fluid level is decreased the lungs may 
not develop properly (pulmonary hypoplasia), which is potentially life-threatening. The 
amniotic fluid also provides a cushioning for the foetus in the uterus, therefore low levels of 
fluid can lead to deformations of the face and extremities due to the pressure from the walls 
of the uterus. The kidneys can also become damaged due to back pressure caused by the 
obstruction.155 Diagnosis of congenital LUTO is usually made by the routine ultrasound in the 
mid-second trimester (20 week scan). Further evaluation determines whether prenatal 
intervention may be beneficial to the foetus. If cysts are present on the kidneys this is an 
indication that there is likely irreversible kidney damage in which case fetal intervention will 
not be performed.155 
3.2.2 Inclusion criteria 
The inclusion criteria were consenting pregnant women who has a singleton male foetus with 
a diagnosis of LUTO (diagnosed on the basis of the results in the ultrasound scans). The 
obstruction of the lower urinary tract had to be complete and isolated, and the foetus was 
presenting without any other abnormalities. Inclusion was also for those about whom the 
clinician was uncertain as to the optimum management.42,153 Female foetus’ were excluded 
because they are more likely to have a complex cause of the condition and a very poor 




Twenty-one fetal medicine centres in England, Scotland, Ireland, and the Netherlands 
recruited women to the trial. Pregnancies were allocated to the intervention or conservative 
management by a telephone and web-based randomisation service by the University of 
Birmingham Clinical Trials Unit. Randomisation by minimisation was used to achieve balance 
in the baseline characteristics between the treatment groups for gestational age at 
randomisation (<24 or ≥24 weeks), amniotic fluid volume (≤5th centile or >5th centile), and 
mother’s age (<20, 20 to 35, or >35 years). Allocation could not be masked from the 
participant or the clinician because of the surgical nature of the trial. All vesico-amniotic 
shunts were inserted within seven days of randomisation. 
3.2.4 Vesico-amniotic shunting 
The VAS is a hollow tube that temporarily bypasses the obstruction in the lower urinary tract 
and provides an alternative path for the urine to pass from the bladder to the amniotic fluid 
space around the foetus.155 This allows the amniotic fluid to build up, which is vital for the 
development of the lungs, and also helps prevent any further damage to the bladder and 
kidneys, which has been caused by the blockage. The procedure is performed by inserting a 
hollow needle through the mother’s abdomen and uterus and into the fetal bladder. The VAS 
is passed through the needle and placed in the bladder.155 After insertion of the VAS, follow-
up scans were arranged no less frequent than every four weeks. Before the PLUTO trial, 
there have been no large-scale prospective RCTs assessing the risks and benefits of the 
VAS in this setting. 
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3.2.5 Conservative care 
Conservative care in the PLUTO trial was the alternative treatment option that was compared 
to the intervention arm (VAS). This was a non-interventional care that included regular scans 
of the mother and foetus, no less frequently that every four weeks, which monitored the 
development of the foetus. 
3.2.6 Failure to recruit 
The original sample size calculation for the PLUTO trial was based on a meta-analysis of 
observational studies that compared the shunt with conservative care.156 The target sample 
size was 150 pregnancies however, after the first phase of recruitment, only 31 pregnancies 
had been enrolled in the RCT and so accrual was halted. The trial failed to recruit for many 
reasons including the rare nature of the condition, the large number of women that opted for 
a termination of pregnancy, and the ethical obligation for clinicians to provide the best 
standard of care, which meant that many patients could not be randomised. 
3.2.7 Outcome measures 
Mothers entered the study on the date of randomisation and the endpoint is one of the 
following: death of the foetus, termination of the pregnancy, or the end of follow-up. Patients 
were censored due to loss of follow-up, if they had not died before the end of the first follow-
up phase (all babies had at least one year follow-up by 1st January 2012), or if they were a 
termination of pregnancy that was not considered to be due to failure of the intervention. The 
survival time is measured as the length of time in the study, in weeks, from the estimated 
date of conception. The presumed conception date is calculated from the estimated date of 
delivery minus 267 days (date of the last menstrual period) plus 14 days. The survival time is 
measured from the date of conception (rather than date of randomisation) because the 
60 
 
gestational age of the foetus’ varied when they were diagnosed (and thus randomised), but 
the detection of congenital LUTO at an earlier gestational age could be associated with a 
higher risk of mortality. It was possible to have a common start of follow-up for all foetus’ by 
estimating the presumed date of conception. 
3.2.8 Data 
The analysis of the PLUTO trial was conducted assuming a censor date of 1st January 2012. 
All babies had been followed up for at least one year from conception but follow-up is still 
ongoing beyond this date. Information was collected on a number of variables at baseline, 
which are displayed in Table 3.1. 
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Table 3.1: Dataset variables with descriptions. 
Variable Description 
Trial number Patient identifier 
Mother’s age Mother’s age at conception of baby 
Continuous; years 
Gestational age Gestational age at randomisation 
Continuous; weeks 
Liquor volume Volume of amniotic fluid at randomisation by maximum pool depth (MPD) 
Binary; </> 5th centile157 
Renal pelvis dilation Transverse length of renal pelvis 
Binary; </> 90th centile 
Kidney length Length of left and right kidney 
Binary; </> 90th centile 
Renal cysts Renal cysts present 
Categorical; unilateral, bilateral or none 
Bladder wall thick Thick bladder wall 
Binary, </> 3mm 
Echogenicity Increased echogenicity of the kidney 
Categorical; unilateral, bilateral or no 
Renal pelvis 
hydronephrosis 
Kidney swollen or stretched as a result of a build-up of urine inside the 
kidneys 
Categorical; unilateral, bilateral or no 





The analysis of the trial was conducted using both frequentist and Bayesian analysis 
methods. A survival analysis was performed to determine whether there is a difference in 
mortality rates up to one year from conception between those that received the vesico-
amniotic shunt and those that received conservative care. An intention-to-treat and an as-
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treated analysis were considered in the publication of the results,42,153 however only the 
results from an intention-to treat assumption are reported in this chapter. 
Initially, a Kaplan-Meier plot for treatment arm was produced to show unadjusted differences 
in the probability of survival over time. The semi-parametric Cox proportional hazards (PH) 
model158 was then fitted using classical and Bayesian methods159 to obtain estimates of the 
ratio of mortality rates to compare the two randomisation arms. The Cox PH regression 
model is shown in equation (3.1), where h(t;X) is the hazard rate for an individual, i, at time t, 
with covariate vector X=(X1,X2,…,Xp). 
 h(t;X)=h0(t)exp �� βiXipi=1 � ,    t≥0 (3.1) 
Here, h0(t) denotes the baseline hazard, which is unknown, and βi denotes the regression 
coefficients (log hazard ratios) of interest in relation to the covariates Xi. Before the analysis it 
was decided that, although there are possible covariates of interest, the sample size was too 
small to adjust for them.160 Thus, only the intervention variable was fitted in the model, where 
X1=0 for those subjects that were randomised to conservative care, and X1=1 for those that 
were randomised to VAS. For all results in this chapter, a hazards ratio (HR) that is less than 
one indicates that those in the VAS group have a lower mortality rate compared to those in 
the conservative care group. 
3.3.1 Proportional hazards assumption 
The Cox proportional hazards model in (3.1) assumes that the hazard ratio (exp(β)) for a 
variable of interest, X, remains constant over time,158 i.e. the hazard rates for those in the 
VAS group are proportional to those in the conservative care group.161 To check whether the 
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hazard rates are proportional, the log cumulative hazard (log(-log(S(t))) was plotted against 
time (Figure 3.1), where S(t) is the probability of surviving until at least time t. 
 
Figure 3.1: Log cumulative hazard plot for intervention arm under ITT analysis. 
 
Figure 3.1 shows that the hazard rates for the treatment groups may not be proportional 
because the curves cross. However, the dataset is very small and so observed differences 
may simply be due to chance. Hence, the analysis was conducted under two assumptions. 
The first analysis assumes that the hazards are proportional over the entire length of follow-
up, therefore the hazard ratio estimate is an average of the treatment effect over time. The 
second assumption is that the relationship that is displayed in Figure 3.1 is the true 
relationship and therefore the survival data was split at the time point when the lines cross (at 
36.5 weeks, which is approximately the time of birth) and a Cox proportional hazards model 
was fitted with two coefficients for treatment effect (one for before 36.5 weeks [before birth], 


























are assumed proportional. In order to implement this model, a new binary variable, X2, was 
created to allow for the interaction between the time period and the intervention variable. For 
the first time interval X2=0, and for the second time interval X2=1. Thus, the Cox PH 
regression model can now be written as in equation (3.2): 
 h(t;X)=h0(t)exp�β1X1+β2X1X2� (3.2) 
Here, X1 denotes the intervention variable and exp(𝛽1�) is the estimated hazard ratio that 
compares the intervention groups when X2=0, i.e. the hazard ratio from conception to 36.5 
weeks (expected time of birth). Therefore, exp(β�1+β�2) is the estimate of the hazard ratio for 
the intervention versus conservative care when X2=1, i.e. the HR from 36.5 weeks (after 
expected time of birth) to the end of follow up. 
3.3.2 Bayesian survival analysis with the poisson counting process 
notation 
The Cox regression model using a Bayesian approach can be specified in numerous ways, 
such as the piecewise constant model, gamma process models or beta process models.162 In 
this chapter, the Cox proportional hazards model is formulated using the poisson counting 
process notation, which is a piecewise constant model.159 With this notation, for subjects 
i=1,...,n, Ni(t) denotes the processes that count the observed events that have occurred up to 
time t. Ii(t) is the corresponding intensity process given by (3.3)163 
 Ii(t)dt=E(dNi(t)|Ft-) (3.3) 
Where dNi(t) is the change in Ni in the time interval [t, t+dt] and Ft- denotes the data that is 
available just before time t. Therefore, Ii(t)dt is the probability that subject i has the event of 
interest in this interval, since dNi(t) equals one if subject i experiences the event of interest, 
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and otherwise dNi(t) equals zero. As dt tends to zero the probability becomes the 
instantaneous hazard for subject i at time t. The intensity process is assumed to have 
proportional hazards form:163 
 Ii(t)=Yi(t)λ0(t)exp �� βiXipi=1 � (3.4) 
So, Yi(t) is one if subject i is in the risk set at time t and zero otherwise, and thus accounts for 
those subjects that have been censored. The familiar Cox model is λ0(t)exp�∑ βiXipi=1 �. The 
joint posterior distribution for the regression coefficients, β, and the underlying cumulative 
hazard function, Λ0(t), is derived using Bayes theorem and is shown in equation (3.5).163 
 P(β, Λ0()|D)∝P(D|β,Λ0())P(β)P(Λ0()) (3.5) 
D denotes the data which includes the processes, Ni(t), the covariate values and Yi(t). P(β) is 
the prior distribution for the regression coefficients, P(Λ0()) is the prior distribution for the 
underlying hazard function, and the likelihood is denoted by P(D|β,Λ0()). Based on the 
assumption that censoring is non-informative, the likelihood is the same as if the counting 
process increments dNi(t) for the interval [t,t+dt] are independent Poisson random variables 
with means Ii(t)dt, so dNi(t)~poisson(Ii(t)dt). The intensity process can be written as:163 
 Ii(t)dt=Yi(t)exp(βXi)dΛo(t) (3.6) 
In this equation, dΛ0(t) is the change in the cumulative baseline hazard function during the 
interval [t,t+dt]. It is assumed that dΛ0(t) are distributed by a gamma distribution, 
dΛ0(t)~gamma(dΛ*0(t),c), where dΛ*0(t) is a prior belief about the unknown hazard function 
and c denotes the uncertainty surrounding this prior belief.163 This assumption is convenient 
since the conjugate prior for the poisson likelihood is the gamma distribution. For the analysis 
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of the PLUTO trial, Λ0*(t)=rdt where r is a guess at the failure rate per unit time and dt is the 
size of the time interval between failure times and the prior assumption of r was 0.1.156 The 
value c represents the degree of confidence in this assumption (small values of c represent 
weak prior belief) thus c=0.001 since there was no prior information to inform this value. 
3.3.3 Prior distribution for the treatment effect estimate 
For the Bayesian analyses, prior distributions need to be specified for the estimate of 
treatment effect, β1 (log(HR)). The incorporation of prior evidence may be useful to support 
the findings in the trial, which is largely underpowered due to its small sample size. However, 
it is also important to determine whether the prior distributions may be too informative in this 
dataset when there is so little data. Three off-the-shelf prior distributions (vague, enthusiastic 
and sceptical) were considered that used evidence from previous observational studies. Four 
subjective prior distributions using elicited prior beliefs from specialist clinicians were also 
derived prior to the trial.153,164 
Derivation of off-the-shelf prior distributions 
To construct the off-the-shelf priors we followed methods that have been outlined by others 
and the method is now described.165 All prior distributions for the log hazard ratio were 
assumed to be normally distributed. The enthusiastic prior was centred at the alternative 
hypothesis that PLUTO was designed to test, which was based on the results from a 
previous meta-analysis of observational studies.156 The original meta-analysis pooled odds 
ratios across four studies, however the prior distribution for this trial is for a log relative risk 
(log(RR)). Of course, a prior distribution for the log(RR) is not a perfect match for a log(HR), 
however, it was considered a suitable prior distribution for the log HR by assuming that the 
HR is constant and instantaneous for the entire period of follow-up. Therefore, the pooled RR 
was derived from the summary data from the four studies using the frequentist fixed-effect 
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meta-analysis model described in section 1.4.1. The mean of the prior distribution is a HR of 
0.646 (log(HR)=-0.437). The standard deviation for this prior distribution was derived by 
computing the value for which the enthusiastic prior has a 5% probability that the log hazard 
ratio favours conservative care.22 Thus, the enthusiastic prior was log(HR)~N(-0.437, 
sd=0.266). The sceptical prior distribution was constructed similarly, but centred at the value 
of no difference (i.e. log(HR)=0, and so harmful effects possible) and with a 5% probability 
that the treatment effect was greater than a log(HR) of -0.437. This prior distribution for the 
log(HR) was therefore N(0,SD=0.266). The sceptical and enthusiastic prior distributions for 
the log(HR) and HR scales are displayed in Figure 3.2. The vague prior distribution for the 
log(HR) was centred at the value of no effect (i.e. log(HR)=0) with a very large variance so 
log(HR)~N(0, sd=10002).166 
 
Figure 3.2: Sceptical and enthusiastic prior distributions for log(HR) and HR for VAS 




Elicited prior distributions 
The elicited prior distributions were obtained prior to the start of the trial from consultant 
members of either of the British Maternal and Fetal Medicine Society, the British Association 
of Paediatric Nephrologists, or the British Association of Paediatric Urologists.164 These three 
groups are referred to as fetal medicine (FM) experts (35 specialists), paediatric urologists 
(PU) (5 specialists) and paediatric nephrologists (PN) (10 specialists). Details of how the 
prior distributions were derived from each clinician, and how the prior distributions were 
combined, have been described extensively elsewhere.153 Figure 3.3 displays the prior 
distributions by speciality and for all specialists (50 specialists) combined. All elicited prior 
distributions are centred on a treatment effect that favours the intervention but include the 
harmful effects of the intervention. The fetal nephrologists are the least enthusiastic 
regarding the effect (log(HR)~N(-0.03,sd=0.15)). The fetal medicine experts and the all 
experts prior distributions are very similar because 35 out of 50 (70%) of the experts were 




Figure 3.3: Elicited prior distribution for log(HR) for intervention compared to 
conservative treatment. 
 
Table 3.2: Prior distributions for log(HR) for intervention versus conservative care. 




Fetal medicine experts N(-0.12,sd=0.17) 
Paediatric nephrologists N(-0.03,sd=0.15) 
Paediatric urologists N(-0.10,sd=0.14) 




3.3.4 Posterior probability estimates 
The Bayesian framework can be used to additionally estimate posterior probabilities of effect 
sizes greater (or less than) some clinically meaningful value, which may aid clinical decision-
making. The PLUTO trial was designed to detect a hazard ratio of 0.646 (log(HR)=-0.437) 
from the previous meta-analysis,156 which is described in section 3.3.3. A discussion was 
held with clinicians to decide what difference they would consider as a clinically meaningful 
difference between the mortality rates in the VAS and conservative care treatment groups. 
They decided that the estimate obtained in the meta-analysis was an appropriate difference 
to observe. Therefore, the posterior probability that the HR<0.646 was considered the 
clinically meaningful difference. However, the clinically meaningful difference of 0.646 is a 
large difference and therefore posterior probability estimates for the HR<1 were also 
calculated to show the probability that the mortality rates for those on the VAS arm are lower 
compared to the mortality rate for those that received conservative care. 
3.3.5 Implementation 
The frequentist survival analyses and the exploration of the data, including the Kaplan-Meier 
plots and log cumulative hazard plots, were performed using Stata version 12.1.167 The 
frequentist estimation of the hazard ratios used maximum likelihood estimation and there 
were no tied events. The Bayesian survival analyses were performed using MCMC methods 
using Gibbs sampling within WinBUGS version 1.4.32 The posterior distributions were 
assessed to check that they had converged to a stationary distribution by inspecting the trace 
and history plots. Auto-correlation was also checked by looking at the auto-correlation plots. 
The results were obtained with a burn in length of 20,000 iterations and a sampling length of 
100,000 iterations. Bayesian summary estimates provided are the median and 95% credible 




3.4.1 Summary of data 
Table 3.3 is a table of baseline characteristics by intervention group. Fifteen subjects were 
randomised to the conservative care arm and 16 to the VAS arm. Of the 15 babies that were 
randomised to conservative care, 3 (20%) were alive at the end of follow-up, 2 (13.33%) 
were termination of pregnancies, and 10 (66.67%) died. Of the 16 babies randomised to the 
VAS arm, 7 (43.75%) were alive at the end of the study, 3 (18.75%) were termination of 
pregnancies and 6 (37.50%) died. 
Despite the small sample size, the differences between the intervention groups were no 
more than expected by chance. However, for some characteristics the magnitude of the 
difference was quite large. For example, the range for gestational age for those randomised 
to VAS was 14 to 32 weeks, whereas the range was much narrower for those randomised to 
conservative care (16 to 24 weeks). Also, the mother’s age is higher for those randomised to 
conservative care (29.1 years) compared to those on the VAS (27.7 years). If these 
characteristics are truly associated with a higher risk of mortality there could be some bias in 
the estimate of treatment effect that is not adjusted for these variables. 
Out of the five mothers that had a termination of pregnancy, two were caused by a 
spontaneous rupture of membranes, believed to be a result of the shunt. Therefore, these 
two termination of pregnancies were analysed as deaths for the primary analysis and the 
remaining three termination of pregnancies were analysed as censored observations. There 
was little sensitivity to the classification of the termination of pregnancies, which has been 
investigated and reported elsewhere.153 
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Table 3.3: Summary of key baseline characteristics, outcome and length of follow-up by randomised intervention group. 
  VAS (n=16) Conservative care (n=15) Overall (n=31) 
Baseline characteristics     
 
Mother’s age, years 
Mean (SD) 27.68 (7.16) 29.05 (6.12) 28.35 (6.60) 
 Range 15.7 to 42.3 20.1 to 42.4 15.7 to 42.4 
 
Gestational age, weeks 
Mean (SD) 20.30 (4.74) 20.80 (2.30) 20.54 (3.71) 
 Range 14 to 32 16 to 24 14 to 32 
 
Liquor volume, n (%) 
<5th centile 10 (62.50) 9 (60.00) 19 (61.29) 
 >5th centile 6 (37.50) 6 (40.00) 12 (38.71) 
 
Left kidney length, n (%) 
<90th centile 4 (26.67) 4 (26.67) 8 (26.67) 
>90th centile 11 (73.33) 11 (73.33) 22 (73.33) 
 
Right kidney length, n (%) 
<90th centile 1 (6.67) 5 (33.33) 6 (20.00) 
>90th centile 14 (93.33) 10 (66.67) 24 (80.00) 
 
Renal cysts present, n(%) 
No 14 (87.50) 10 (66.67) 24 (77.42) 
Unilateral 2 (12.50) 4 (26.67) 6 (19.35) 
Bilateral 0 (0.0) 1 (6.67) 1 (3.23) 
 
Bladder wall thick, n (%) 
Yes 6 (42.86) 9 (64.29) 15 (53.57) 
No 8 (57.14) 5 (35.71) 13 (46.43) 
 
Echogenicity, n (%) 
No 7 (58.33) 5 (41.67) 12 (50.00) 
Unilateral 3 (25.00) 3 (25.00) 6 (25.00) 
Bilateral 2 (16.67) 4 (33.33) 6 (25.00) 
 
Hydronephrosis, n (%) 
No 13 (86.67) 13 (92.86) 26 (89.66) 
Unilateral 1 (6.67) 1 (7.14) 2 (6.90) 
Bilateral 1 (6.67) 0 (0.0) 1 (3.45) 
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  VAS (n=16) Conservative care (n=15) Overall (n=31) 
Follow-up     
 
Outcome, n(%) 
Death 6 (37.50) 10 (66.67) 16 (51.61) 
 Termination of 
pregnancy* 
3* (18.75) 2 (13.33) 5 (16.13) 
 Censored 7 (43.75) 3 (20.00) 10 (32.26) 
 Length of follow-up, person-weeks Total 1568.71 868.29 2436.99 
* Two of these terminations were analysed as deaths in the primary analysis of the trial. 
Table 3.3: continued. 
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3.4.2 Survival analyses 
The Kaplan-Meier unadjusted survival curves by intervention arm are shown in Figure 3.4. 
This plot suggests that, for approximately the first 36.5 weeks, those who received the VAS 
have a lower probability of survival compared to those that received conservative care. After 
this time, the probability of survival is higher for those that received the VAS. The probability 
of survival to one year from conception is approximately 23% for those that receive 
conservative care compared to approximately 54% for those that receive the VAS. 
 




Results assuming the hazard rates are proportional from conception to end of follow-
up 
Table 3.4 presents the results under the first assumption that the hazard rates are 
proportional from conception to the end of follow-up, for both the frequentist and Bayesian 
approaches. This table includes the estimate of the HR with its 95% CrI for the Bayesian 
analyses, and the estimated HR with its 95% CI for the frequentist analysis. The Bayesian 
analyses also include two posterior probabilities: the estimated HR is less than one, and the 
estimated HR is less than 0.646 for all prior distributions for the log(HR). 
Table 3.4: Bayesian and frequentist results from a univariable Cox model assuming 
proportional hazards for the entire length of follow-up. 
Analysis HR (95% CrI) Prob (HR<1) Prob (HR<0.646) 
Frequentist 0.622 (0.241 to 1.605)* - - 
Bayesian    
Vague: log(HR)~N(0,10002) 0.616 (0.226 to 1.598) 0.840 0.542 
Enthusiastic: log(HR)~N(-
0.44,0.27) 0.640 (0.406 to 1.009) 0.973 0.517 
Sceptical: log(HR)~N(0,0.27) 0.897 (0.570 to 1.411) 0.682 0.079 
FM experts: log(HR)~N(-0.12,0.17) 0.850 (0.621 to 1.170) 0.843 0.044 
PN: log(HR)~N(-0.03,0.15) 0.927 (0.700 to 1.230) 0.701 0.006 
PU: log(HR)~N(-0.10,0.14) 0.874 (0.674 to 1.138) 0.842 0.011 
All experts: log(HR)~N(-0.10,0.17) 0.865 (0.634 to 1.183) 0.818 0.032 
* 95% CI with corresponding p-value=0.301; FM is fetal medicine experts; PN is paediatric 
nephrologists; PU is paediatric urologists; 0.646 was considered clinically meaningful from the original 
meta-analysis.156 
Assuming a vague prior distribution for the log(HR) within a Bayesian survival model, the 
posterior estimate of the HR is 0.62 (95% CrI: 0.23 to 1.60) suggesting an average reduction 
in mortality rate of 38.4% for those that receive the shunt compared to those that received 
conservative care. The frequentist estimate of the hazard ratio is 0.62 (95% CI: 0.24 to 1.61), 
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which corresponds to a mortality rate that is lower for those that received the shunt 
compared to the conservative care by 37.8%. As expected, these results are very similar to 
the Bayesian results with a vague prior distribution. 
Perhaps surprisingly, the posterior estimate of the HR under the enthusiastic prior is a little 
closer to the null compared to the vague prior analysis (HR=0.64, 95% CrI: 0.41 to 1.01), 
however the 95% credible interval is narrower compared to the 95% CrI for the vague prior 
distribution analysis. As expected, the sceptical prior distribution draws the posterior 
distribution for the HR even closer towards the null compared to the enthusiastic prior 
distribution (estimated HR=0.90, 95% CrI: 0.57 to 1.41). 
The posterior results with the elicited prior distributions are all similar to each other. The 
median of the posterior distribution suggests that the intervention reduces mortality rates 
compared to conservative care. For example, using the FM prior the estimated HR is 0.85 
(95% CrI: 0.62 to 1.17). They all suggest a treatment effect that is closer to the value of no 
difference compared to the frequentist analysis and the Bayesian analyses with a vague or 
enthusiastic prior. 
All Bayesian analyses indicate a strong probability that the VAS is effective (i.e. HR<1) with 
estimates of this probability greater than 0.7 for all prior distributions. For example, this 
probability is as high as 0.97 with the enthusiastic prior distribution. However, there is no 
strong evidence that the VAS is clinically relevant (i.e. HR<0.646) since even the enthusiastic 
prior analysis estimates this probability to be 0.52, and this probability is as low as 0.01 with 
the paediatric nephrologist prior distribution. 
A plot of the posterior distributions using the three off-the-shelf and the four elicited prior 
distributions is shown in Figure 3.5. Figure 3.6 shows the prior distributions overlaid with the 
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updated posterior distributions. The posterior distributions are very close to their prior 
distributions, which is expected because there is very little data to update either the location 
or variance of the prior distribution. 
 
Figure 3.5: Posterior distributions for HRs using all prior distributions and assuming 



















Figure 3.6: Prior and posterior distributions overlaid. 
(HR scale; black: prior; grey: posterior) assuming proportional hazard rates 
Results with a time-dependent treatment effect 
The Bayesian and frequentist results assuming the time-dependent treatment effect are 
shown in Table 3.5. HR1 is the estimate of the treatment effect between conception and 36.5 
weeks (expected time of birth), and HR2 is the estimate of the treatment effect between 36.5 
weeks and the end of follow-up. Figure 3.7 displays the prior distributions overlaid with their 
updated posterior distributions for the estimate of HR1. Figure 3.8 is the corresponding figure 
for HR2.  
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Table 3.5: Posterior estimates of unadjusted HR for death given time-dependent treatment effect and Bayesian p-values. 










Frequentist* 1.116 (0.340 to 3.657)† - - 0.217 (0.039 to 1.207)$ - - 
Bayesian       
Vague: log(HR)~N(0,10002) 1.111 (0.328 to 3.956) 0.435 0.186 0.215 (0.027 to 1.101) 0.970 0.904 
Enthusiastic: log(HR)~N(-0.44,0.27) 0.705 (0.438 to 1.137) 0.927 0.358 0.583 (0.360 to 0.948) 0.984 0.659 
Sceptical: log(HR)~N(0,0.27) 1.018 (0.635 to 1.642) 0.478 0.030 0.866 (0.527 to 1.411) 0.722 0.124 
FM experts: log(HR)~N(-0.12,0.17) 0.903 (0.653 to 1.248) 0.732 0.022 0.836 (0.601 to 1.161) 0.862 0.063 
PN: log(HR)~N(-0.03,0.15) 0.974 (0.731 to 1.300) 0.572 0.002 0.919 (0.687 to 1.230) 0.718 0.009 
PU: log(HR)~N(-0.10,0.14) 0.910 (0.699 to 1.186) 0.756 0.005 0.864 (0.661 to 1.131) 0.857 0.017 
All experts: log(HR)~N(-0.10,0.17) 0.918 (0.668 to 1.262) 0.699 0.015 0.850 (0.615 to 1.173) 0.839 0.049 
* 95% CI for the HR estimates are presented for frequentist analysis; † the p-value corresponding to this estimate is 0.857; $ the p-value corresponding 
to this estimate is 0.081. 
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The frequentist results suggest that there could be a harmful or beneficial effect of the VAS in 
the first time period (up to the expected time of birth [36.5 weeks]) with an estimated HR1 of 
1.12 (95% CI: 0.34 to 3.66), but that there is perhaps a beneficial effect of the intervention 
after this time period with an estimated HR2 of 0.22 (95% CI: 0.04 to 1.21). However, these 
results are not statistically significant. Similar to the proportional hazards assumption over 
the whole year, the Bayesian results are very similar to the frequentist results for the vague 
prior distribution analysis. The posterior estimate of HR1 is 1.11 (95% CrI: 0.33 to 3.96), and 
the estimate of HR2 is 0.22 (95% CrI: 0.03 to 1.10). The Bayesian posterior probability 
estimate that HR1<1 is only 0.44, however the probability that HR2<1 is much higher with an 
estimate of 0.97. 
Only the results with an enthusiastic prior distribution suggests that the intervention improves 
survival rates from time of birth (36.5 weeks) onwards with an estimated HR2 of 0.58 (95% 
CrI: 0.36 to 0.95). However, the posterior probability estimates that the HR2<1 are above 0.7 
for all analyses, which may aid the update of the guidelines for clinical practice. 
The posterior distributions vary largely depending on the choice of prior distribution when 
there is such little data to update the prior distribution. For example, with a vague prior 
distribution, the estimated HR2 is 0.22 (95% CrI: 0.04 to 1.21) and the posterior probability 
that HR2<1 is 0.97. However, the estimated HR2 with the paediatric nephrologist prior 
distribution is 0.92 (95% CrI: 0.69 to 1.23) with an estimate of the probability HR2<1 equal to 
0.72. If the decision regarding clinical practice is just based on the evidence about HR2 in the 
data (i.e. the vague prior or the frequentist analysis), then they may decide to use the VAS. 
However, the evidence based on HR2 from the data combined with the paediatric 
nephrologist prior evidence suggests that the VAS may not provide a benefit above the 
conservative care, or it may be harmful. 
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The posterior distributions for the elicited prior analyses are particularly similar to their prior 
distributions for HR1 (Figure 3.7). This is because there is very little data to update the prior 
distribution compared to the relatively small standard deviations in the prior distributions. For 
example, the fetal medicine experts’ prior distribution is log(HR)~N(-0.12, sd=0.17). The 
posterior distribution for HR1 is logHR1~N(-0.10, sd=0.17). 
 
Figure 3.7: Prior and posterior distributions for HR1 (period conception to (expected 
time of birth) 36.5 weeks) overlaid. 





























































Figure 3.8: Prior and posterior distributions for HR2 (period 36.5 weeks (expected time 
of birth) to the end of follow-up) overlaid. 
(HR scale; black: prior; grey: posterior) 
3.5 Discussion 
The PLUTO trial was a randomised surgical intervention trial that compared the insertion of a 
VAS to conservative care in foetus’ with blocked lower urinary tracts. The trial failed to meet 
recruitment targets and closed after recruiting just 31 pregnancies. For several reasons, 
including the rare nature of the condition, another trial is unlikely to be more successful in 
terms of recruiting more patients. For this reason, and because the intervention was being 
used in practice under certain conditions prior to the trial, it is imperative to make the best 
use of the data from the PLUTO trial. Therefore, both frequentist and Bayesian survival 
methods have been adopted and compared. Within the Bayesian framework, several prior 
























































regarding the effectiveness of the intervention. The key findings are shown in Figure 3.9 and 
are discussed in more detail below. 
Figure 3.9: Key findings. 
• There is strong evidence in all Bayesian analyses (assuming proportional hazards for the 
entire follow-up period) that the VAS is effective (i.e. prob(HR<1) is high). But this effect is 
unlikely to be clinically relevant since the probability that HR<0.646 is low for all analyses. 
Further, it may be that VAS is harmful for the first 36.5 weeks (before expected time of birth) 
and the survival benefit of VAS is only after this point. 
• A Bayesian framework can be useful to analyse a clinical trial with a small sample size to 
incorporate additional data in a prior distribution. 
• It is difficult to assess proportional hazards in a dataset with very small numbers. Thus, 
several assumptions about the relationship between the hazard rates may be necessary. 
• If prior distributions have small variances they may have a large influence on the posterior 
distributions when there are few events. 
• When several, diverse prior distributions are explored it may be more difficult to make a 
clinical decision if the consequence is diversity in the posterior distributions. Thus, realistic 
prior distributions are preferred. 
 
Under the proportional hazards assumption for the entire follow-up, the only analysis that 
resulted in convincing evidence that the shunting is beneficial was the Bayesian analysis with 
the enthusiastic prior (HR 0.640 95% CrI 0.406, 1.009), and the probability that the hazard 
ratio is less than one is 0.97. However, the probability that this difference is a clinically 
important difference (i.e. a posterior probability that the hazard ratio is less than 0.646) is just 
0.52. Furthermore, under the sceptical prior, the posterior probability that the treatment effect 
is clinically important is just 0.08. 
As expected, the results from the frequentist analysis under both assumptions regarding the 
proportional hazards closely mirrored the results from the corresponding Bayesian approach. 
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For example, under the proportional hazard assumption for the entire follow-up within a 
frequentist framework, the estimated HR is 0.62 (95% CI: 0.24 to 1.61). The corresponding 
estimate within the Bayesian framework is 0.62 (95% CrI: 0.23 to 1.60). Additionally, the 
Bayesian framework provided posterior probability estimates. For this analysis, the 
probability that the HR<1 is 0.84, which suggested that there is a large probability that the 
VAS provides an improvement in mortality rate compared to conservative care. 
Under the assumption that there is a time-dependent treatment effect, the Bayesian and 
frequentist results all included harmful effects of VAS from conception to 36.5 weeks 
(expected time of birth). The probability that the estimate of HR1<0.646 is very low for all 
prior distributions with a posterior probability of just 0.03 for the sceptical prior and only 0.36 
for the enthusiastic prior distribution. From 36.5 weeks onwards, only the enthusiastic prior 
distribution gave convincing evidence that the intervention is beneficial (HR2 0.58, 95% CrI: 
0.36 to 0.95). For all other priors the results suggested that there may be harmful effects of 
the intervention. However, the posterior probability that HR2<1 is fairly high for all prior 
distributions (>0.7). 
3.5.1 Does the Bayesian framework provide any additional benefit in the 
PLUTO trial? 
Classical hypothesis tests depend on the data having high power (usually 0.8 or 0.9) and a 
low significance level, or type one error rate (usually 0.05). However, with a small dataset like 
the PLUTO trial, the power is low and the data will often yield non-significant results even 
when in truth the intervention provides a clinically important benefit. The PLUTO trial deals 
with a life-threatening condition found in unborn babies and procedures need to be 
developed to improve the chances of survival. Therefore, even with a small amount of data, 
the information from the PLUTO trial is important and needs to be appropriately used to 
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inform clinical decisions. A Bayesian analysis provided an alternative method to deal with the 
data that could include additional data in the form of external evidence. The Bayesian 
analysis allows direct probability statements from posterior distributions for the treatment 
effect. Probabilities can be calculated such as the posterior probability that the treatment 
effect is less than some clinically important value. These probabilities are a more intuitive 
way of making decisions that cannot be calculated within a frequentist framework. However, 
the clinically meanful difference of a HR less than 0.646 is a large difference to detect, which 
explains why the probabilities regarding this value are low for all analyses. It is important to 
ensure that any pre-specified clinically meaningful difference is also a realistic difference that 
the clinicians believe could be observed. 
A number of prior distributions have been derived to determine whether the shunt is effective 
compared to conservative care, including off-the-shelf and elicited prior distributions. The 
vague prior allows for the results to be almost entirely based on the data and the results 
closely mirrored the results from the frequentist analysis. The results based on the elicited 
priors may represent a reflection of the updated beliefs that a clinician may have based on 
the additional results from the PLUTO trial. However, it is not easy to arrive at a conclusion 
when there are several different results as a consequence of the different prior distributions; 
in particular the decision for future practice is difficult when the evidence from the trial is not 
convincing. For example, in the results in Table 3.5, the posterior HR2 estimate (estimate of 
HR for expected time of birth until the end of follow-up) for the vague prior analysis is 0.212 
(95% CrI: 0.027 to 1.101), whereas the posterior HR2 estimate from the paediatric 
nephrologist prior analysis is just 0.919 (95% CrI: 0.687 to 1.230). But, the conclusions are 
clearer across the various prior distribution assumptions with the proportional hazards 




The dataset is particularly small (31 subjects), therefore, although it is possible to conduct a 
Bayesian analysis as an alternative to a frequentist analysis, there must be caution 
interpreting any of the results without consideration of the other choices of prior distribution 
when making changes within clinical practice. 
Due to the small sample size some important assumptions were made, including whether to 
assume proportional hazard rates in the Cox regression analysis. Since the assumption of 
proportionality could have a profound impact on the results of the trial, a number of analyses 
were conducted by assuming proportional hazards, and alternatively including a time-
dependent treatment effect. 
3.6 Conclusion 
In conclusion, the PLUTO trial failed to recruit its target sample size and therefore, any 
frequentist hypothesis tests would be severely underpowered. A Bayesian statistical analysis 
offers an alternative approach alongside the classical framework to deal with a small dataset. 
The Bayesian approach can additionally incorporate external “data” in the form of prior 
distributions and calculate direct posterior probabilities that the treatment effect is less than 
some pre-specified clinically important difference. The posterior distributions suggest that the 
insertion of the VAS may increase survival rates in comparison to conservative care. 
However, almost all of the results indicate that there may also be harmful effects of the 
intervention in the weeks before birth (i.e. before 36.5 weeks). The results from this survival 
analysis were combined with several other analyses, including a cost-effectiveness analysis 
to recommend an update of the National Institute for Health and Care Excellence 
interventional procedures guidelines that will reflect the new evidence, whilst continuing to 
follow-up the babies in the PLUTO trial for long term outcomes.153 Currently, the NICE 
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guidelines state that the evidence regarding the safety and efficacy of VAS for LUTO “does 
not appear adequate for this procedure to be used without special arrangements for consent 
and for audit or research.”168 The implications for practice from the PLUTO trial is that the 
results of the RCT and observational evidence are consistent and suggest that VAS 
improves perinatal survival compared with conservative care, but that the long-term 
prognosis for these babies into infant life is poor. The health economic analysis suggests that 
the costs associated with this small gain in disability-free survival at the end of one year are 
high and therefore VAS is unlikely to be deemed cost-effective.153 
In the next chapter, Bayesian analyses of randomised trials with small sample sizes will 
continue but in the context of randomised phase II trials, which tend to be small by design 






CHAPTER 4:  UNIVARIATE META-ANALYSIS  
OF PHASE II TRIALS 
4.1 Context and objective 
The previous chapter explored the use of Bayesian methods to analyse a single randomised 
trial with a small sample size. Phase II trials also tend to have small sample sizes by design, 
however sometimes there may be several phase II trials that aim to answer the same 
question. Multiple phase II trials could thus be considered collectively before initiation of a 
phase III trial, for example within a meta-analysis. Meta-analysis methods were introduced in 
Chapter 1, and they combine quantitative data from several studies to produce pooled overall 
results that aid evidence-based clinical decision making.35 A meta-analysis is able to quantify 
effect sizes and their uncertainty, and to increase sample size and thus power. Where there 
are multiple phase II studies, a meta-analysis could therefore be beneficial to synthesise all 
the evidence and inform the decision of whether or not to proceed to phase III. 
The objective in this chapter is to consider the use of meta-analysis methods in the context of 
phase II trials. In particular, to apply Bayesian meta-analysis approaches that summarise the 
evidence and account for all uncertainty in order to estimate the probability that the treatment 
is effective on average for each outcome of interest. Furthermore, the Bayesian framework 
could allow one to predict whether the treatment will be effective if a new (phase III) trial of 
that treatment was undertaken. This information can be used to inform the decision about 
proceeding to phase III. However, many issues may arise for a meta-analysis in this context. 
Phase II trials are often small, low powered and conducted in different ways, which may 
cause heterogeneity in treatment effects between trials and large uncertainty in the summary 
results. Therefore, this chapter evaluates the benefits and limitations of Bayesian meta-
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analysis of phase II trials, and exemplifies how they can be useful toward phase III decisions. 
The focus here is on univariate meta-analysis approaches, which is the standard method that 
considers a separate meta-analysis for each outcome of interest. In Chapter 5, extension is 
made to this work to multivariate meta-analysis, which synthesises all outcomes jointly. 
4.2 Data, outcomes and clinical objectives 
Eikelboom et al.169 conducted a meta-analysis to examine serious adverse safety outcomes 
within phase II and phase III randomised controlled trials that evaluated the efficacy of bolus 
thrombolytic therapy compared with standard infusion therapy for the in-hospital treatment of 
acute myocardial infarction (AMI). Effective treatment of AMI is crucial. The incidence of 
hospitalised AMI in England in 2010 was 122 per 100,000 for men and 53 per 100,000 for 
women.170 Thrombolytic therapy is an accepted form of treatment for AMI, which aims to 
reduce mortality and restore normal blood flow by dissolving clots in blood vessels.171 
However, there are potential serious adverse events, such as intracranial haemorrhage (ICH) 
and mortality.171 
Eikelboom et al. focussed on the disagreement between phase II and phase III results in this 
field. This chapter reveals new insight into this comparison. Nine randomised, controlled 
phase II trials were utilised by Eikelboom and in this chapter they are first used to 
methodologically examine univariate meta-analysis methods for combining small phase II 
trials.171-179 They are then used to predict phase III trial results. The outcomes of interest are 
the four serious adverse events reported: ICH, stroke, reinfarction and mortality. The data 
were extracted from the original nine published papers of the phase II randomised trials and 
the data is shown in Table 4.1 and Table 4.2. This includes the agents compared, the total 
number of patients, the length of follow-up, and the percentage of patients with each adverse 
event. Patients entered the trials from the date of hospital admission with AMI. Similar length 
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of follow-up was reported for most of the trials. The trial by Vanderschueren et al.174 and the 
BASE175 study did not report the actual length of follow-up; however, the adverse event 
outcomes in these studies were monitored during the length of patient stay in hospital. All 
trials recorded the four outcomes except one by Kawai et al.,173 which did not report the 
number of patients with stroke. 
The clinical objective of the meta-analysis of the trials is to assess if there is any difference in 
the risk of adverse event outcomes for patients who receive bolus therapy compared to those 
patients that receive infusion therapy. The hope is that bolus therapy reduces the risk of 
adverse outcomes, and if so, further phase III research might be funded. For all results in this 
chapter, an odds ratio (OR) that is less than one indicates that those patients who receive 




Table 4.1: Phase II randomised trials of bolus vs. infusion thrombolytic therapy in AMI. 
Trial Bolus (No. of boluses) Infusion† N (Bolus) N (Infusion) Length of follow-up 
RAPID,171 1995 Reteplase, 5-15 MU (1 or 2) Alteplase, 100 mg 452 154 30 days 
RAPID-II,172 1996 Reteplase, 5-10 MU (2) Alteplase 169 155 35 days 
Kawai et al.,173 1997 E6010, 0.22 mg/kg Tisokinase, 14.4 MU 97 102 7 days 
Vanderschueren et al.,174 1997 Staphylokinase, 15 mg doses (2) Alteplase 50 52 Hospital stay 
BASE,175 1998 Saruplase, 40-80 mg (1 or 2) Saruplase, 80 mg 139 53 Hospital stay 
DOUBLE,176 1998 Alteplase, 50 mg (2) Alteplase 224 237 30 days 
lnTIME,177 1998 Lanoteplase, 15-120 kU/kg (1) Alteplase 478 124 30 days 
TIMI-10B,178 1998 Tenecteplase, 30-50 mg (1) Alteplase 540 316 30 days 
TIMIKO,179 1998 Urokinase, up to 1.5 MU (2) Alteplase 350 268 30 days 
† Alteplase infusion was given according to the accelerated and weight-adjusted GUSTO regimen180 in all trials except in RAPID in which a 3-hour 
infusion was used. 
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Table 4.2: Incidence of ICH, stroke, reinfarction, and mortality in nine phase II trials of bolus vs. infusion thrombolytic therapy in 
AMI.171-179 
Trial Outcome 
Sample size, N No. of events (%) 
Log(OR) Var(log(OR)) OR 95% CI OR 




1 (0.2) 4 (2.6) -2.49 1.26 0.08 0.01 to 0.75 
Stroke 1 (0.7) 6 (3.9) -1.80 0.51 0.17 0.04 to 0.67 
Reinfarction 20 (4.4) 7 (4.5) -0.03 0.20 0.97 0.40 to 2.35 




2 (1.2) 3 (1.9) -0.50 0.85 0.61 0.10 to 3.68 
Stroke 3 (1.8) 4 (2.6) -0.38 0.60 0.68 0.15 to 3.10 
Reinfarction 8 (4.7) 7 (4.5) 0.05 0.28 1.05 0.37 to 2.97 
Mortality 7 (4.1) 13 (8.4) -0.75 0.23 0.47 0.18 to 1.22 
Kawai et al.,173 1997 
ICH 
97 102 
0 (0) 1 (1.0) -1.06 2.69 0.35 0.01 to 8.62 
Stroke - - - - - - 
Reinfarction 4 (4.1) 7 (6.9) -0.54 0.41 0.58 0.17 to 2.06 
Mortality 4 (4.1) 1 (1.0) 1.470 1.27 4.34 0.48 to 39.57 




0 (0) 0 (0) -0.04 3.90 0.96 0.02 to 46.06 
Stroke 0 (0) 1 (1.9) -1.08 2.71 0.34 0.01 to 8.54 
Reinfarction 5 (10.0) 7 (13.4) -0.34 0.39 0.71 0.21 to 2.42 




2 (1.4) 0 (0) 0.67 2.43 1.95 0.09 to 41.19 
Stroke 2 (1.4) 0 (0) 0.67 2.43 1.95 0.09 to 41.19 
Reinfarction 9 (6.5) 1 (1.9) 1.28 1.14 3.60 0.44 to 29.13 




Sample size, N No. of events (%) 
Log(OR) Var(log(OR)) OR 95% CI OR 




2 (0.9) 1 (0.4) 0.75 1.51 2.13 0.19 to 23.61 
Stroke 6 (2.7) 2 (0.8) 1.17 0.68 3.23 0.65 to 16.19 
Reinfarction 5 (2.2) 12 (5.1) -0.85 0.29 0.43 0.15 to 1.24 




0 (0) 1 (0.8) -2.45 2.68 0.09 0.00 to 2.12 
Stroke 0 (0) 1 (0.8) -2.45 2.68 0.09 0.00 to 2.12 
Reinfarction 9 (1.9) 8 (6.5) -1.28 0.25 0.28 0.11 to 0.74 




9 (1.7) 6 (1.9) -0.13 0.28 0.88 0.31 to 2.48 
Stroke 14 (2.6) 9 (2.8) -0.10 0.19 0.91 0.39 to 2.12 
Reinfarction 28 (5.2) 18 (5.7) -0.10 0.10 0.91 0.49 to 1.66 




1 (0.3) 3 (1.1) -1.37 1.34 0.25 0.03 to 2.45 
Stroke 1 (0.3) 3 (1.1) -1.37 1.34 0.25 0.03 to 2.45 
Reinfarction 11 (3.1) 9 (3.4) -0.07 0.21 0.93 0.38 to 2.29 
Mortality 16 (4.6) 12 (4.5) 0.02 0.15 1.02 0.48 to 2.20 
An OR<1 favours bolus therapy 
Table 4.2: continued. 
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4.3 Univariate fixed-effect meta-analysis methods using a 
frequentist approach 
There are various estimation methods that can be adopted to carry out a meta-analysis. This 
section will explore the available methods, and aims to determine which approaches may be 
more appropriate for the meta-analysis of phase II trials. The methods will be illustrated using 
the AMI dataset with the four outcomes, which will be analysed separately in univariate meta-
analyses using both a frequentist and Bayesian framework in order to compare the results. 
The frequentist analyses are implemented within Stata version 12.1167 and the Bayesian 
analyses are implemented within WinBUGS version 1.4.32 In this section frequentist fixed-
effect models are introduced. 
4.3.1 A general fixed-effect meta-analysis model (inverse variance) 
A meta-analysis can be performed assuming a fixed-effect approach, which assumes that 
there is a single (fixed) treatment effect across all studies, θ.39 The summary (pooled) 
estimate (θ�) from a meta-analysis gives the best estimate of this single treatment effect, 
using the evidence from all available studies included in the meta-analysis. The general 
(‘inverse variance’) fixed-effect model has already been described in Chapter 1 but for 
completeness this model is repeated briefly here. This assumes the observed treatment 
effect estimate, Yi, in study i, follows a normal distribution with known variance, Si2, as shown 
in equation (4.1). The fixed-effect assumption implies that the observed differences between 
the Yi are due to chance alone. Yi and Si2 in this chapter will relate to the log odds ratio and 
its variance for a particular outcome. 




The fixed-effect inverse variance method assigns weights to each trial,34 which are shown in 
equation (4.2), where Si
2 is the variance of the log odds ratio (log OR) from each study, i. The 
pooled treatment effect, θ� (log OR), can be estimated using maximum likelihood estimation 






















4.3.2 Mantel-Haenszel method 
In the article by Eikelboom et al.,169 the authors used a Mantel-Haenszel approach for meta-
analysis,34 which assumes a fixed-effect model. They also performed a separate meta-
analysis for each outcome, i.e. univariate meta-analysis. The Mantel-Haenszel method is 
often used for pooling ORs and it has been shown to have better statistical properties when 
there are few events, compared to alternative methods such as the inverse variance method 
of equation (4.1).34 Table 4.3 shows the 2x2 table for an outcome of interest, by treatment 
arm in study i, where ai+bi+ci+di=ni. 
Table 4.3: Event in study i. 
Study i Event Non-event 
Treatment ai bi 




The sample estimate of the OR in study i, ORi, is shown in equation (4.5). The Mantel-
Haenszel method assigns a weight (equation (4.6)) to each trial so that the results of some 
studies make a greater contribution than others to the pooled result. The estimated pooled 


























Continuity correction in phase II meta-analysis 
The individual OR estimates by the Mantel-Haenszel and inverse variance methods require a 
continuity correction if there are zero cells in the 2x2 table (Table 4.3). The standard 
approach is to add a constant correction factor of 0.5 to all cells.181 However, a correction 
factor of 0.5 may not perform well when the groups are severely unbalanced with respect to 
the number of subjects in each treatment arm, which is the case in this example in AMI 
(Table 4.2). The continuity correction factors influence the estimates of the variance, which 
affects the weighting given to each study, as well as the estimate of the treatment effect. 
Given the imbalance between treatment groups, an alternative proposed method is referred 
to as the ‘opposite treatment arm’ continuity correction.181 This method adds the reciprocal of 
the opposite treatment arm total sample size to the number of events and number of non-
events, for each treatment arm. 
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Table 4.4: An illustration of a trial in which a continuity correction may be required to 
calculate the odds ratio. 
Vanderschueren et al.174 ICH No ICH Total 
Bolus therapy 0 50 50 
Infusion therapy 0 52 52 
Total 0 102 102 
 
To illustrate this, Table 4.4 shows the trial by Vanderschueren et al., where there are no 
events of ICH in either treatment arm. If a correction factor of 0.5 is added to each cell, the 
Mantel-Haenszel method estimates the OR for this study to be 1.04 with a weighting of 
1.88%. This is compared to an OR of 1 if the ‘opposite treatment arm’ continuity correction is 
applied with the study weighting of 0.08%, which is clearly a more appropriate estimate of the 
OR, and the weighting is reduced as there is very little information in this study to contribute 
to the pooled estimate. Due to the large imbalance in sample size in many studies, and the 
multiple zero event rates, the meta-analysis in this chapter will adopt the ‘opposite treatment 
arm’ continuity correction method, for those methods that require a continuity correction. 
4.3.3 Peto method 
The Peto method182 is a fixed-effect method that can only be used to pool ORs (compared to 
approaches that also pool alternative summary measures such as relative risks). This 
method estimates the OR in study i, ORi, by equation (4.8), where ai, bi, ci, di, and ni are the 
elements of the 2 x 2 table in Table 4.3. The pooled OR is shown in equation (4.9), and the 
CI for the pooled OR is shown in equation (4.10), where α is the significance level that is 
usually chosen to be 0.05 in order to obtain a 95% CI. The Peto method does not require 
continuity correction. The Peto method works well when the intervention effects are small 
(ORs that are close to one), and when the events are rare. When this is not the case the 
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4.3.4 Fixed-effect logistic regression 
A univariate meta-analysis can also be implemented using a logistic regression model, which 
models the exact binomial distribution of the data. This method does not require continuity 
correction.184 Let rij denote the binary variable for the adverse event of interest, which is 1 if 
subject j has the event in trial i, and zero otherwise. The event is binomially distributed with 
probability, πij, i.e., rij~Bin(1,πij), which is equivalent to a Bernoulli distribution with event 
probability of πij. 
Model (4.11) shows the logistic regression fixed-effect meta-analysis model with a binary 
covariate for the treatment, Drugij, which represents the drug for patient j in study i (i=1,...,9). 
This covariate is zero for those that receive infusion therapy, and one for those that receive 
bolus therapy. The model assumes that the treatment effect (θ) is fixed at the trial level, 
where logit(πij) denotes log(πij/(1-πij)); the log odds of the event for patient j in trial i. The 
100 
 
model accounts for clustering of patients within trials by a separate intercept term, αi, which 
denotes the baseline (control group) risk for each trial, i.185 This is important because it is 
inappropriate to analyse the data as if it is coming from a single study.185 
 logit�πij�=αi +  θ·Drugij (4.11) 
Maximum likelihood (ML) estimation can be used to estimate the parameters of interest in 
this fixed-effect logistic regression meta-analysis model. 
4.4 Univariate random-effects meta-analysis methods using a 
frequentist approach 
4.4.1 A general random-effects meta-analysis model (inverse variance) 
In contrast to the fixed-effect approach, a random-effects approach assumes a distribution of 
treatment effects across studies as shown in model (4.12), which has already been 
described in Chapter 1. Each study can now be estimating a different treatment effect, θi, and 
therefore the summary (pooled) estimate, β�, from the meta-analysis gives an estimate of the 
average treatment effect, β, across studies. Individual studies may therefore have a 
treatment effect that varies considerably from this average value, and this between-study 
variance in the treatment effect is known as tau-squared (τ2). 
 Yi ~ N(θi, Si
2) 
θi ~ N(β, τ2) 
(4.12) 
An estimate of the between-study variance, τ2, must be obtained to calculate a pooled 
treatment effect estimate from a random-effects meta-analysis model. Restricted maximum 
likelihood estimation (REML) is typically preferred for the random-effects model in order to 
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estimate both τ2 and β appropriately. Maximum likelihood (ML) can also be used but REML is 
usually preferred as ML is likely to underestimate τ2. The DerSimonian and Laird “method of 
moments” method is also popular, which is shown in equations (1.17) to (1.20) in section 
1.4.2 of Chapter 1. However, REML, ML and MM estimation does not account for the fact 
that that the estimated τ2 has uncertainty. Some authors and packages try to account for the 
uncertainty post-estimation, for example by inflating the estimate of the standard error of the 
pooled log OR, or by using a t-distribution to derive CIs, in order to increase the width of the 
confidence interval (CI) for the pooled result.186 
4.4.2 Examining heterogeneity in a meta-analysis of phase II trials 
Eikelboom et al. chose a fixed-effect approach to meta-analysis, rather than a random-
effects approach, but did not explain or justify this decision. Various methods are commonly 
implemented to determine the level of heterogeneity in a meta-analysis187; one method is the 
Q-statistic. The Q-statistic is a chi-squared test that tests the null hypothesis that the 
treatment effect is equal (fixed) in the k studies. This statistic is compared to the chi-squared 
distribution with k-1 degrees of freedom to obtain a p-value. A statistically significant p-value 
suggests there is more variation between the trials than expected by chance. The Q-statistic 
is calculated by equation (4.13), where wi is the weight given to trial i by the fixed-effect 
method of choice, Yi is the estimated treatment effect (log OR) from study i, and θ� is the 








This test has low power when there are a small number of studies and so a significance level 
of 10% is often used. The Q-statistic is a test for heterogeneity but it does not measure it. 
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The estimate of τ2 after fitting equation (4.15) directly quantifies the between-study 
heterogeneity. Also, the I2 statistic is an estimate of the percentage of the total variation that 
is due to between-trial variation. I2 is calculated by equation (4.14), where Q is the Q statistic 
estimated by equation (4.13).187 If the value of I2 is large this indicates that there may be a 
large amount of between-study variation, and therefore a random-effects meta-analysis may 
be more appropriate than a fixed-effect analysis. A tentative guide to the interpretation of I2 
is: 0% represents no heterogeneity; 25% represents low heterogeneity; 50% represents 







In this chapter the p-values from the Q-statistic test will be presented and discussed 
alongside the I2 estimates to determine whether these measures are useful within a meta-
analysis of phase II trials. 
4.4.3 Random-effects logistic regression 
Model (4.15) is the random-effects logistic regression model assuming that the log odds ratio 
for the treatment effect is random at the trial level. The average treatment effect is denoted 
by β, and the study specific effect, ui, has been included to account for the difference 
between trials in the true treatment effect; the variance for this is denoted by τ2. 
 logit�πij�=αi + θi·Drugij; 
θi=β+ui; ui~N�0, τ2� 
(4.15) 
Maximum likelihood (ML) estimation is used to estimate the parameters of interest. The log-
likelihood for the random-effects model has no closed form; therefore it is approximated by 
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adaptive Gaussian quadrature167 with five integration points used in this chapter. The 
estimation again does not account for the uncertainty in ?̂?2 although this only affects the error 
in the parameter estimates and not their point estimates. 
4.5 Univariate meta-analysis methods using a Bayesian 
framework 
A univariate meta-analysis can also be implemented within a Bayesian framework. Potential 
advantages of this approach include the ability to easily estimate the uncertainty of the 
between-study variance, the ability to make direct probability statements regarding quantities 
of interest, and to make predictive statements, conditional on the current state of 
knowledge.19 
4.5.1 Bayesian approach to inverse-variance meta-analysis methods 
Fixed-effect and random-effects meta-analysis models using a Bayesian approach to the 
inverse-variance method will be implemented in this chapter. The fixed-effect meta-analysis 
model assumes the log OR from each study, Yi, is normally distributed about a mean θ and 
known variance, Si2, as shown by model (4.16) The Bayesian approach additionally requires 
prior distributions to be specified for unknown parameters. For the fixed-effect model, in this 
chapter a vague normal prior distribution is assumed for the true underlying fixed treatment 
effect. 




The random-effects model additionally allows for heterogeneity (τ2) about an average effect, 
β, as described by model (4.17). In this model, a vague normal prior distribution is assumed 
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for the average treatment effect and a vague normal prior distribution, truncated at zero 
(N(0,1)I(0,)), is assumed for the between-trial standard deviation. However, the correct 
choice of distribution for τ is often disputed and thus a sensitivity analysis for its prior 
distribution is described in Section 4.5.5. In contrast to the frequentist approach, the posterior 
distribution for β in the Bayesian models accounts for the uncertainty in τ.36 
 Yi ~ N(θi, Si
2) 




4.5.2 Bayesian approach to logistic regression meta-analysis model 
A Bayesian approach to the logistic regression models in section 4.3.4 is also possible. The 
fixed-effect meta-analysis model is shown in model (4.18) where rij denotes the binary 
variable for the adverse event of interest, which is 1 if subject j has the event in trial i, and 
zero otherwise. The estimate of the fixed pooled logOR for bolus therapy compared to 
infusion therapy is denoted by θ. For this model a vague normal prior distribution is assumed 
for αi, (i=1,…,9) and θ with a mean zero and a variance 10002. 
 rij~Bin(1,πij) 




The random-effects logistic regression model is shown in model (4.19), with the same vague 
normal distribution for αi and β, and a vague normal distribution assumed for the between-
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trial standard deviation. The choice of prior distribution for the between-study standard 







4.5.3 Probability statements 
Following a Bayesian analysis, the posterior distributions can be used to make probability 
statements about the probability that the treatment will be effective. These probabilities may 
be especially useful in the decision to proceed to phase III. For example, it is possible to 
calculate the probability that the treatment will reduce the odds of intracranial haemorrhage 
compared to the standard treatment by at least 10%, i.e. the probability that the summary OR 
is less than 0.90. Similarly, for each outcome, the estimate of the probability that the 
posterior OR is less than one can be obtained, i.e. the probability that bolus therapy is 
beneficial at all compared to infusion therapy. 
4.5.4 Estimation and reporting of Bayesian models 
Following a Bayesian analysis, the summary estimates of interest in this chapter are the 
median of the posterior distribution for the summary log OR, the median of the posterior 
distribution for the summary OR, the posterior for the standard deviation of the log OR, the 
95% posterior credible interval (CrI) for the summary OR, the posterior probability that the 
OR is less than one, and the median of the posterior distribution of the between-trial variance 
(if applicable). Posterior estimates of the model parameters are obtained using the Gibbs 
Sampler Markov chain Monte Carlo (MCMC) method,189 which is implemented in WinBUGS 
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version 1.4.32 The code for the random-effects logistic regression model is shown in 
Appendix B1. The analyses were performed with 100,000 iterations after allowing for a 
100,000 iteration burn in and checking for convergence using several common measures, 
including the history and trace plots. An example of the history and trace plots is given for the 
univariate random-effects logistic regression model in Appendix B2. 
4.5.5 Prior distribution for between-study variance 
As discussed briefly in Chapter 1, the appropriate prior distribution for τ is often debated.29 In 
this chapter, a sensitivity analysis is therefore performed for the prior distribution for the 
between-study variation within the random-effects logistic regression method as an example. 
This is to ensure that the selected prior distribution does not largely influence the results. The 
prior distributions considered are shown in Table 4.5.29 Since standard 
deviation=√variance=√1/precision, the prior distribution can be put on the variance, standard 
deviation or precision. Priors 1a to 6b are non-informative prior distributions. Prior 6a is the 
distribution that has been applied for all meta-analyses in this chapter. Prior 1a is a common 
choice of prior distribution for the between-study standard deviation. Priors 1b and 1c are the 
same distributional form of Prior 1a, but assess the sensitivity to the choice of parameter 
values. Prior 2 is a commonly used prior distribution for variance parameters with a ‘spike’ of 
probability mass close to zero. Prior 3a is a prior distribution on the log variance scale. Prior 
3b is a weak informative version of Prior 3a but goes to a maximum of log(4.0)=1.386, which 
assumes that the variance is unlikely to be greater than 4.0. Prior 4a is a prior on the 
variance scale and Prior 4b is a weak informative version of Prior 4a with a maximum of 
τ2=4.0. Prior 5a is on the precision scale with Prior 5b as a weak informative version of Prior 
5a. Prior 5a is equivalent to Prior 1c. Prior 6b is a weak informative version of Prior 6a. Priors 
7a and 7b are empirical prior distributions that were derived by Turner et al. for a future 
meta-analysis with a binary outcome where there may be few studies to estimate this 
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parameter.36 Prior 7a is the prior distribution that was derived for a pharmacological 
intervention where the outcome is all-cause mortality and this prior distribution is used for the 
analysis of death. Prior 7b is the prior distribution for a semi-objective outcome with a 
pharmacological intervention and this prior distribution is used for the analysis of ICH. 
Table 4.5: Sensitivity analysis prior distributions for between-study variance. 
Prior Target parameter Distribution 
Form of probability 
density function 
Prior parameters 
1a τ Uniform  a=0, b=10 
1b τ Uniform  a=0, b=100 
1c τ Uniform  a=0, b=2 




3a Log(τ2) Uniform  a=-10, b=10 
3b Log(τ2) Uniform  a=-10, b=1.386 
4a τ2 Uniform  a=0.001, b=1000 
4b τ2 Uniform  a=0.001, b=4 
5a 1/τ2 Pareto αcαx-(a+1), x>c α=1, c=0.001 
5b 1/τ2 Pareto  α=1, c=0.25 










6b τ Half-Normal  λ=100, μ=0 








7b τ2 lognormal  λ=1.852, μ=-3.02 
 
4.6 Deriving prediction intervals following a random-effects meta-
analysis 
The random-effects meta-analyses present estimates of the average treatment effect across 
studies. When considering whether to conduct a phase III trial, focusing on the posterior 
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distribution for β may be misleading when heterogeneity in present. The effect in a new trial 
(θinew) may be very different to the average effect (β), due to the causes of heterogeneity from 
trial to trial (or setting to setting)39. Ideally, the factors causing the heterogeneity would be 
known, so that new trials could focus on implementation strategies (e.g. doses) and 
populations most likely to show benefit. However, identifying causes of heterogeneity is 
problematic given the typical (<10) studies in a meta-analysis and the potential for trial-level 
confounding. Therefore, the focus here is on situations where the phase II trials in the meta-
analysis all include pertinent places, populations and strategies (e.g. doses, timing, length of 
treatment) for which the intervention effect is of interest. After a random-effects meta-
analysis, a prediction interval can be calculated to give a range of values for the predicted 
treatment effect in a single new study, e.g. a new phase II trial or a phase III trial.39 These 
prediction intervals can be calculated and compared in both the frequentist and Bayesian 
frameworks. 
4.6.1 Frequentist prediction intervals 
Frequentist prediction intervals are approximated based on the estimated amount of 
between-trial variation, the uncertainty in the pooled estimate, and a t-distribution to account 
for uncertainty in the estimate of τ. Equation (4.20) displays the approximate 95% prediction 
interval,39,190 where β� represents the (pooled) average log OR; tk-2 is the 100(1-α/2) percentile 
of the t-distribution with k-2 degrees of freedom (k=number of studies) and α is 0.05; ?̂? is the 
estimated between-trial standard deviation; SE(β�) is the standard error of β�. 
 
β� ± tk-2*� τ̂2 +SE(β�)2 (4.20) 
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4.6.2 Bayesian prediction interval for the true treatment effect in a new 
trial 
Bayesian prediction intervals for the treatment effect in a future study are easily derived 
following MCMC estimation of the model. As specified in model (4.17), θi~N(β,τ2) and so the 
95% predictive distribution for θinew (equation (4.21)) is the true intervention effect (log odds 
ratio) in a new trial, where: 
 θinew~N(β,τ
2) (4.21) 
If the true value of β and τ2 are known, a 95% probability interval for a new study,  θinew, can 
be obtained by taking the 2.5% and 97.5% values of the posterior distribution of θinew. 
However, when β and τ2 are unknown, this 95% interval can be obtained immediately after 
fitting model (4.17) and it will account for the uncertainty in β and τ2 through samples from 
their posterior distributions. Therefore, the Bayesian prediction intervals will incorporate more 
uncertainty compared to the frequentist prediction intervals, though the t-distribution (rather 
than the normal distribution) tries to address this in the frequentist equation. This predictive 
distribution can also be used to calculate the probability that the intervention will be truly 
effective in a new trial,191 either at all (i.e. probability(true OR in a new trial<1)) or by some 
clinically relevant amount, such as the odds being reduced by at least 10% (i.e. 
probability(true OR in a new trial<0.9)). 
4.6.3 Bayesian prediction interval for the treatment effect estimate in a 
trial with a given sample size 
Though the true intervention effect ( θinew) is of fundamental interest, a more pertinent 
question facing phase III funders is: what is the probability that the intervention will be 
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identified as beneficial in a new trial with a given sample size? To help answer this, during 
estimation of Model (4.17), one can also derive an approximate predictive distribution for the 
intervention effect estimate, Yinew , in a new trial of particular sample size, Ninew: 
 Yinew~N�θinew,var(Yinew)� (4.22) 
where θinew is the true intervention effect in a new trial. A standard approximation of a 









 192 where ainew and 
cinew  are the number of events in the new trial’s experimental groups and control groups, 
respectively; binew and dinew are the number of non-events in the new trial’s experimental and 
control groups, respectively and the total sample size Ninew=ainew+binew+cinew+dinew. Clearly, 
ainew, binew, cinew and dinew are not known and so some assumptions are needed in order to 
derive them for each  Yinew sampled during the estimation process. The following two options 
are considered in this chapter. 
Option 1: Estimate the variance of Yinew in each drawn sample assuming a fixed 
baseline risk and sample size 
First, assume a fixed proportion of events (baseline risk) in the control group in the new trial; 
this could be chosen to reflect the baseline risk in the intended population. Thus, cinew
cinew+dinew
 is 
specified. Then, also specify the sample size of the control group (ncinew=cinew+dinew). The 
chosen baseline risk and sample size thereby fix cinew and dinew. Also, specify the treatment 
group sample size (ntinew=ainew+binew). Then, assuming that each Yinew that is sampled during 
the MCMC estimation process is the same as the mean θinew (which on average will be true), 















In equation (4.23), ntinew, cinew  and dinew  are fixed (specified in advance), and θinew  is the 
current sampled true intervention effect for the new trial. In this way, each Yinew that is 








  , where cinew and dineware 
chosen and ainew and binew are obtained from equation (4.23) for that sample. 
Option 2: Assume a fixed variance of Yinew 
A simpler, but potentially less accurate approach than option (1), is to specify a fixed 
variance of Yinew, regardless of the θinew sampled. To do this, in addition to specifying cinew 
and dinew based on the assumed baseline risk and control group sample size (see option (1)), 
one needs to also fix ainew  and binew. One therefore needs to assume θinew is fixed at some 
value (=log �ainewdinew
binewcinew
�). For example, one might fix θinew to be the mean of the posterior 
distribution for θinew (i.e. fix it to be β). Then ainew and binew can be obtained. 
Options (1) or (2) allow an approximate 95% probability interval for θinewto be calculated 













Therefore, across all samples during the estimation process, one can also derive predictive 
distributions for the lower and upper bounds of the 95% interval for Yinew. One can then 
calculate probabilities to inform phase III decisions. In particular the probability that, in a new 
trial with a sample size of Ninew and a control group risk of 
cinew
cinew+dinew
, the upper bound of the 
95% interval for Yinew will be lower than 0 (i.e. that the lower bound of the CrI for the OR will 
be <1); in other words, the probability that the new trial will identify the intervention as 
effective by the entire 95% interval for the OR being in favour of the intervention. 
4.6.4 Comparison with subsequent phase III trials 
The prediction intervals from the meta-analysis of phase II trials predict treatment effects in 
new trials. Therefore, it is of interest to compare the results of subsequent phase III trials and 
see if they are consistent with the prediction intervals. Data are available from six 
subsequent phase III trials. The primary endpoint in these phase III trials was death from any 
cause.193-198 Secondary endpoints included ICH, other stroke, and reinfarction. When 
comparing meta-analysis results for phase II and III trials, Eikelboom et al. did not consider 
prediction intervals and rather focussed only on the compared the pooled results for the log 
odds ratios. The limitation of their approach is shown in section 4.8.3. 
4.7 Results I: Pooled results for the treatment effect 
4.7.1 Original frequentist results of Eikelboom et al. 
The results for each outcome when applying the Mantel-Haenszel fixed-effect estimation 
method are shown in Table 4.7 to Table 4.10. This is the method used by Eikelboom et al. 
The pooled estimates of the ORs are in favour of the bolus therapy compared to the infusion 
therapy for all outcomes. For example, the estimated pooled OR for ICH is 0.552 with 95% 
CI (0.287, 1.063). However, the 95% CIs suggest that there is large uncertainty in the pooled 
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estimates and statistical significance is not obtained at the 5% significance level for any of 
the outcomes. This is perhaps not surprising given how small the phase II trials are. 
4.7.2 Heterogeneity results 
The original method of Eikelboom et al.169 did not consider heterogeneity when they applied 
a fixed-effect meta-analysis method. To examine whether they should have accounted for 
heterogeneity, Table 4.6 shows the I2 statistic, the Q-statistic chi-squared test (χ2), and 
between-study variance, τ2, frequentist estimates for each outcome. The chi-squared test 
reports a p-value and τ2 is estimated by the DerSimonian and Laird method-of-moments. The 
results demonstrate the difficulty in using these statistics to identify whether a random-effects 
meta-analysis of phase II trials is more sensible than a fixed-effect model. 
Q-statistic 
Most of the p-values are statistically non-significant, which suggests there is no strong 
evidence of heterogeneity. However, there are only nine trials and therefore there is low 
power to detect heterogeneity if it truly existed. The Cochrane Handbook states that it is 
inappropriate to decide to choose between a fixed-effect and a random-effects model based 
solely on a test for heterogeneity.34 As a meta-analysis of phase II trials will usually contain 
fewer than 10 trials, the Q-statistic is thus unlikely to be useful on its own. 
τ2 
Of more interest is the estimate of τ2, which is non-zero for stroke, reinfarction and mortality. 
These estimates suggest heterogeneity is present for these outcomes. Further, they seem 
especially large for stroke and mortality (>0.1). 
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Table 4.6: Heterogeneity measures for ICH, stroke, reinfarction, and mortality. 
Outcome I2 (%) χ2 p-value τ�2 
ICH    
Fixed MH 0.0 0.661 - 
Fixed IV 0.0 0.665 - 
Peto 44.0 0.085 - 
Random MM 0.0 0.665 <0.001 
Stroke    
Fixed MH 25.6 0.225 - 
Fixed IV 25.6 0.225 - 
Peto 56.6 0.024 - 
Random MM 25.6 0.225 0.306 
Reinfarction    
Fixed MH 8.6 0.364 - 
Fixed IV 8.2 0.367 - 
Peto 23.1 0.238 - 
Random MM 8.2 0.367 0.023 
Mortality    
Fixed MH 34.3 0.144 - 
Fixed IV 33.9 0.146 - 
Peto 43.0 0.081 - 
Random MM 33.9 0.146 0.144 
MH is the Mantel-Haenszel method, IV is the inverse variance method, MM is the method-of-moments 
estimation by DerSimonian and Laird. 
I2 
The estimate of I2 is less than 40%, in general, for all outcomes, even when ?̂?2 is large. In 
particular, given than ?̂?2 is non-zero and large for stroke and mortality it is surprising that I2 is 
not higher than observed for these outcomes. Further, given that the value of ?̂?2 is far larger 
for stroke, it is also surprising that I2 is similar for both mortality and stroke. The I2 statistic 
may thus also not be the best indicator of heterogeneity in meta-analysis of phase II trials. I2 
is the percentage of between-trial variation out of the total variation, where the total variation 
is the sum of the within-study variation plus the between-study variation. I2 may be lower than 
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expected here because the phase II trials are small and the event rate is low as the 
outcomes in AMI are rare. Thus, regardless of the size of τ, the total variation will always be 
dominated by the within-study variation, and so I2 will usually be small, even when 
heterogeneity exists.199 
Differences between methods 
The results for I2 and the Q-statistic for the Peto method are different compared to the other 
methods. The Q-statistic p-values are smaller when based on the Peto method, and, for ICH, 
stroke and mortality, there is evidence of statistical significance at the 10% significance level 
in the Peto method but not the other methods. Thus, the estimated values of I2 are larger for 
all outcomes. However, in this dataset of phase II trials, there are imbalances in the sample 
sizes for the treatment arms, and the event rate is also low for the outcomes of interest 
(Table 4.2). These two factors cause differences between the methods in the trial ORs and 
their weights since these estimates are calculated differently in the Peto method (equation 
(4.8)) compared to other methods, such as the Mantel-Haenszel method (equations (4.5) and 
(4.6)). This leads to different estimates of Q and I2, and thus confusion if trying to use these 
measures to decide between a fixed-effect and a random-effects model. 
Summary 
In summary, the heterogeneity statistics of Q and I2 appear limited for identifying 
heterogeneity in a meta-analysis of phase II trials due to the small number of studies and the 
small number of patients within studies. This suggests that clinical judgement and prior 
beliefs about heterogeneity should also be accounted for. Given that these phase II trials 
were conducted separately, it seems more plausible to assume, a priori, that heterogeneity 
exists. This is also a more conservative assumption. Further, the estimates of τ2 are non-zero 
for most outcomes, and thus a random-effects model seems more sensible. 
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4.7.3 Comparison of fixed-effect and random-effects meta-analysis 
pooled results for frequentist and Bayesian methods 
Table 4.7 to Table 4.10 display the pooled results from the univariate meta-analysis models 
for ICH, stroke, reinfarction, and mortality for all the fixed-effect and random-effects models 
introduced earlier, for both frequentist and Bayesian approaches. The key findings are now 
discussed. 
Pooled results are uncertain 
The point estimates for the pooled ORs are in favour of the bolus therapy compared to 
infusion therapy for all outcomes (i.e. ORs are less than one), and under all meta-analysis 
models. However, there is large uncertainty in the estimates, resulting in wide CIs (and 
credible intervals) and thus the results are inconclusive. This is perhaps unsurprising given 
these are small phase II trials being synthesised. The forest plots from the fixed-effect Peto 
model are shown in Figure 4.1 to Figure 4.4. These show that the pooled results have 
narrower CIs than the CIs for each of the individual trials. This demonstrates an increase in 
the certainty of the treatment effect once the study results have been pooled, and hence why 




Table 4.7: Pooled treatment effect results for bolus versus infusion therapy for intracranial haemorrhage. 
Assumption Frequentist Method Log(OR) SE(log(OR)) OR 95% CI OR 𝝉�𝟐  
Fixed-effect Mantel-Haenszel -0.594 0.334 0.552 0.287 to 1.063 -  
Fixed-effect Inverse variance -0.521 0.378 0.594 0.283 to 1.249 -  
Fixed-effect Peto -0.644 0.351 0.525 0.264 to 1.043 -  
Fixed-effect Logistic regression -0.621 0.342 0.537 0.275 to 1.050 -  
Random-effects REML (nounc) -0.577 0.429 0.561 0.242 to 1.301 0.136  
Random-effects REML -0.577 0.492 0.561 0.214 to 1.473 0.136  
Random-effects ML (nounc) -0.521 0.379 0.594 0.283 to 1.249 <0.001  
Random-effects ML -0.521 0.379 0.594 0.283 to 1.249 <0.001  
Random-effects MM (nounc) -0.521 0.379 0.594 0.283 to 1.249 <0.001  
Random-effects MM -0.521 0.379 0.594 0.283 to 1.249 <0.001  
Random-effects Logistic regression -0.621 0.342 0.537 0.275 to 1.050 <0.001  
Assumption Bayesian Method Log(OR) SE(log(OR)) OR 95% CrI OR 𝝉�𝟐 (95% CrI) Prob OR<1 
Fixed-effect Inverse variance* -0.522 0.379 0.593 0.282 to 1.248 - 0.916 
Fixed-effect Logistic regression† -0.623 0.347 0.536 0.271 to 1.057 - 0.964 
Random-effects Inverse variance$ -0.615 0.549 0.541 0.169 to 1.492 0.316 (0.001 to 3.095) 0.889 
Random-effects Logistic regression# -0.724 0.524 0.485 0.155 to 1.266 0.435 (0.002 to 3.662) 0.937 
OR<1 indicates the treatment is beneficial; REML is restricted maximum likelihood method; ML is maximum likelihood method; MM is method-of-
moments method; nounc indicates assumption of no uncertainty in between-study variance estimate. *Prior distribution for θ~N(0,10002). †Prior 
distribution for θ~N(0,10002) and αj~N(0, 10002). $Prior distribution for β~N(0,10002) and τ~N(0,1)I(0,). #Prior distribution for β~N(0,10002), αj~N(0, 
10002), and τ~N(0,1)I(0,). 
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Table 4.8: Pooled treatment effect results for bolus versus infusion therapy for stroke. 
Assumption Frequentist Method Log(OR) SE(log(OR)) OR 95% CI OR 𝝉�𝟐  
Fixed-effect Mantel-Haenszel -0.354 0.271 0.702 0.413 to 1.192 -  
Fixed-effect Inverse variance -0.362 0.298 0.696 0.388 to 1.248 -  
Fixed-effect Peto -0.384 0.284 0.681 0.390 to 1.188 -  
Fixed-effect Logistic regression -0.375 0.278 0.688 0.399 to 1.186 -  
Random-effects REML (nounc) -0.451 0.490 0.637 0.244 to 1.666 0.648  
Random-effects REML -0.451 0.493 0.637 0.242 to 1.674 0.648  
Random-effects ML (nounc) -0.430 0.421 0.650 0.285 to 1.484 0.355  
Random-effects ML -0.430 0.425 0.650 0.283 to 1.496 0.355  
Random-effects MM (nounc) -0.425 0.408 0.654 0.294 to 1.453 0.306  
Random-effects MM -0.425 0.408 0.654 0.294 to 1.453 0.306  
Random-effects Logistic regression -0.375 0.278 0.688 0.399 to 1.186 <0.001  
Assumption Bayesian Method Log(OR) SE(log(OR)) OR 95% CrI OR 𝝉�𝟐 (95% CrI) Prob OR<1 
Fixed-effect Inverse variance* -0.364 0.299 0.695 0.387 to 1.247 - 0.889 
Fixed-effect Logistic regression† -0.373 0.281 0.689 0.399 to 1.205 - 0.906 
Random-effects Inverse variance$ -0.432 0.515 0.649 0.219 to 1.747 0.488 (0.002 to 3.236) 0.829 
Random-effects Logistic regression# -0.486 0.512 0.615 0.201 to 1.578 0.652 (0.004 to 3.896) 0.862 
OR<1 indicates the treatment is beneficial; REML is restricted maximum likelihood method; ML is maximum likelihood method; MM is method-of-
moments method; nounc indicates assumption of no uncertainty in between-study variance estimate. *Prior distribution for θ~N(0,10002). †Prior 
distribution for θ~N(0,10002) and αj~N(0, 10002). $Prior distribution for β~N(0,10002) and τ~N(0,1)I(0,). #Prior distribution for β~N(0,10002), αj~N(0, 
10002), and τ~N(0,1)I(0,). 
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Table 4.9: Pooled treatment effect results for bolus versus infusion therapy for reinfarction. 
Assumption Frequentist Method Log(OR) SE(log(OR)) OR 95% CI OR 𝝉�𝟐  
Fixed-effect Mantel-Haenszel -0.250 0.161 0.779 0.568 to 1.066 -  
Fixed-effect Inverse variance -0.282 0.164 0.754 0.546 to 1.041 -  
Fixed-effect Peto -0.255 0.164 0.775 0.562 to 1.067 -  
Fixed-effect Logistic regression -0.251 0.161 0.778 0.568 to 1.066 -  
Random-effects REML (nounc) -0.282 0.164 0.754 0.546 to 1.041 <0.001  
Random-effects REML -0.282 0.164 0.754 0.546 to 1.041 <0.001  
Random-effects ML (nounc) -0.282 0.164 0.754 0.546 to 1.041 <0.001  
Random-effects ML -0.282 0.164 0.754 0.546 to 1.041 <0.001  
Random-effects MM (nounc) -0.288 0.174 0.750 0.533 to 1.055 0.023  
Random-effects MM -0.288 0.174 0.750 0.533 to 1.055 0.023  
Random-effects Logistic regression -0.251 0.161 0.778 0.568 to 1.066 <0.001  
Assumption Bayesian Method Log(OR) SE(log(OR)) OR 95% CrI OR 𝝉�𝟐 (95% CrI) Prob OR<1 
Fixed-effect Inverse variance* -0.284 0.165 0.753 0.544 to 1.040 - 0.958 
Fixed-effect Logistic regression† -0.250 0.160 0.779 0.571 to 1.066 - 0.941 
Random-effects Inverse variance$ -0.284 0.213 0.753 0.491 to 1.139 0.066 (0.000 to 0.758) 0.922 
Random-effects Logistic regression# -0.258 0.214 0.773 0.502 to 1.179 0.076 (0.000 to 0.864) 0.901 
OR<1 indicates the treatment is beneficial; REML is restricted maximum likelihood method; ML is maximum likelihood method; MM is method-of-
moments method; nounc indicates assumption of no uncertainty in between-study variance estimate. *Prior distribution for θ~N(0,10002). †Prior 
distribution for θ~N(0,10002) and αj~N(0, 10002). $Prior distribution for β~N(0,10002) and τ~N(0,1)I(0,). #Prior distribution for β~N(0,10002), αj~N(0, 
10002), and τ~N(0,1)I(0,). 
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Table 4.10: Pooled treatment effect results for bolus versus infusion therapy for mortality. 
Assumption Frequentist Method Log(OR) SE(log(OR)) OR 95% CI OR 𝝉�𝟐  
Fixed-effect Mantel-Haenszel -0.064 0.165 0.938 0.679 to 1.294 -  
Fixed-effect Inverse variance -0.106 0.170 0.899 0.644 to 1.255 -  
Fixed-effect Peto -0.066 0.167 0.936 0.675 to 1.299 -  
Fixed-effect Logistic regression -0.066 0.166 0.936 0.676 to 1.296 -  
Random-effects REML (nounc) -0.045 0.221 0.956 0.620 to 1.475 0.1262  
Random-effects REML -0.045 0.244 0.956 0.592 to 1.543 0.1262  
Random-effects ML (nounc) -0.097 0.176 0.906 0.642 to 1.280 0.0124  
Random-effects ML -0.099 0.219 0.906 0.590 to 1.391 0.0124  
Random-effects MM (nounc) -0.039 0.227 0.962 0.617 to 1.501 0.1437  
Random-effects MM -0.039 0.227 0.962 0.617 to 1.501 0.1437  
Random-effects Logistic regression -0.066 0.166 0.936 0.676 to 1.296 <0.0001  
Assumption Bayesian Method Log(OR) SE(log(OR)) OR 95% CrI OR 𝝉�𝟐 (95% CrI) Prob OR<1 
Fixed-effect Inverse variance* -0.107 0.170 0.899 0.644 to 1.254 - 0.736 
Fixed-effect Logistic regression† -0.066 0.166 0.936 0.681 to 1.303 - 0.656 
Random-effects Inverse variance$ -0.038 0.276 0.962 0.594 to 1.780 0.164 (0.000 to 1.443) 0.565 
Random-effects Logistic regression# -0.008 0.283 0.992 0.599 to 1.843 0.213 (0.000 to 1.588) 0.513 
OR<1 indicates the treatment is beneficial; REML is restricted maximum likelihood method; ML is maximum likelihood method; MM is method-of-
moments method; nounc indicates assumption of no uncertainty in between-study variance estimate. *Prior distribution for θ~N(0,10002). †Prior 
distribution for θ~N(0,10002) and αj~N(0, 10002). $Prior distribution for β~N(0,10002) and τ~N(0,1)I(0,). #Prior distribution for β~N(0,10002), αj~N(0, 




Figure 4.1: Forest plot for intracranial haemorrhage using the fixed-effect Peto meta-
analysis model. 
 
Figure 4.2: Forest plot for stroke using the fixed-effect Peto meta-analysis model. 
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Figure 4.3: Forest plot for reinfarction using the fixed-effect Peto meta-analysis model. 
 
Figure 4.4: Forest plot for mortality using the fixed-effect Peto meta-analysis model. 
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Fixed-effect versus random-effects meta-analysis models 
Under the frequentist and Bayesian frameworks, the random-effects meta-analysis models 
estimate a standard error of the log OR that is either similar to, or larger than, the standard 
error estimated by the fixed-effect methods, which results in wider CIs and CrIs. This is 
because the estimate of τ2 is additionally included in the variance of the pooled log OR from 
the random-effects model (equation (1.18) and (1.20)). For example, for the frequentist fixed-
effect Mantel-Haenszel method for mortality, the standard error of the log OR is 0.165 (95% 
CI OR: 0.679 to 1.294). Using REML (not accounting for uncertainty in ?̂?2), the standard error 
of the log OR is 0.221 (95% CI OR: 0.620 to 1.475). 
The standard errors are only similar for the fixed-effect and random-effects models if the 
latter estimates τ2 to be close to zero, because there is then only small additional variation to 
account for. For example, for reinfarction, ?̂?2 is <0.0001 using REML and the standard error of 
the log OR is 0.164, which is equal to the standard error that is estimated by the fixed-effect 
inverse variance method. This leads to the same confidence intervals under both the 
random-effects and fixed-effect models. 
Frequentist results 
Within the frequentist framework, there are differences in meta-analysis results between the 
estimation methods, although no estimation method results in a different overall clinical or 
statistical conclusion compared to the other approaches. 
For the random-effects models, the standard error of the pooled log OR and ?̂?2 are lower for 
the meta-analysis method that uses ML compared to REML. For example, for mortality, the 
standard error is estimated to be 0.176 using ML (no uncertainty in ?̂?2), compared to 0.221 
using REML, which results in a wider confidence interval for REML. The logistic regression 
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model also estimates τ2 to be very small with ?̂?2 less than 0.0001, for all four outcomes. This 
is because the logistic regression also uses ML to estimate τ2. However, ML gives a 
downwardly biased estimate of τ, whereas REML and MM try to address this.200 Therefore, 
ML may not be the best method of estimation for meta-analysis of phase II trials where τ2 is 
potentially large. For example, for stroke, τ2 is estimated as 0.648 using REML but 0.355 
using ML. Interestingly, MM and REML can also disagree. For example, for stroke the value 
of ?̂?2 is 0.306 using MM and 0.648 using REML. 
As expected, for REML, ML, and MM the 95% CIs are wider when the uncertainty in the 
estimated between-trial variance is accounted for in the frequentist analysis by inflating the 
standard error of the pooled log OR. For example, for mortality, using REML the pooled OR 
has a 95% CI of 0.620 to 1.475 assuming no uncertainty in ?̂?2, but is 0.592 to 1.543 when 
assuming uncertainty in ?̂?2. 
Frequentist versus Bayesian results 
The pooled results within the Bayesian framework give similar conclusions to those within the 
frequentist framework for all four outcomes. However, the standard errors are larger for the 
Bayesian models, which results in wider 95% CrIs when compared to the 95% CIs in the 
equivalent frequentist models. For example, for reinfarction, the Bayesian logistic regression 
model with random-effects obtains the pooled OR of 0.773 with 95% CrI 0.502 to 1.179. The 
frequentist logistic regression with random-effects estimates the pooled OR to be 0.778 with 
95% CI 0.568 to 1.066. The wider CrI is due to the uncertainty in ?̂?2 in the Bayesian model, 
which the frequentist model does not automatically account for. Also, the values of ?̂?2 are 
larger for the Bayesian meta-analysis models compared to the equivalent frequentist models. 
For the Bayesian inverse variance model, for stroke, ?̂?2 is 0.488 (95% CrI 0.002 to 3.236) 
compared to 0.306 for the frequentist inverse variance model (using MM). For the Bayesian 
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logistic regression model, ?̂?2 is 0.652 (95% CrI 0.004 to 3.896) compared to ?̂?2<0.0001 for the 
frequentist logistic regression model; a dramatic difference potentially due to the downward 
bias in the frequentist ML estimation of τ, but also may be due to the influence of the prior 
distribution for τ (see section 4.11). 
Bayesian results 
The median estimates and 95% CrI for ?̂?2 are larger for the logistic regression model 
compared to the inverse variance model. For example, for ICH and using the inverse 
variance method, the median value of ?̂?2 is 0.316 (95% CrI 0.001 to 3.095). Whereas, for the 
logistic regression model for ICH, the median value of ?̂?2 is 0.435 (95% CrI 0.002 to 3.662). 
The Bayesian meta-analysis models also provide estimates of the probability that the 
summary OR is less than one (i.e. the probability that the effect of bolus therapy will be 
beneficial, on average across all populations). These estimates are shown in Table 4.7 to 
Table 4.10. For all estimation methods, the probability that the pooled OR is in favour of the 
bolus therapy is high for ICH, stroke, and reinfarction, with values greater than 0.80. For 
mortality, the probability is lower compared to the other outcomes with values between 0.50 
and 0.75 depending on the model used. 
The probability that the summary OR is less than one is lower for the random-effects 
analyses compared to the fixed-effect analyses as a result of the additional variation in the 
random-effects model. For example, for reinfarction, the fixed-effect logistic regression 
analysis estimates the probability to be 0.941, compared to an estimate of 0.901 that is 
estimated by the random-effects logistic regression analysis. 
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4.8 Results II: Prediction intervals for the treatment effect in a new 
trial 
The prediction intervals for the true treatment effect in a new trial for each of the four 
outcomes, within the frequentist and Bayesian frameworks, are shown in Table 4.11 to Table 
4.14. The Bayesian approach also allows us to obtain the predictive probability that the true 
OR in a new trial is less than one. 
There is greater uncertainty in the predicted true ORs in a new trial compared to the average 
effect estimate. The 95% prediction intervals are wider compared to the corresponding 95% 
CIs and CrIs intervals of the pooled estimates within the frequentist and Bayesian 
frameworks, respectively. This is because the 95% CIs (and CrIs) relate to the uncertainty of 
the average effect, whereas the prediction intervals relate to the whole distribution of all 
effects. For example, for ICH, for the frequentist logistic regression method, the 95% CI for 
the summary OR is 0.275 to 1.050 and the 95% prediction interval for the true OR in a new 
trial is 0.239 to 1.207. 
Where the estimate of ?̂?2 has large uncertainty in the Bayesian analyses, the estimated 
prediction interval is very wide. For example, for ICH, ?̂?2 is 0.435 (95% CrI 0.002 to 3.662) for 
the logistic regression analysis. The corresponding 95% CrI for the summary OR is 0.155 to 
1.266 and the resulting 95% prediction interval for the true OR in a new trial is 0.049 to 
3.809. The wide interval reflects the large estimated τ2 combined with large uncertainty in β 
and τ. 
4.8.1 Frequentist versus Bayesian prediction intervals 
The Bayesian prediction intervals for the true ORs are considerably wider compared to the 
equivalent frequentist prediction intervals. This is because the Bayesian estimation accounts 
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for uncertainty in ?̂?2, whereas the frequentist methods do not (equation (4.20)). For example, 
using the Bayesian logistic regression method and for mortality, the 95% prediction interval 
for the true OR in a new trial is 0.261 to 4.293, whereas the 95% prediction interval for the 
OR in the frequentist logistic regression analysis is 0.632 to 1.386. 
4.8.2 Bayesian predictive probability 
The estimated probability that the true OR in a new trial will be less than one provides the 
probability that the bolus therapy will show a beneficial effect compared to the infusion 
therapy in a new trial. The predictive probability remains high for ICH, stroke, and 
reinfarction, with probability estimates of 0.7 or greater. These probabilities suggest that 
there is evidence of a potentially beneficial true treatment effect that may therefore motivate 
further investigation in a large phase III trial. The predictive probability for mortality is lower 
compared to the other outcomes, but the probability estimates are still greater than 0.50. 
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Table 4.11: Prediction results for ICH after the random-effects meta-analyses. 
Frequentist method Pooled log(OR) Pooled OR 
95% prediction interval for 
true OR in a new trial 
𝝉�2  
REML (nounc) -0.577 0.561 0.147 to 2.139 0.136  
REML -0.577 0.561 0.131 to 2.405 0.136  
ML (nounc) -0.521 0.594 0.242 to 1.456 <0.0001  
ML -0.521 0.594 0.242 to 1.456 <0.0001  
MM (nounc) -0.521 0.594 0.242 to 1.456 <0.0001  
MM -0.521 0.594 0.242 to 1.456 <0.0001  
Logistic regression -0.621 0.537 0.239 to 1.207 <0.0001  
Bayesian method Pooled log(OR) Pooled OR 
95% prediction interval for 
true OR in a new trial 
𝝉�2 (95% CrI) 
Prob (new trial 
true OR <1) 
Inverse variance* -0.615 0.541 0.065 to 3.678 0.316 (0.001 to 3.095) 0.797 
Logistic regression† -0.724 0.485 0.049 to 3.809 0.435 (0.002 to 3.662) 0.824 
nounc denotes assumption of no uncertainty in between-study variance estimate. *Prior distribution for β~N(0,10002), and τ~N(0,1)I(0,). †Prior 
distribution for β~N(0,10002), αj~N(0, 10002), and τ~N(0,1)I(0,). 
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Table 4.12: Prediction results for stroke after the random-effects meta-analyses. 
Frequentist method Pooled log(OR) Pooled OR 
95% prediction interval for true 
OR in a new trial 
𝝉�2  
REML (nounc) -0.451 0.637 0.064 to 6.389 0.648  
REML -0.451 0.637 0.063 to 6.414 0.648  
ML (nounc) -0.430 0.650 0.109 to 3.875 0.355  
ML -0.430 0.650 0.109 to 3.898 0.355  
MM (nounc) -0.425 0.654 0.122 to 3.511 0.306  
MM -0.425 0.654 0.122 to 3.511 0.306  
Logistic regression -0.375 0.688 0.348 to 1.357 <0.0001  
Bayesian method Pooled log(OR) Pooled OR 
95% prediction interval for true 
OR in a new trial 
𝝉�2 (95% CrI) 
Prob (new trial 
true OR <1) 
Inverse variance* -0.432 0.649 0.070 to 5.367 0.488 (0.002 to 3.236) 0.721 
Logistic regression† -0.486 0.615 0.052 to 5.659 0.652 (0.004 to 3.896) 0.729 
nounc denotes assumption of no uncertainty in between-study variance estimate. *Prior distribution for β~N(0,10002), and τ~N(0,1)I(0,). †Prior 
distribution for β~N(0,10002), αj~N(0, 10002), and τ~N(0,1)I(0,). 
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Table 4.13: Prediction results for reinfarction after the random-effects meta-analyses. 
Frequentist method Pooled log(OR) Pooled OR 
95% prediction interval for true 
OR in a new trial 
𝝉�2  
REML (nounc) -0.282 0.754 0.512 to 1.112 <0.0001  
REML -0.282 0.754 0.512 to 1.112 <0.0001  
ML (nounc) -0.282 0.754 0.512 to 1.112 <0.0001  
ML -0.282 0.754 0.512 to 1.112 <0.0001  
MM (nounc) -0.288 0.750 0.463 to 1.214 0.0227  
MM -0.288 0.750 0.463 to 1.214 0.0227  
Logistic regression -0.251 0.778 0.532 to 1.139 <0.0001  
Bayesian method Pooled log(OR) Pooled OR 
95% prediction interval for true 
OR in a new trial 
𝝉�2 (95% CrI) 
Prob (new trial 
true OR <1) 
Inverse variance* -0.284 0.753 0.300 to 1.879 0.066 (0.000 to 0.758) 0.814 
Logistic regression† -0.258 0.773 0.295 to 2.054 0.076 (0.000 to 0.864) 0.787 
nounc denotes assumption of no uncertainty in between-study variance estimate. *Prior distribution for β~N(0,10002), and τ~N(0,1)I(0,). †Prior 
distribution for β~N(0,10002), αj~N(0, 10002), and τ~N(0,1)I(0,). 
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Table 4.14: Prediction results for mortality after the random-effects meta-analyses. 
Frequentist method Pooled log(OR) Pooled OR 
95% prediction interval for true 
OR in a new trial 
𝝉�2  
REML (nounc) -0.045 0.956 0.355 to 2.572 0.1262  
REML -0.045 0.956 0.345 to 2.651 0.1262  
ML (nounc) -0.097 0.906 0.554 to 1.483 0.0124  
ML -0.099 0.906 0.507 to 1.618 0.0124  
MM (nounc) -0.039 0.962 0.338 to 2.736 0.1437  
MM -0.039 0.962 0.338 to 2.736 0.1437  
Logistic regression -0.066 0.936 0.632 to 1.386 <0.0001  
Bayesian method Pooled log(OR) Pooled OR 
95% prediction interval for true 
OR in a new trial 
𝝉�2 (95% CrI) 
Prob (new trial 
true OR <1) 
Inverse variance* -0.038 0.962 0.290 to 3.889 0.164 (0.000 to 1.443) 0.554 
Logistic regression† -0.008 0.992 0.261 to 4.293 0.213 (0.000 to 1.588) 0.520 
nounc denotes assumption of no uncertainty in between-study variance estimate. *Prior distribution for β~N(0,10002), and τ~N(0,1)I(0,). †Prior 




4.8.3 Bayesian prediction intervals for estimates of treatment effect in a 
new trial with a given sample size 
The previous section focussed on the predicted true treatment effect in a new trial, θinew. 
Consider now predictions for the estimated treatment effect in a new trial, Yinew. For 
simplicity, focus solely on the outcome of ICH. Under the assumption of a baseline risk of 
0.01 for ICH,201 the 95% prediction intervals for the estimated treatment effect (Yinew) for ICH, 
for various given sample sizes, are shown graphically in Figure 4.5. These results were 
obtained using the logistic regression model (equation (4.19)) and option (1) for the variance 
of the treatment effect in a new trial with a given sample size (section 4.6.3). As the sample 
size per treatment group increases, the prediction interval narrows until approximately 2000 
patients per arm where the increase in sample size reduces the width of the prediction 
interval by a negligible amount. Therefore, if a future trial is planned using the information in 
Figure 4.5, the recommendation would likely be to recruit no more than 2000 patients per 
treatment group. 
 
Figure 4.5: Prediction intervals for estimated treatment effect in a new trial (Yinew) with 
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The probability that bolus therapy will be shown to be effective in the new trial is illustrated in 
Figure 4.6, for varying chosen sample sizes and for each of options (1) and (2). This refers to 
the proportion of samples in the MCMC estimation where the CrI around the estimated Yinew 
does not contain an OR of 1. As the sample size increases, the probability of success in a 
new trial also increases, which reflects the narrower credible intervals that arise from larger 
patient numbers. Options (1) and (2) give reasonably similar results. 
When the sample size is unrealistically large (10,000,000 patients per arm), such that the 
trial is tending toward an infinite sample size, the probability of success tends to the 
probability that exp(θinew) is less than one, which equals 0.824 as noted in Table 4.11. For 
more realistic sample sizes, the probability of success is much lower. For example, with 2000 
patients in each arm of the trial the probability of success is only about 0.4. However, 
increasing to 4000 patients per arm increases the success probability to about 0.6. 
Therefore, if this figure is used to design a future trial, the recommended sample size would 
probably not exceed 4000 patients per treatment group. This information would need to be 
combined with several other factors, such as costs and prevalence of the condition of 




Figure 4.6: Probability that the upper bound of the estimated OR's 95% credible 
interval will be less than 1 in a new trial for ICH with a given sample size. 
Plots such as Figure 4.5 and Figure 4.6 could be useful for the design of a new trial to 
determine what sample size is necessary to achieve a high probability of obtaining a result 
that favours the new treatment, whilst also enabling the investigator to determine where an 
increased sample size may not provide a reduction in the variance, or an increase in the 
probability of a positive result that are large enough to justify the additional cost and time of 
recruiting the extra patients. 
4.8.4 Comparison with subsequent phase III results 
Comparing summary effects 
The comparison of phase II and phase III trial meta-analyses, by Eikelboom et al., for the 
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and their CIs. The results for ICH appear to show dramatically different conclusions between 
phase II and phase III results, whereas the results for stroke, reinfarction and mortality 
appear similar in the phase II and phase III trials. For ICH, the pooled summary OR is 0.53 
(95% CI OR: 0.27 to 1.01) for the phase II meta-analysis and 1.25 (95% CI OR: 1.06 to 1.49) 
for the phase III meta-analysis. This led Eikelboom et al. to state that the phase III trial 
results contradicted the phase II trial results, i.e. the phase III results were unexpected. 
 
Figure 4.7: Phase II and phase III meta-analyses comparison plot by Eikelboom et al.169 
 
Comparing individual phase III trial results with phase II prediction intervals 
The derived prediction intervals can also be compared to the results of the individual phase 
III trials themselves, not just their average effect. This comparison is actually more 
appropriate since the intention of the prediction intervals is to predict the true treatment effect 
(θinew) in a new study. The trial estimates from four of the subsequent phase III trials in 
AMI193-196 are displayed in and Table 4.16 (results from the other two trials from the original 
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paper were not accessible for use in this chapter). In contrast to the phase II trials, only some 
point estimates are in favour of bolus therapy compared to infusion therapy, whereas others 
are in favour of infusion therapy. Figure 4.8 shows the log OR estimates and their 95% CIs 
for ICH in the four phase III trials and compares them to the 95% prediction interval for θinew 
from the phase II meta-analysis using the Bayesian inverse variance method and frequentist 
maximum likelihood. Figure 4.9 to Figure 4.11 are similar plots for stroke, reinfarction and 
mortality. 
The estimated ORs for ICH, stroke, reinfarction and mortality in the subsequent phase III 
trials are supported by Bayesian and frequentist prediction intervals from the phase II meta-
analysis (Figure 4.8 to Figure 4.11, Table 4.11 to Table 4.14). Therefore, if one had used the 
prediction intervals using the phase II trials, then all the subsequent phase III trial results 
were plausible. This contradicts Eikelboom et al. who considered them to be unexpected, but 
they ignored heterogeneity and uncertainty, and this has now been accounted for, 
particularly for the Bayesian models. 
Summary 
In summary, this work enhances the work of Eikelboom et al. and shows that after a phase II 
meta-analysis, the 95% prediction interval for the true treatment effect in a new trial (or the 
estimated treatment effect in a new trial) should be used to help decide whether to proceed 
to phase III, rather than just the 95% CI of the summary pooled estimate. The pooled 
estimate relates to the average effect across all trials, but a single trial’s treatment effect may 




Table 4.15: Phase III randomised trials of bolus vs. infusion thrombolytic therapy in AMI. 
Trial Bolus (No. of boluses) Infusion N (Bolus) N (Infusion) Length of follow-up 
INJECT,193 1995 Reteplase, 10 MU (2) Streptokinase, 1.5 MU 2992 2994 35 days 
COBALT,194 1997 Alteplase, 40-50 mg, (2) Alteplase, 100 mg 3584 3585 30 days 
GUSTO III,195 1997 Reteplase, 10 MU (2) Alteplase, up to 100 mg 4921 10138 30 days 
ASSENT-2,196 1999 Tenecteplase 30-50 mg (1) Alteplase, 100 mg 8488 8461 30 days 
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Table 4.16: Results from subsequent randomised phase III trials comparing bolus to infusion thrombolytic therapy for the in-
hospital treatment of AMI. 
Outcome Phase III trial No. of events on bolus/N (%) 
No. of events on infusion/N 
(%) 
OR 95% CI OR 
ICH 
INJECT193 23 / 3004 (0.8) 11 / 3006 (0.4) 2.092 1.018 - 4.300 
COBALT194 40 / 3585 (1.1) 29 / 3584 (0.8) 1.379 0.853 to 2.229 
GUSTO III195 92 / 10138 (0.91) 43 / 4921 (0.87) 1.039 0.722 to 1.494 
ASSENT-2196 79 / 8461 (0.9) 80 / 8488 (0.9) 0.991 0.725 to 1.354 
Stroke 
INJECT 14 / 3004 (0.5) 19 / 3006 (0.6) 0.737 0.369 to 1.474 
COBALT 31 / 3585 (0.86) 25 / 3584 (0.7) 1.240 0.730 to 2.104 
GUSTO III 61 / 10138 (0.6) 37 / 4921 (0.7) 0.800 0.531 to 1.206 
ASSENT-2 72 / 8461 (0.85) 61 / 8488 (0.72) 1.184 0.841 to 1.668 
Reinfarction 
INJECT 150 / 3004 (5.0) 162 / 3006 (5.4) 0.927 0.738 to 1.164 
COBALT 140 / 3585 (3.9) 147 / 3584 (4.1) 0.952 0.752 to 1.206 
GUSTO III 426 / 10138 (4.2) 207 / 4921 (4.2) 0.999 0.843 to 1.183 
ASSENT-2 347 / 8461 (4.1) 323 / 8488 (3.8) 1.078 0.923 to 1.258 
Mortality 
INJECT 270 / 3004 (9.0) 285 / 3006 (9.5) 0.948 0.797 to 1.128 
COBALT 286 / 3585 (8.0) 270 / 3584 (7.5) 1.059 0.891 to 1.259 
GUSTO III 757 / 10138 (7.47) 356 / 4921 (7.24) 1.032 0.906 to 1.176 




Figure 4.8: Comparison of prediction intervals for θinew from a phase II meta-analysis 
with the estimate and 95% CI for the ln(OR) from phase III trials for ICH. 
 
Figure 4.9: Comparison of prediction intervals for θinew from a phase II meta-analysis 
with the estimate and 95% CI for the ln(OR) from phase III trials for stroke. 
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Figure 4.10: Comparison of prediction intervals for θinew from a phase II meta-analysis 
with the estimate and 95% CI for ln(OR) from phase III trials for reinfarction. 
 
Figure 4.11: Comparison of prediction intervals for θinew from a phase II meta-analysis 
with the estimate and 95% CI for the ln(OR) from phase III trials for mortality. 
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4.9 Results III: Assessment of publication bias 
A concern is that phase II trials are prone to bias, especially in the reporting of their results. 
Publication bias is an issue that occurs if studies with more favourable results are more likely 
to be published than those with less favourable results. Other types of bias related to 
publication bias can also occur, such as language bias and selective outcome reporting bias. 
These forms of bias can lead to potentially distorted results.202 The threat of publication bias 
can be explored with funnel plots of study standard error of log(OR) versus log(OR) for each 
outcome. If there is no publication bias the assumption is that the studies should be 
symmetrically distributed about the summary estimate of the effect size in a funnel-like 
shape. Eikelboom et al. suggest that for the AMI trials there is evidence of publication bias 
shown in the funnel plot in Figure 4.12. However, this plot includes the study estimates from 
the phase II and phase III trials all together. This may not be appropriate if the summary 
effect estimate is different for the phase II and phase III trial meta-analyses since the funnel 





Figure 4.12: Funnel plot of 1/SE(log(OR)) versus OR for ICH for phase II and phase III 
trials. 
(Note: The dotted line represents the summary treatment effect estimate for ICH from the 
Bayesian random-effects logistic regression analysis of the phase II trials; the dashed line 
indicates the summary treatment effect estimate for ICH by Eikelboom et al. for the phase III 
trials. The OR axis is shown on the log-scale.) 
Therefore, separate funnel plots are now shown for the phase II trials only for each outcome 
in Figure 4.13 to Figure 4.16. They all suggest there is no clear evidence of publication bias 
since the studies with high standard error are observed equally in both directions of the 
summary effect estimate (the summary estimate shown in the figures corresponds to the 
Bayesian random-effects logistic regression analysis of the phase II trials). Therefore, these 
results cast doubt on the conclusion by Eikelboom et al. that publication bias could be a 





Figure 4.13: Funnel plot of 1/SE(log(OR)) vs. log(OR) for ICH in phase II trials. 
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Figure 4.15: Funnel plot of 1/SE(log(OR)) vs. log(OR) for reinfarction in phase II trials. 
 






























4.10 Results IV: What if we thought the phase II results have 
occurred by chance? 
Although section 4.9 suggests there is no clear evidence of publication bias, the phase II trial 
results may still be optimistic compared to the results in the subsequent phase III trials. The 
results of the individual phase III trials in Table 4.16 show that the treatment effect estimates 
are lower, with ORs closer to one, than those from the phase II trials (Table 4.2). 
Hypothetically, if the difference in risk between the treatment arms in the phase II trials has 
occurred by chance, it may be important to account for this optimism in the predictions of 
phase III results. Further, even if they are always published, phase II trials may be more 
prone to bias in their design, execution, analysis, and reporting, which may also cause 
optimistic summary meta-analysis results for phase II trials. 
It is possible to limit the potential optimism in phase II trials by using a Bayesian meta-
analysis and estimating the predictive probability that the true OR in a new trial will be less 
than 0.9 or 0.8, rather than less than 1, which is essentially a more stringent criterion for 
success. The results for reinfarction, as an example, are shown in Table 4.17. 
The optimism can also be accounted for with a sceptical prior distribution on the pooled 
treatment effect that does not allow for large treatment effects.22 In a paper by Higgins & 
Spiegelhalter204, they considered a sceptical prior distribution on the pooled log OR such that 
there is little chance (5%) that the new treatment would reduce the odds of myocardial 
infarction by more than 25%. This results in a normal distribution for the log OR which is 
centred on zero and has variance 0.03. The results for reinfarction, assuming this sceptical 
prior distribution, are also shown in Table 4.17. 
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Table 4.17: Accounting for potential optimism in phase II trials in Bayesian meta-analysis: results for reinfarction. 
Method 
Summary OR from phase II 
meta-analysis 
95% prediction interval 
new trial OR 
Prob (new trial 
OR <1) 
Prob (new trial OR 
<0.9) 
Prob (new trial 
OR <0.8) 
Inverse variance      
Vague prior 0.753 0.300 to 1.879 0.814 0.719 0.580 
Sceptical prior 0.882 0.391 to 2.109 0.701 0.548 0.362 
Logistic regression      
Vague prior 0.773 0.295 to 2.054 0.787 0.692 0.545 




Probability of an OR<0.9 
As expected, the estimated probability that the pooled OR is less than 0.9 or less than 0.8 is 
lower compared to the estimated probability that the OR is less than 1. For example, for the 
logistic regression model with random-effects and using the vague prior distributions (model 
(4.19)), the estimated probability that the true OR in a new trial is less than one is 0.787 
compared to 0.692 for the probability that the true OR in a new trial is less than 0.9. If the 
conclusion to progress to Phase III is based on this probability of a larger summary treatment 
effect then this may alter the decision here. 
Prediction interval following sceptical prior 
The 95% prediction intervals for the true OR in a new trial, assuming the sceptical prior 
distribution for log OR, are closer to one compared to the results that assume the vague 
prior. For example, for the logistic regression model assuming the vague prior distribution, 
the 95% prediction interval for the true OR is 0.295 to 2.054. Whereas, assuming the 
sceptical prior distribution, the prediction interval is 0.381 to 2.218. Also, the predictive 
probabilities that the true OR is less than 1, 0.9, and 0.8, are lower for the sceptical prior 
distribution analysis compared to the vague prior analysis. For example, for the vague prior 
logistic regression analysis, the predictive probabilities are 0.787, 0.692, and 0.545, for the 
probability that the true OR is less than 1, 0.9, and 0.8, respectively. However, these 
probability estimates are 0.682, 0.531, and 0.348 when the sceptical prior distribution for the 
log OR is assumed. This again may alter the decision to proceed to phase III. The posterior 
distributions for the true treatment effect in a new study, using the vague and sceptical prior 
distributions for the pooled treatment effect, and the logistic regression model, are shown in 




Figure 4.17: Posterior distributions for the treatment effect (log(OR)) in a new trial for 




This example shows that potential bias and optimism can be considered in the inference of 
results from a meta-analysis from phase II trials. The Bayesian framework can limit such bias 
through sceptical prior distributions and by estimating probabilities of a larger treatment 
effectiveness. 
AUC: Prob(decreased odds reinfarction)=0.68
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4.11 Results V: choice of prior distribution for between-study 
variance 
As there are only nine trials in the phase II meta-analysis, a concern is the potential influence 
of prior distributions in the Bayesian analyses. So far, all the Bayesian analyses have used a 
prior distribution for the between-study standard deviation of N(0,1)I(0,). The results of the 
sensitivity analysis for the prior distribution for the between-study variance, using the 
random-effects logistic regression model, are shown in Table 4.18 for the pooled results, and 
Table 4.19 for the prediction results, for mortality. Table 4.20 and Table 4.21 show the 
corresponding results for ICH. For mortality in the logistic regression model using 
τ~N(0,1)I(0,), ?̂?2 is 0.213 (95% CrI: 0.000 to 1.588), whereas for ICH ?̂?2 is 0.435 (95% CrI: 
0.002 to 3.662). The sensitivity analysis considers 14 different prior distributions for the 
between-study variance (Table 4.5). 
For mortality, the summary results for the log OR are similar for all prior distributions. The 
standard deviation of the pooled log OR, and the estimate of τ2, vary slightly for the different 
priors, which results in different CrI for the summary log(OR). For example, the standard 
deviation of the pooled log OR is 0.432 for prior 4a, whereas it is 0.230 for prior 3a. The 
median estimate of τ2 for prior 4a is 0.663 (95% CrI 0.043 to 5.632), whereas for prior 3a, the 
median is 0.018 (95% CrI 0.000 to 1.157). The 95% CrI for the summary OR is 0.462 to 
2.521 for prior 4a, whereas the CrI is 0.636 to 1.578 for prior 3a. 
For ICH, the summary results are also similar for the log OR. Figure 4.18 shows the posterior 
distribution of the true treatment effect in a new trial (θinew) for priors 2 and 6b. However, 
compared to the results for mortality, the differences in the estimated standard error of 
log(OR) and ?̂?2 between the 14 prior distributions are larger. For example, for prior 3a the 
standard deviation of the pooled log OR is 0.505, whereas for prior 1b it is 0.917. The 
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median estimate of τ2 for prior 3a is 0.028 (95% CrI 0.000 to 5.606), whereas for prior 1b, the 
median is 1.421 (95% CrI 0.007 to 26.53). The 95% CrI for the summary OR is 0.175 to 
1.216 for prior 3a, whereas the CrI is 0.056 to 2.039 for prior 1b. The prior distribution also 
has a large effect on the prediction interval for ICH. For prior 3a the 95% prediction interval 
for the true OR in a new trial is 0.065 to 2.945, whereas for prior 1b the interval is 0.004 to 
30.27. 
 
Figure 4.18: Posterior distribution for the true treatment effect in a new trial (θinew) for 
ICH assuming two different prior distributions for the heterogeneity parameter. 
The differences in the standard error and between-study variance estimates are partly due to 
the varying degree of information in the prior distribution because there is always some 
information, even in a supposedly vague distribution. The differences also arise because the 
prior distribution is placed on different scales, which include the standard deviation, variance, 
log(variance) and precision. The results for ICH and mortality show that it may also arise due 
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to the size of ?̂?2 and the uncertainty of this estimate, as the results are more sensitive for ICH 
compared to mortality. 
Perhaps most importantly, for either mortality or ICH, the probability that the average OR and 
the true OR in a new trial are less than one is similar for most of the prior distributions for 
both outcomes. The probabilities for Prior 3a and 3b and 7a (or 7b) are slightly higher 
compared to the remaining prior distributions. Empirical priors 7a and 7b were, however, 
developed for use in meta-analysis of phase III trials, and thus may not reflect the greater 
magnitude of heterogeneity that is expected in phase II trials. 
In summary, although the prior distribution is intended to be vague and thus not influence the 
results, Table 4.18 to Table 4.21 show that a vague prior distribution may still contribute 
substantially to the meta-analysis results when there is only a small amount of data,29 which 
is the case in a meta-analysis of phase II trials. The prior distribution for the between-study 
uncertainty must be selected with caution and a sensitivity analysis is advisable to ensure the 
results are not influenced by the choice this distribution. Prediction probabilities for the true 




Table 4.18: Results of sensitivity analysis on prior distribution for between-study variance for pooled results for mortality using 
random-effects logistic regression model. 
Prior distribution for τ Log(OR) SE(log(OR)) Summary OR 95% CrI OR 𝝉�𝟐 (95% CrI) Prob summary OR<1 
1a: τ~Unif(0,10) 0.008 0.322 1.008 0.565 to 2.044 0.278 (0.001 to 2.734) 0.488 
1b: τ~Unif(0,100) 0.008 0.322 1.008 0.565 to 2.045 0.278 (0.001 to 2.739) 0.488 
1c: τ~Unif(0,2) -0.002 0.313 0.998 0.565 to 1.995 0.278 (0.001 to 2.352) 0.502 
2: 1/τ2 ~ Gamma(0.1, 0.1) 0.018 0.307 1.018 0.578 to 1.961 0.295 (0.047 to 1.961) 0.474 
3a: Log(τ2)~Unif(-10,10) -0.039 0.230 0.961 0.636 to 1.578 0.018 (0.000 to 1.157) 0.577 
3b: Log(τ2)~Unif(-10,1.386) -0.043 0.229 0.958 0.644 to 1.585 0.020 (0.000 to 1.113) 0.585 
4a: τ2~Unif(0.001,1000) 0.036 0.432 1.037 0.462 to 2.521 0.663 (0.043 to 5.632) 0.456 
4b: τ2~Unif(0.001,4) 0.037 0.379 1.038 0.504 to 2.350 0.614 (0.040 to 3.172) 0.453 
5a: 1/ τ2~Pareto(1,0.001) 0.039 0.421 1.040 0.465 to 2.508 0.641 (0.043 to 5.379) 0.453 
5b: 1/ τ2~Pareto(1,0.25) 0.040 0.382 1.041 0.501 to 2.370 0.614 (0.041 to 3.165) 0.451 
6a: τ~N(0,100)I[0,] 0.010 0.324 1.010 0.562 to 2.044 0.285 (0.001 to 2.750) 0.484 
6b: τ~N(0,1)I[0,]* -0.008 0.283 0.992 0.599 to 1.843 0.213 (0.000 to 1.588) 0.513 
7a: τ2~logN(-4.06,1.452) -0.050 0.192 0.952 0.664 to 1.411 0.021 (0.001 to 0.300) 0.604 
* Primary prior distribution for between-study variance. 
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Table 4.19: Results of sensitivity analysis on prior distribution for between-study variance for prediction intervals for true 
treatment effect for mortality using random-effects logistic regression model. 
Prior distribution for τ 95% prediction interval new trial OR Prob (new trial OR<1) 
1a: τ~Unif(0,10) 0.205 to 5.786 0.504 
1b: τ~Unif(0,100) 0.205 to 5.800 0.504 
1c: τ~Unif(0,2) 0.208 to 5.518 0.516 
2: 1/τ2 ~ Gamma(0.1, 0.1) 0.231 to 5.035 0.493 
3a: Log(τ2)~Unif(-10,10) 0.396 to 2.765 0.577 
3b: Log(τ2)~Unif(-10,1.386) 0.396 to 2.725 0.585 
4a: τ2~Unif(0.001,1000) 0.102 to 11.80 0.486 
4b: τ2~Unif(0.001,4) 0.134 to 9.041 0.485 
5a: 1/ τ2~Pareto(1,0.001) 0.102 to 11.44 0.484 
5b: 1/ τ2~Pareto(1,0.25) 0.132 to 9.057 0.483 
6a: τ~N(0,100)I[0,] 0.202 to 5.854 0.501 
6b: τ~N(0,1)I[0,]* 0.261 to 4.293 0.520 
7a: τ2~logN(-4.06,1.452) 0.536 to 1.797 0.585 
* Primary prior distribution for between-study variance. 
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Table 4.20: Results of sensitivity analysis on prior distribution for between-study variance for pooled results for ICH using 
random-effects logistic regression model. 
Prior distribution for τ Log(OR) SE(log(OR)) Summary OR 95% CrI OR 𝝉�𝟐 (95% CrI) Prob summary OR<1 
1a: τ~Unif(0,10) -0.785 0.877 0.456 0.059 to 2.055 1.380 (0.004 to 24.78) 0.892 
1b: τ~Unif(0,100) -0.785 0.917 0.456 0.056 to 2.039 1.421 (0.007 to 26.53) 0.893 
1c: τ~Unif(0,2) -0.755 0.579 0.470 0.135 to 1.403 0.838 (0.004 to 3.685) 0.923 
2: 1/τ2 ~ Gamma(0.1, 0.1) -0.766 0.657 0.465 0.114 to 1.472 0.681 (0.060 to 9.896) 0.919 
3a: Log(τ2)~Unif(-10,10) -0.638 0.505 0.529 0.175 to 1.216 0.028 (0.000 to 5.608) 0.946 
3b: Log(τ2)~Unif(-10,1.386) -0.695 0.436 0.499 0.201 to 1.086 0.019 (0.000 to 2.735) 0.960 
4a: τ2~Unif(0.001,1000) -0.916 1.723 0.400 0.009 to 6.323 5.001 (0.193 to 128.8) 0.834 
4b: τ2~Unif(0.001,4) -0.800 0.652 0.449 0.113 to 1.525 1.581 (0.086 to 3.839) 0.908 
5a: 1/ τ2~Pareto(1,0.001) -0.911 1.586 0.402 0.012 to 5.289 4.507 (0.170 to 107.2) 0.840 
5b: 1/ τ2~Pareto(1,0.25) -0.806 0.657 0.447 0.113 to 1.560 1.587 (0.086 to 3.842) 0.904 
6a: τ~N(0,100)I[0,] -0.798 0.914 0.450 0.060 to 2.031 1.383 (0.008 to 26.87) 0.898 
6b: τ~N(0,1)I[0,]* -0.724 0.524 0.485 0.155 to 1.266 0.435 (0.002 to 3.662) 0.937 
7b: τ2~logN(-3.02,1.852) -0.652 0.371 0.521 0.244 to 1.051 0.052 (0.009 to 0.295) 0.965 
* Primary prior distribution for between-study variance. 
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Table 4.21: Results of sensitivity analysis on prior distribution for between-study variance for prediction intervals for true 
treatment effect for ICH using random-effects logistic regression model. 
Prior distribution for τ 95% prediction interval new trial OR Prob (new trial OR<1) 
1a: τ~Unif(0,10) 0.004 to 28.95 0.753 
1b: τ~Unif(0,100) 0.004 to 30.27 0.749 
1c: τ~Unif(0,2) 0.032 to 5.751 0.788 
2: 1/τ2 ~ Gamma(0.1, 0.1) 0.021 to 7.938 0.787 
3a: Log(τ2)~Unif(-10,10) 0.065 to 2.945 0.888 
3b: Log(τ2)~Unif(-10,1.386) 0.094 to 2.097 0.907 
4a: τ2~Unif(0.001,1000) 0.000 to 1788.0 0.671 
4b: τ2~Unif(0.001,4) 0.020 to 8.652 0.741 
5a: 1/ τ2~Pareto(1,0.001) 0.000 to 970.6 0.677 
5b: 1/ τ2~Pareto(1,0.25) 0.020 to 8.496 0.742 
6a: τ~N(0,100)I[0,] 0.004 to 29.93 0.753 
6b: τ~N(0,1)I[0,]* 0.049 to 3.809 0.824 
7b: τ2~logN(-3.02,1.852) 0.203 to 1.260 0.929 




This chapter has considered many possible statistical methods for meta-analysis of phase II 
trials, and shown how the results may be used to make predictions and thus inform decisions 
about new phase III trials. Key findings of the work are summarized in Figure 4.19, and it has 
raised a number of interesting questions, which are now discussed. The work has recently 
been published in the journal Trials27 (Appendix B3). 
4.12.1 Is a meta-analysis useful to the phase III trial decision? 
The decision to progress to phase III is based on all existing evidence, which includes 
information other than the results of phase II trials, such as cost and feasibility. However, if 
multiple phase II trials exist, a meta-analysis of the phase II trials should be considered 
important. The work in this chapter shows how univariate meta-analysis of phase II trials can 
inform the decision by summarizing existing evidence and predicting treatment effects in new 
trials. The Bayesian approach appears most natural for this as it accounts for all parameter 
uncertainty in the predictions and estimation. 
A meta-analysis of phase II trials can also reveal the large uncertainty upon which the phase 
III trial decision is based, even after the results of the individual trials have been pooled. For 
example, for stroke, the median OR is 0.615 with a 95% CrI 0.201 to 1.578 (using a 
Bayesian random-effects logistic regression model). The 95% prediction interval for the true 
treatment effect in a new trial, using the same estimation method, is wider than the CrI from 
0.052 to 5.659. The small sample sizes in phase II trials, and the rare event rate in these 
particular trials, combined with large between-trial heterogeneity in treatment effects, are the 
key contributing factors to the large uncertainty in this prediction. 
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Figure 4.19: Key findings. 
• It is difficult to examine and quantify heterogeneity in a meta-analysis of phase II trials due to 
the small number of studies and the small number of patients within studies. 
• Bayesian credible intervals (and prediction intervals) are wider compared to the equivalent 
frequentist intervals because the Bayesian model accounts for more uncertainty compared to 
the frequentist approach. 
• Prediction intervals for the true (or estimated) treatment effect in a new study should be 
derived to help consider whether to proceed to phase III rather than just considering the 95% 
CI of the summary pooled estimate. 
• Bayesian meta-analysis additionally allows us to estimate probabilities regarding parameters 
of interest, which can contribute to phase III trial decisions, such as the probability the 
treatment is truly effective in a new trial, or the probability, in a new trial with a given sample 
size, that the CrI of the estimated treatment effect will not contain the null value. 
• Bayesian meta-analysis methods can limit potential bias and optimism in the prediction 
intervals from phase II results through sceptical prior distributions and by estimating 
probabilities of more stringent or large treatment effectiveness. 
• Prior distributions for heterogeneity in Bayesian meta-analysis can influence the summary 
results when there are few phase II trials, and so sensitivity analysis to the choice of prior is 
recommended and consideration of empirical prior distributions for the size of heterogeneity in 
previous phase II meta-analyses. 
 
The analysis in Section 4.8 has shown that 95% prediction intervals for the true treatment 
effect in a new trial may help the decision process to proceed to phase III because the 
intervals consider the potential effect of the new treatment when it is applied in a new 
individual study, i.e. a phase III trial, rather than the uncertainty of the average treatment 
effect that is calculated in a 95% CI. For example, for reinfarction, the 95% CIs for the OR 
are narrow and only just include one (95% CI OR using REML: 0.546 to 1.041), which 
suggests strong evidence that the bolus therapy reduces the risk of reinfarction compared to 
infusion therapy on average. However, the 95% prediction intervals include values larger 
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than one, so although on average the bolus therapy seems effective, it may not always be 
beneficial in an individual trial or population (95% prediction interval for true OR using MM: 
0.463 to 1.214). 
4.12.2 Advantages of Bayesian meta-analysis compared to meta-
analysis in a frequentist framework 
Bayesian probability estimates can aid the decision to proceed to phase III by properly 
quantifying the uncertainty in the results. For example, for reinfarction, the probability that the 
true OR in a new trial will be less than one is estimated at 0.814 (using the inverse variance 
method). This large probability may encourage the decision to proceed to phase III. Likewise, 
the probability estimates can also reveal the uncertainty in the treatment effect estimates, 
such as for mortality. The probability that the true OR is less than one for this outcome is 
estimated to be 0.554 (using the inverse variance method), which suggests that there is large 
uncertainty as to whether the new treatment will reduce the risk compared to the standard 
treatment. Decision-makers and pharmaceutical companies may be less inclined to spend 
investments when probabilities are this low. 
The Bayesian framework naturally incorporates uncertainty in the summary results and the 
between-trial variance. This leads to prediction intervals that can account for more of the 
uncertainty, and thus are wider, compared to the frequentist equivalent, which assumes that 
the between-trial variance is fixed. Frequentist methods that inflate the standard error of the 
pooled effect estimate to account for the uncertainty in the between-study variance still have 
narrower prediction intervals compared to the Bayesian prediction intervals. 
The Bayesian framework can also account for any potential bias or optimism by adopting 
methods such as estimating probabilities of large treatment effectiveness, or assuming 
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sceptical prior distributions when calculating prediction intervals. The quality of the phase II 
trials was not formally evaluated in this chapter, but this could also be done to identify the 
higher quality phase II trials. Funnel plots can also be used to check for small study effects 
and potential publication bias, but this did not appear to be an issue for the AMI phase II 
trials available. 
4.12.3 Quantifying heterogeneity in phase II meta-analysis 
The estimates of the Q-statistic, I2 and τ2 show that it is difficult to quantify and examine the 
potential heterogeneity in a meta-analysis of phase II trials due to the small sample sizes, 
which causes low power and large within-study variation. I2 is always likely to be small when 
within-study variances are large and p-values from the Q-test are unlikely to reach 
significance given less than 10 trials, even when heterogeneity truly exists. Since these 
phase II trials have small patient numbers and have been conducted separately it is likely 
that there is heterogeneity that needs to be accounted for, and so researchers may decide, a 
priori, that a random-effects model will be used. 
4.12.4 Recommendations for undertaking phase II meta-analyses of 
binary outcomes 
The choice of meta-analysis methods can influence the decision about whether to proceed to 
phase III. Table 4.22 summarises the recommendations for good practice within meta-
analysis of phase II trials with binary outcomes. The logistic regression approach is 
recommended because there is no need to add a continuity correction given a zero count in 
one treatment, and it avoids the need to approximate the observed data by a normal 
distribution,184,205,206 which is unlikely to be appropriate when the event rate is rare.   
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Use a logistic regression model to model the binomial distribution of the data 
within studies, and to avoid continuity corrections given a zero event in one 
arm. 
Choice of model 
Do not make decisions to use a fixed-effect or a random-effects model based 
on I2 or tests for heterogeneity. 
Heterogeneity 
State a priori that a random-effects model will be used to account for 
heterogeneity in treatment effects. 
Prediction intervals 
Report 95% prediction intervals as they reveal the potential treatment effect 
in a new population, and inform subsequent phase III decisions. 
Bias 
Use sceptical prior distributions for the treatment effect if there is evidence to 
suggest the phase II trials may be biased in favour of the treatment. 
 
4.12.5 Relevance of this work to recent meta-analyses of phase II 
trials 
This chapter has focussed on the meta-analysis of phase II trials conducted by Eikelboom et 
al.169 in which they ignored heterogeneity by using a fixed-effect model. There are other 
examples, in more recent years, where the method for meta-analysing phase II studies could 
be improved similarly. In particular, the decision to use a fixed-effect or a random-effects 
model is often based on the p-value derived from the Q statistic chi-squared test for 
heterogeneity,41 and/or the I2 statistic.207-210 The fixed-effect model is selected if the p-value is 
not statistically significant and/or the I2 is low. However, if there are few studies there is very 
low power to detect heterogeneity, and therefore a significant p-value is unlikely in the meta-
analysis of phase II trials. Thus, genuine heterogeneity may be ignored. Similarly, the 
example in AMI in this chapter showed low values of I2 are also potentially misleading for 
phase II meta-analysis. 
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There are two known meta-analyses of phase II trials where the authors decided a priori that 
a random-effects model was more appropriate because of the expectation that the studies 
would estimate different, yet related, treatment effects.211,212 However, in these and other 
articles using a random-effects model, the conclusions only focussed on the pooled estimate 
of treatment effect, and the prediction interval for the treatment effect in a new trial was not 
considered.207-212 Thus, the full uncertainty of the potential treatment effect in new 
populations (or phase III trials) is often ignored. 
4.12.6 Further work 
This chapter has explored the use of univariate meta-analysis of the comparison between 
bolus therapy and infusion therapy, which assumes that the treatment effect is independent 
for the four outcomes. However, the effect of the treatment may be correlated for the 
outcomes and a multivariate meta-analysis can account for this. A multivariate approach 
allows the joint synthesis of all the outcomes, which can use more statistical information, and 
joint inferences can be made for multiple outcomes. Therefore, Chapter 5 is an exploration of 
the use of multivariate meta-analysis on the same dataset in AMI. 
In the sensitivity analysis for the prior distribution for the between-study variance in the 
random-effects meta-analysis model, two empirical prior distributions were considered that 
were derived by Turner et al.36 for a future meta-analysis with a binary outcome. Empirical 
prior distributions have been derived for several health-care settings, for both binary36 and 
continuous outcomes.38 However, they have not been considered specifically in the context 
of phase II trial meta-analysis, therefore further work is needed to consider whether the 




Univariate meta-analysis of phase II trials can inform phase III trial decisions. A frequentist or 
Bayesian framework can be applied, a fixed-effect or random-effects approach can be 
assumed, and multiple estimation methods can be adopted. These choices can influence the 
decision about whether to proceed to phase III and thus need to be clearly documented and 
investigated whenever a phase II meta-analysis is performed. 
Eikelboom et al. originally applied a fixed-effect Mantel-Haenszel meta-analysis of phase II 
trials and compared the results to a meta-analysis of subsequent phase III trials. They 
concluded that there were conflicting results between the two meta-analyses for ICH. 
However, in this chapter, random-effects meta-analysis with estimated prediction intervals 




CHAPTER 5:  MULTIVARIATE META-ANALYSIS OF PHASE 
II TRIALS WITH MULTIPLE OUTCOMES 
5.1 Context and objective 
The previous chapter investigated the use of univariate meta-analysis when there are 
multiple phase II studies in order to account for all available evidence when planning a phase 
III trial. However, if there are multiple outcomes in these trials, a multivariate meta-analysis 
approach may be more statistically efficient as it can account for correlation between the 
outcomes.213 For example, overall survival is likely to be correlated to progression-free 
survival; therefore a bivariate meta-analysis of both outcomes is potentially more efficient 
than separate meta-analyses, as the correlation provides additional information to the 
estimation of both outcomes.214,215 However, although appealing, multivariate meta-analyses 
are often rejected in favour of separate univariate meta-analyses, due to the added 
complexity of the multivariate approach and the requirement to specify correlations, which 
are often unknown. 
The objective of this chapter is to consider the use of multivariate meta-analysis in the 
context of Phase II trials with multiple outcomes. In particular, to examine how results from a 
Bayesian multivariate meta-analysis can be used to estimate the probability that the 
treatment is effective for each outcome separately or across combinations of the outcomes. 
Furthermore, to evaluate whether the multivariate approach adds value over the univariate 
approach from Chapter 4, in regards to predicting treatment efficacy in new (phase III) trials. 
Thus, this chapter evaluates the benefits and limitations of multivariate meta-analysis of 
phase II trials, and shows how they can be useful toward phase III decisions. The chapter will 
also explore how applicable the multivariate meta-analysis approach is in the setting of 
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phase II trials. The focus here is on bivariate meta-analysis approaches, which is a joint 
meta-analysis of two outcomes. The bivariate results will be compared to the univariate 
meta-analysis results, of Chapter 4, to determine the impact of borrowing strength and 
accounting for potential correlation between outcomes, and to determine: (i) whether the 
conclusions remain the same if the correlations are accounted for; (ii) how the posterior 
probabilities for each outcome’s treatment effect are affected jointly; and (iii) whether joint 
probability estimates across both outcomes can further aid the decision to conduct a phase 
III trial. 
5.2 Clinical data and multiple outcomes of interest 
The clinical example in this chapter is the same nine randomised controlled phase II trials 
that were used to explore univariate meta-analysis methods in Chapter 4.169 These phase II 
trials evaluated the efficacy of bolus thrombolytic therapy compared with standard infusion 
therapy for the in-hospital treatment of acute myocardial infarction (AMI). The trials are used 
to examine multivariate meta-analysis methods for combining small phase II trials. They are 
also used to predict phase III trial results. The clinical objective of the meta-analysis is to 
assess if there is any difference in the risk of adverse event outcomes for patients who 
receive bolus therapy compared to those patients that receive infusion therapy. The hope is 
that bolus therapy reduces odds of the adverse event compared to those that receive 
infusion therapy, and if so, further phase III research might be funded to demonstrate this 
formally. As seen in Chapter 4, for all results in this chapter, an odds ratio (OR) less than one 
indicates that those patients who receive bolus therapy have lower odds of the event 
compared to those that receive infusion therapy. 
The multiple outcomes of interest in this chapter are three serious adverse events that were 
examined in Chapter 4: stroke, reinfarction, and mortality. The primary objective is to explore 
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the use of a bivariate meta-analysis of stroke and mortality. These outcomes are selected as 
the primary focus because treatment effects for stroke are likely to be correlated with 
treatment effects for mortality; also, if a patient has had a stroke they may have a higher risk 
of mortality.216. Further, stroke is missing for one study, which allows one to utilise correlation 
by borrowing strength from the data for mortality when estimating the treatment effect for 
stroke. A secondary analysis explores the bivariate meta-analysis of reinfarction and 
mortality. The data from the original nine papers of the phase II randomised trials is shown in 




Table 5.1: Incidence of stroke, reinfarction, and mortality in nine phase II trials of bolus vs. infusion thrombolytic therapy in 
AMI.171-179 
Trial 
Sample size, N 
Outcome 
No. of events (%) 
Log(OR) Var(log(OR)) OR 95% CI OR 
Bolus Infusion Bolus Infusion 
RAPID,171 1995 452 154 
Stroke 1 (0.7) 6 (3.9) -1.80 0.51 0.17 0.04 to 0.67 
Reinfarction 20 (4.4) 7 (4.5) -0.03 0.20 0.97 0.40 to 2.35 
Mortality 20 (4.4) 6 (3.9) 0.13 0.23 1.14 0.45 to 2.90 
RAPID-II,172 1996 169 155 
Stroke 3 (1.8) 4 (2.6) -0.38 0.60 0.68 0.15 to 3.10 
Reinfarction 8 (4.7) 7 (4.5) 0.05 0.28 1.05 0.37 to 2.97 
Mortality 7 (4.1) 13 (8.4) -0.75 0.23 0.47 0.18 to 1.22 
Kawai et al.,173 1997 97 102 
Stroke - - - - - - 
Reinfarction 4 (4.1) 7 (6.9) -0.54 0.41 0.58 0.17 to 2.06 




Stroke 0 (0) 1 (1.9) -1.08 2.71 0.34 0.01 to 8.54 
Reinfarction 5 (10.0) 7 (13.4) -0.34 0.39 0.71 0.21 to 2.42 
Mortality 0 (0) 1 (1.9) -1.08 2.71 0.34 0.01 to 8.54 
BASE,175 1998 139 53 
Stroke 2 (1.4) 0 (0) 0.67 2.43 1.95 0.09 to 41.19 
Reinfarction 9 (6.5) 1 (1.9) 1.28 1.14 3.60 0.44 to 29.13 
Mortality 10 (7.2) 2 (3.8) 0.68 0.63 1.98 0.42 to 9.34 
DOUBLE,176 1998 224 237 
Stroke 6 (2.7) 2 (0.8) 1.17 0.68 3.23 0.65 to 16.19 
Reinfarction 5 (2.2) 12 (5.1) -0.85 0.29 0.43 0.15 to 1.24 




Sample size, N 
Outcome 
No. of events (%) 
Log(OR) Var(log(OR)) OR 95% CI OR 
Bolus Infusion Bolus Infusion 
lnTIME,177 1998 478 124 
Stroke 0 (0) 1 (0.8) -2.45 2.68 0.09 0.00 to 2.12 
Reinfarction 9 (1.9) 8 (6.5) -1.28 0.25 0.28 0.11 to 0.74 
Mortality 15 (3.1) 8 (6.5) -0.76 0.20 0.47 0.19 to 1.13 
TIMI-10B,178 1998 540 316 
Stroke 14 (2.6) 9 (2.8) -0.10 0.19 0.91 0.39 to 2.12 
Reinfarction 28 (5.2) 18 (5.7) -0.10 0.10 0.91 0.49 to 1.66 
Mortality 24 (4.4) 18 (5.7) -0.26 0.10 0.77 0.41 to 1.44 
TIMIKO,179 1998 350 268 
Stroke 1 (0.3) 3 (1.1) -1.37 1.34 0.25 0.03 to 2.45 
Reinfarction 11 (3.1) 9 (3.4) -0.07 0.21 0.93 0.38 to 2.29 
Mortality 16 (4.6) 12 (4.5) 0.02 0.15 1.02 0.48 to 2.20 
 
Table 5.1: continued. 
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5.3 Multivariate random-effects meta-analysis methods using a 
Bayesian approach 
In contrast to Chapter 4, where frequentist and Bayesian methods were compared, this 
chapter assumes a Bayesian approach only. This decision is for a number of reasons; one of 
which is that Chapter 4 highlighted several advantages of the Bayesian approach compared 
to the frequentist approach, such as the ability to easily account for uncertainty in parameters 
of interest. Also, many of the comparisons between the Bayesian and frequentist methods 
are likely to be similar for the analyses in this chapter, such as wider Bayesian credible 
intervals compared to frequentist confidence intervals for pooled treatment effects, due to the 
additional uncertainty that is accounted for in the Bayesian approach. 
This chapter focuses on the use of bivariate meta-analysis, which is a joint meta-analysis of 
two outcomes; however the methods that are explored can be extended to more than two 
outcomes. The methodology for multivariate meta-analysis within a Bayesian framework has 
recently been developed although it remains underexplored.17,18 The potential advantages of 
this approach, compared to the frequentist equivalent, include the ability to make joint 
probability statements regarding quantities of interest, and the ability to make predictive 
statements, conditional on the current state of knowledge. Prior distributions can also be 
specified to quantify the evidence prior to the meta-analysis data, and to account for 
uncertainty in the parameters, which may not be easily accounted for in the frequentist 
framework, such as the uncertainty in the estimate of between-study heterogeneity. 
5.3.1 Random-effects multinomial regression analysis 
Chapter 4 highlighted that the meta-analysis of binary data should ideally model the binomial 
distribution of the data exactly, and this is especially important when there are small numbers 
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of patients and rare event rates. If this is not possible (e.g. if only odds ratios are available 
rather than two-by-two tables) an approximation can be made by assuming that the 
treatment effect estimates in each trial are normally distributed. The extension to the logistic 
regression model for a single outcome to when there are multiple binary outcomes is a 
multinomial regression analysis. In order to use this approach, the responses must be 
mutually exclusive and exhaustive.217 For example, the four response categories for stroke 
and mortality are shown in Table 5.2, where πikl denotes the probability of response k=1,…,4 
in trial i (i=1,…,9) for those in treatment group l (l=0 or 1). 
Table 5.2: Probability of observed event for four mutually exclusive and exhaustive 
responses in study, i, for treatment group, l. 
Prob (Outcome 1): 
Stroke, dead 
Prob (Outcome 2): No 
stroke, dead 
Prob (Outcome 3): 
Stroke, alive 
Prob (Outcome 4): No 
stroke, alive 
πi1l πi2l πi3l 1- πi1l- πi2l- πi3l 
 
In order to implement a multinomial model one would need to know the number of patients 
with response k in trial i for treatment group l.217 Then from a multinomial model, the OR for 
the treatment effect in each of the categories for stroke and mortality can be derived. 
Unfortunately, without individual patient data (IPD) this model is not possible to fit as the 
number of events for each category in Table 5.2 is usually unknown; one just knows the 
number of strokes and the number of deaths, but not the number with both stroke and death. 
Thus, in this chapter, an approximate and more general method is necessary to undertake a 
joint analysis of these outcomes. 
5.3.2 A general bivariate normal random-effects meta-analysis model 
Since there is no IPD, an approximation assumes the two estimated treatment effects (one 
for each outcome) in each study are from a bivariate normal distribution, which leads to a 
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random-effects bivariate normal meta-analysis model on a logistic scale. This is the general 
framework to bivariate meta-analysis, and therefore can be applied to effects that relate to 
any outcomes (binary/continuous/survival, etc.). The approach considers i=1 to n studies, 
which examine the effect of treatment on two outcomes (j=1 or 2), and the bivariate model is 
written in model (5.1) where two observed treatment effects in study i, Yi1 and Yi2 (the log 
ORs for outcomes 1 and 2), have a bivariate normal distribution with means, θi1 and θi2, 
respectively, and known within-study covariance matrix, Si. The within-study variance in trial i 
for outcome, j, is represented by sij2 (the variance of logOR, Yij). The within-study covariances 
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This bivariate random-effects model assumes that the true underlying effects in the ith study, 
θi1 and θi2, arise from a bivariate normal distribution with average treatment effects, β1 and β2, 
and between-study covariance matrix, D. The diagonal elements of D represent the between-
study variances, τj2, for the treatment effect for outcome j, which represent the heterogeneity 
in θi1 and θi2 across studies. The off-diagonal elements, ρBτ1τ2, are the between-study 
covariances, where ρB represents the between-study correlation for θi1 and θi2. When 
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ρWi=ρB=0, i.e. when the outcomes are assumed independent, the model reverts to two 
separate univariate meta-analyses; one for each outcome. The interpretation of within and 
between study correlation is explained further in section 5.3.3. 
The Bayesian model (5.1) also specifies prior distributions for the average treatment effects, 
β1 and β2, which are given vague normal prior distributions. The prior distribution for the 
between-study standard deviation is a normal distribution truncated at zero (N(0,1)I(0,)), and 
a prior uniform(-1,1) distribution is specified for the between-study correlation parameter, ρB. 
Chapter 4 showed that the choice of prior distribution for between-study variance parameters 
can have an impact on conclusions, and this will remain valid in the multivariate setting. 
However, in this chapter the focus is on whether the multivariate model (5.1) adds value over 
the univariate model of each outcome separately (i.e. where ρB=ρWi=0 in model (5.1)), and so 
only the prior distributions given in model (5.1) will be considered in this chapter. 
Where there are zero event rates for stroke and death in some of the studies, the ‘treatment 
arm’ continuity correction is applied.181 This continuity correction method was explored in 
Chapter 4, and it is an appropriate continuity correction if there is imbalance in the sample 
sizes in the treatment groups. 
5.3.3 Within-study and between-study correlation 
The within-study correlations for study i, ρWi, and between-study correlation, ρB, are two 
measures of correlation in a multivariate meta-analysis model.215 The within-study correlation 
for study i,  ρWi, is a measure of the association between the treatment effect estimates, Yi1 
and Yi2.218 In the phase II trials in this chapter, potential within-study correlation arises from 
the fact that each individual in a study contributes information toward each of the multiple 
outcomes. This induces correlation in the effect estimates. For example, a patient who 
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experienced a stroke is at higher risk of death, and therefore individuals with a stroke in the 
dataset are often those who are dead. The within-study correlations in model (5.1) are 
assumed known.215 
The between-study correlation, ρB, is generally unknown and must be estimated in the meta-
analysis model. This is a measure of how the true underlying outcome effects, θi1 and θi2, are 
related across studies, which may have occurred because of between-study differences in 
the patient characteristics, such as age215. For example, those studies with lower average 
age may have higher treatment effects on both stroke and mortality. 
5.3.4 Unknown within-study correlations 
In the bivariate meta-analysis model (5.1), the within-study correlations must be specified in 
addition to the sij2 needed in a univariate meta-analysis. However, they are rarely reported 
within the original published articles and are often difficult to obtain.213 There have been 
various suggestions for how to adequately deal with the unknown within-study 
correlations.219,220 The use of IPD has been described as the gold standard approach in 
which bootstrapping methods can be used to obtain estimates of the within-study 
correlations.213,221,222 If the IPD is not available for all studies, the within-study correlation 
estimates from the IPD in one study can be used to inform the likely value of the within-study 
correlation for the remaining studies.213 Another option is to impute correlations over the 
entire range of values from -1 to 1 as a sensitivity analysis to determine how the correlations 
alter the pooled estimates.213,223 
The within-study correlation estimates were not reported within any of the nine phase II trials, 
and there is no available IPD. If the individual studies have large sample sizes, the impact of 
incorrectly specifying the within-study correlation is small because the within-study variation 
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is relatively small compared to between-study variation.215 However, in general, phase II 
trials have small sample sizes, and so the within-study variations are relatively large. Thus, in 
this chapter, a number of different options are investigated to determine the impact of the 
within-study correlation values on the pooled estimates. 
Option (1): Fixed values for within-study correlations 
Within-study correlations lie between -1 and 1. An estimate of the overall correlation for the 
log ORs (which is an amalgam of within-study and between-study correlation215) can be 
obtained by estimating the Pearson correlation coefficients using the summary estimates 
from each trial, and the correlation estimates are shown in Table 5.3. These estimates 
suggest that the overall correlations are positive between each pair of outcomes. This is also 
clinically sensible. The estimate of overall correlation is particularly strong for stroke and 
mortality (0.659), as expected, and this is also shown in Figure 5.1. Therefore, the within-
study correlation estimates might also be assumed positive for these two outcomes. Indeed, 
Kirkham et al. suggest using the observed overall correlation to approximate the within-study 
correlation.221 Therefore, positive within-study correlations are assumed here for stroke and 
mortality, and a range of different values from zero to 0.9 are investigated for all studies. 
Note that the correlation is also positive, but only mildly so, between mortality and 
reinfarction. For brevity, although there is evidence of correlation between reinfarction and 
stroke (correlation estimate of 0.402), a bivariate analysis of these two outcomes is not 
considered in this chapter. 
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Table 5.3: Pearson correlation coefficients for the estimates of log OR for stroke, 
reinfarction, and mortality. 
 Stroke Reinfarction Mortality 
Stroke 1   
Reinfarction 0.4024 1  
Mortality 0.6586 0.0879 1 
 
 
Figure 5.1: Scatter plot of treatment effect estimates (logOR) for stroke and mortality 
in each trial. 
(Note: there are only eight observations as there is no information for stroke in one trial.) 
Option (2): Prior distributions for within-study correlations 
The Bayesian multivariate meta-analysis model can account for the unknown within-study 
correlations by assuming a prior distribution for these parameters.17 A positive uniform(0,1) 
distribution for the within-study correlations between stroke and mortality allows for all 


















distribution is chosen since the estimate of overall correlation in option (1) is positive, and 
clinically this is sensible, as discussed. A second prior distribution is also considered, based 
on external but related clinical data leading to a uniform(0.02, 0.29) prior distribution. This is 
based on IPD from an original meta-analysis of ten trials in patients with hypertension, which 
investigated the use of anti-hypertensive drugs against placebo or no treatment for the 
prevention of death and stroke, among other outcomes.224,225 The effect estimates in the 
published meta-analysis are log hazard ratios, and the within-study correlations were 
estimated using bootstrapping methods for a bivariate meta-analysis.225 The within-study 
correlation estimates between the log hazard ratios for stroke and mortality are: 0.02, 0.20, 
0.06, 0.11, 0.23, 0.29, 0.15, 0.05, 0.27, and 0.23. Although the effect estimates are log 
hazard ratios, which is not the same measure as the log odds ratio estimates in this analysis, 
the uniform(0.02,0.29) prior distribution is considered a useful and sensible prior distribution 
to use because the context is related in terms of the primary outcomes and the patient 
population having cardiovascular disease. The prior distribution also agrees with the vague 
uniform(0,1) prior distribution in the sense that there are only positive correlation values, but 
it is narrower in terms of the potential values for the within-study correlations. 
Option (3): Alternative overall correlation method (Riley method) 
The impact of incorrectly specifying the unknown within-study correlation will be larger if the 
trials are small, due to relatively large within-study variability, and this is the case in the 
phase II trials in AMI. An alternative method of dealing with unknown within-study 
correlations is to estimate the overall correlation, which is a combination of the within-study 
and between-study correlations.215 The advantage of this method is it avoids the need to 
specify the unknown within-study correlations, or to estimate the between-study correlations. 
In the case of the phase II trials in AMI, this method is especially convenient because there 
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are no available estimates of the within-study correlations, and there is little data (<10 
studies) to estimate the between-study correlation. 
Model (5.2) provides this alternative specification of the bivariate random-effects model.215 In 
this alternative model, the overall variation is still partitioned into within-study variance and 
between-study variance, like in model (5.1). However, the overall correlation is not 
partitioned into within-study and between-study correlation, but a single parameter, ρo, 
models the overall correlation directly. The within-study variances are represented by sij2 and 
are specified and known. The additional variation beyond sampling error is represented by 
ψj
2, which is not equivalent to τj2 from model (5.1), although these two parameters will be 
similar the within-study variation is small.215 This is because as the additional variation 
increases, the within-study variance becomes relatively small, and the covariance in Φi tends 
to ρoψ1ψ2 and the covariance in D tends to ρBτ1τ2. The covariances are then likely to be 
similar because the estimate of ρo will be based mainly on ρB. Thus, τj and ψj will also be 
similar when the within-study parameters are relatively small. On the other hand, when the 
within-study variance is relatively large, the alternative model and the general model are less 
likely to be similar. Riley et al. show, however, that the pooled estimates of µ1 and µ2 are 
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βj~N(0,100);j=1,2 ψj~N(0,1)I(0,), ρo~Uniform(-1,1) 
(5.2) 
Vague normal prior distributions are assumed for the mean pooled treatment effects, βj. A 
normal distribution, truncated at zero, is assumed for the additional standard deviation, ψj. A 
uniform(-1,1) distribution is specified for the overall correlation, ρo. 
5.3.5 Probability statements 
The Bayesian approach enables posterior probabilities of interest to be estimated, which may 
be useful in the decision to progress to a phase III trial, as discussed in Chapter 4. Following 
models (5.1) or (5.2), the probability that the OR is less than one for each outcome 
separately can be estimated. Also, in a multivariate meta-analysis model, it is possible to 
make joint probability statements, such as the probability that, on average, the treatment will 
reduce both the odds of mortality and stroke by at least 10%, i.e. the probability that the OR 
for mortality is less than 0.9 and the OR for stroke is less than 0.9. The ability to make joint 
probability estimates is a potential advantage of the multivariate approach compared to the 
univariate approach, which analyses the outcomes separately. The joint probability estimates 
in this chapter are therefore compared to the probability estimates for the outcomes 




5.3.6 Estimation and reporting of models 
The summary estimates of interest in this chapter are the median of the marginal posterior 
distributions for the summary log ORs, the median of the marginal posterior distributions for 
the summary ORs, the posterior standard deviation of the log ORs, the 95% posterior 
credible intervals (CrI) for the summary ORs, the posterior probability that the individual ORs 
are less than one, the posterior probability that both ORs are less than one, and the median 
and CrI of the marginal posterior distribution of the between-study variances. Also of interest 
are the estimates of the between-study correlation for the general model (5.1), or an estimate 
of the overall correlation in the alternative model (5.2). Posterior estimates of parameters of 
interest are obtained using the Gibbs Sampler Markov chain Monte Carlo (MCMC) 
method,189 which is implemented in WinBUGS version 1.4.3.32 Example code for random-
effects bivariate meta-analysis is given in Appendix C1 and C2. In this chapter, the analyses 
were performed with 300,000 iterations after allowing for a 100,000 iteration burn in, and the 
samples were thinned by 10 to reduce any concerns of auto-correlation. The convergence of 
parameters was checked using history and trace plots. 
5.3.7 Prediction intervals following a Bayesian bivariate random-effects 
meta-analysis 
As shown in Chapter 4, when there is heterogeneity in treatment effects, the effect in a new 
trial, θijnew, may be very different to the average effect, βj. Thus, to inform the decision to 
proceed to a phase III trial following the general meta-analysis model (5.1), the predictive 
distribution for θi1new and θi2new (the true intervention effects (log odds ratios) in a new trial) is 












The 95% prediction interval for θi1new and θi2new can be obtained by taking the 2.5% and 
97.5% values of the posterior samples drawn from model (5.3) during the MCMC process. 
These intervals will also account for the uncertainty in β1 and β2, and the uncertainty in the 
between-study covariance matrix, D. 
It is not possible to derive the prediction intervals for the log odds ratios in a new trial from 
the alternative model (5.2). This is because the alternative model does not partition the 
correlation into within and between-study correlation, and therefore the between-study 
covariance matrix, D, in model (5.3) cannot be specified. 
The prediction distribution for θi1new and θi2new can also be used to calculate the probability 
that the intervention will be truly effective in a new trial for each outcome, either at all (i.e. 
probability(new OR<1)) or by some clinically relevant amount, such as the odds being 
reduced by at least 10% (i.e. probability(new OR<0.9)). Additionally, in the multivariate 
setting it is possible to use the prediction distributions to compute joint probability estimates, 
such as the probability that the intervention will be effective in a new trial for both outcomes 
(i.e. probability(OR for stroke in a new trial<1 and OR for mortality in a new trial<1)). 
5.4 Application of the multivariate meta-analysis methods 
The methods described in section 5.3 are now applied, which focus mainly on the bivariate 
meta-analysis of stroke and mortality. Later in section 5.4.2 a bivariate meta-analysis of 
reinfarction and mortality are briefly considered. 
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5.4.1 Primary analysis: mortality and stroke 
Table 5.4 displays the summary results from the bivariate meta-analyses for stroke and 
mortality, respectively, for the models introduced earlier. The results from the Bayesian 
univariate random-effects model assuming normality (i.e. model (5.1) with ρB=ρWi=0) are also 
shown in Table 5.4 for both outcomes. The key findings are now discussed. 
Estimates of correlation 
The estimate of overall correlation in model (5.2) is quite large since the median of the 
posterior distribution for ρO is 0.425. This indicates why the bivariate model is of interest, over 
and above two separate univariate meta-analyses that assume correlations are zero. The 
95% CrI for the overall correlation is narrower (-0.207 to 0.809) compared to the CrI for the 
between-study correlation, such as -0.912 to 0.961 for model (5.1) with a uniform(0.02,0.29) 
prior distribution for the within-study correlations. Also, as the fixed value of the within-study 
correlation gets too large in relation to the overall correlation, the estimate of between-study 
correlation in model (5.1) adjusts for this with a negative estimate. For example, when the 
within-study correlation is 0.9 the between-study correlation is -0.018 (95% CrI -0.944 to 
0.837). 
Summary of pooled results 
In general, when compared to the univariate analysis, the bivariate analyses reveal that there 
is a slightly larger average treatment effect for both outcomes, but this increase is only 
marginal. For example, for stroke, the pooled OR is 0.649 (95% CrI 0.219 to 1.747) from a 
univariate analysis whereas the pooled OR is 0.625 (95% CrI 0.254 to 1.416) from bivariate 
model (5.1) with a uniform(0.02,0.29) prior distribution for the within-study correlations (i.e. 
the prior based on external evidence). 
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ρB�  (95% CrI) 
 Univariate ρB=ρWi=0 -0.432 0.515 0.649 (0.219 to 1.747) 0.704 (0.048 to 1.818) 0.829 - 
STROKE 
Model (5.1) 
ρWi=0 -0.468 0.443 0.627 (0.248 to 1.454) 0.659 (0.042 to 1.683) 0.877 0.291 (-0.894 to 0.967) 
ρWi=0.2 -0.470 0.430 0.625 (0.254 to 1.419) 0.607 (0.037 to 1.617) 0.884 0.201 (-0.919 to 0.960) 
ρWi=0.5 -0.464 0.422 0.629 (0.260 to 1.404) 0.595 (0.037 to 1.557) 0.884 0.082 (-0.936 to 0.938) 
ρWi=0.9 -0.379 0.415 0.684 (0.292 to 1.528) 0.613 (0.042 to 1.560) 0.839 -0.018 (-0.944 to 0.837) 
ρWi~Unif(0,1) -0.456 0.414 0.634 (0.266 to 1.383) 0.566 (0.033 to 1.530) 0.884 0.093 (-0.935 to 0.940) 
ρWi~Unif(0.02,0.29) -0.471 0.430 0.625 (0.254 to 1.416) 0.613 (0.036 to 1.625) 0.884 0.219 (-0.912 to 0.961) 
Model (5.2) ρO~Unif(-1,1) -0.437 0.450 0.646 (0.254 to 1.545) 0.700* (0.051 to 1.684) 0.854 0.425† (-0.207 to 0.809) 
 Univariate ρB=ρWi=0 -0.038 0.276 0.962 (0.594 to 1.780) 0.405 (0.022 to 1.201) 0.565 - 
MORTALITY 
Model (5.1) 
ρWi=0 -0.058 0.267 0.944 (0.585 to 1.704) 0.396 (0.021 to 1.172) 0.596 0.291 (-0.894 to 0.967) 
ρWi=0.2 -0.051 0.256 0.950 (0.599 to 1.665) 0.353 (0.018 to 1.106) 0.589 0.201 (-0.919 to 0.960) 
ρWi=0.5 -0.025 0.252 0.976 (0.619 to 1.690) 0.355 (0.019 to 1.072) 0.544 0.082 (-0.936 to 0.938) 
ρWi=0.9 0.117 0.286 1.124 (0.646 to 2.026) 0.588 (0.147 to 1.235) 0.325 -0.018 (-0.944 to 0.837) 
ρWi~Unif(0,1) -0.032 0.252 0.969 (0.617 to 1.686) 0.359 (0.019 to 1.078) 0.555 0.093 (-0.935 to 0.940) 
ρWi~Unif(0.02,0.29) -0.054 0.258 0.948 (0.598 to 1.677) 0.359 (0.018 to 1.118) 0.592 0.219 (-0.912 to 0.961) 
Model (5.2) ρO~Unif(-1,1) -0.004 0.283 0.996 (0.613 to 1.904) 0.442* (0.027 to 1.207) 0.507 0.425† (-0.207 to 0.809) 
ρWi is the within-study correlation in model (5.1); τ is the between-study standard deviation; * this is ψ�  - the additional variation in the alternative 
bivariate model (5.2); ρB is the between-study correlation in model (5.1); 
† this is ρO - the overall correlation in model (5.2). 
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Change in standard error of pooled summary effects 
In comparison to the univariate analysis for stroke, the standard errors of the pooled log OR 
are generally smaller for the bivariate meta-analyses since there is missing data for one trial 
for this outcome, and thus strength can be borrowed from the complete data for mortality. For 
example, for stroke the univariate standard error is 0.515, and the standard error is 0.414 for 
bivariate model (5.1) with a uniform(0,1) prior distribution for ρwi.  
Between-study standard deviation 
The estimates of between-study standard deviation tend to be smaller, with narrower credible 
intervals, for model (5.1) for both outcomes, compared to the univariate results. For example, 
for stroke, ?̂? is 0.704 (95% CrI 0.048 to 1.818) for the univariate model, whereas ?̂? is 0.613 
(95% CrI 0.036 to 1.625) for the bivariate model (assuming a uniform(0.02,0.29) prior 
distribution for the within-study correlations). 
The difference in parameter uncertainty and, in particular, estimates of between-study 
variance has an effect on the 95% prediction intervals and probability estimates, which are 
shown in Table 5.5 for stroke and mortality. The 95% prediction intervals for the true odds 
ratio in a new study are narrower for bivariate model (5.1) compared to the univariate 
analyses. For example, for stroke, the univariate 95% prediction interval is 0.070 to 5.367, 
whereas the 95% prediction interval is 0.089 to 3.843 for the bivariate analysis that assumes 
a uniform(0.02,0.29) prior distribution for the within-study correlations. The probability that 
the true OR is less than one in a new study is larger for the bivariate analyses compared to 
the univariate analyses. For example, for stroke the probability estimate is 0.762 for the 
bivariate analysis assuming a uniform(0.02,0.29) prior distribution for the within-study 
correlations compared to an estimate of 0.721 in the univariate analysis. 
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However, in model (5.2) the estimate of additional variation, ψ� , is larger compared to the 
estimate of τ in the univariate analyses for mortality. For mortality, ψ�  is 0.442 (95% CrI 0.027 
to 1.207) whereas ?̂? is 0.405 (95% CrI 0.022 to 1.201) for the univariate analysis. 
Larger probability estimates 
Pooled ORs 
The probability that the pooled OR is less than one is larger for the bivariate model (5.1) 
when using the uniform(0.02,0.29) prior for both outcomes when compared to the univariate 
analyses. For example, in Table 5.4 the probability that the pooled OR is less than one for 
stroke is 0.829 for the univariate model, compared to 0.884 for the bivariate model assuming 
a uniform(0.02,0.29) prior distribution for the within-study correlations. 
The alternative Riley model (5.2) obtains markedly different probability estimates about the 
pooled effect than model (5.1) using the uniform(0.02,0.29) prior distribution, potentially due 
to the larger variances estimated and thus wider credible intervals from this method. For 
mortality, the probability that the pooled OR is less than one is lower for the alternative model 
with an estimate of 0.507, compared to an estimate of 0.592 in model (5.1) (Table 5.4). This 
is because the credible interval for the pooled OR is wider from the Riley model, which is due 




Table 5.5: 95% prediction intervals and posterior probability estimates for stroke and 
mortality from model (5.1). 
 
Assumption 
95% prediction interval for 
true OR in a new trial 
Prob(new trial true 
OR<1) 
Stroke 
ρB=ρWi=0 0.070 to 5.367 0.721 
ρWi=0 0.082 to 4.281 0.751 
ρWi=0.2 0.091 to 3.867 0.762 
ρWi=0.5 0.097 to 3.679 0.762 
ρWi=0.9 0.108 to 4.131 0.720 
ρWi~Uniform(0,1) 0.102 to 3.484 0.884 
ρWi~Uniform(0.02,0.29) 0.089 to 3.843 0.762 
Mortality 
ρB=ρWi=0 0.290 to 3.889 0.554 
ρWi=0 0.284 to 3.654 0.574 
ρWi=0.2 0.308 to 3.362 0.569 
ρWi=0.5 0.325 to 3.352 0.541 
ρWi=0.9 0.256 to 5.163 0.421 
ρWi~Uniform(0,1) 0.326 to 3.386 0.549 
ρWi~Uniform(0.02,0.29) 0.305 to 3.382 0.572 
ORs in a new trial 
The probability estimates for the predicted true ORs in a new trial being less than one, from 
the univariate model and bivariate model (5.1), are shown in Table 5.5. All probability 
estimates are larger from the bivariate model compared to the univariate model for both 
outcomes, other than when the within-study correlation is fixed at 0.9. For example, for 
stroke, the predicted probability that the true treatment effect in a new trial will be less than 
one is 0.721 from the univariate analysis, whereas this estimate is 0.762 assuming a 
uniform(0.02,0.29) prior distribution for ρWi in bivariate model (5.1). 
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If the 95% prediction interval for the true OR in a new trial is narrower with an upper bound 
closer to one, the probability that the true OR will be less than one is larger. For example, for 
stroke when ρWi=0.2, the 95% prediction interval is 0.091 to 3.867 and the probability that the 
true OR will be less than one is 0.762. However, when ρWi~uniform(0,1), the 95% prediction 
interval is narrower (0.102 to 3.484) and the probability estimate is 0.884. 
Joint probabilistic inferences 
Additionally, the joint probability estimates for the pooled and predicted ORs are shown in 
Table 5.6 for the univariate analyses and the bivariate analyses using model (5.1). There is 
positive correlation for stroke and mortality and, as a consequence, the joint probability 
estimates are greater than the product of the individual probability estimates for each 
outcome. For example, for the uniform(0.02,0.29) prior distribution for the within-study 
correlations, the probability that both pooled ORs are less than one is 0.537. However, the 
product of the individual probabilities is 0.468 (the product of 0.829 and 0.565). Thus, there 
appears a greater prospect of bolus therapy improving both outcomes, once the correlation 
has been properly accounted for. 
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new trial true 
ORs<1) 
Between-study 
correlation (95% CrI) 
Model (5.1) 
ρB=ρWi=0 0.468 0.399 - 
ρWi=0 0.533 0.458 0.291 (-0.894 to 0.967) 
ρWi=0.2 0.535 0.457 0.201 (-0.919 to 0.960) 
ρWi=0.5 0.507 0.434 0.082 (-0.936 to 0.938) 
ρWi=0.9 0.307 0.319 -0.018 (-0.944 to 0.837) 
ρWi~Unif(0,1) 0.519 0.446 0.093 (-0.935 to 0.940) 
ρWi~Unif(0.02,0.29) 0.537 0.460 0.219 (-0.912 to 0.961) 
Model (5.2) ρO~Unif(-1,1) 0.469 - 0.425 (-0.207 to 0.809)* 
* an estimate of the overall correlation in the alternative model 
5.4.2 Secondary analysis of reinfarction and mortality 
The pooled results for the secondary analysis of reinfarction and mortality are shown in Table 
5.7. The 95% prediction intervals and the joint posterior probabilities are shown in Table C1 
and Table C2, respectively, in Appendix C3. 
Impact of correlation on parameter estimates 
In this example, the overall correlation estimate, 𝜌𝑜�, in the alternative model (5.2) is only 
0.059 (95% CrI -0.501 to 0.575) and thus there is little extra information here. Therefore, 
there is little impact on the parameters estimates compared to the primary analysis of stroke 
and mortality, where there was stronger correlation between the outcomes. The bivariate 
meta-analysis results are thus similar to those seen in the separate univariate meta-
analyses. The point estimates for the pooled ORs are in favour of the bolus therapy 
compared to infusion therapy for both outcomes (i.e. ORs are less than one), although there 
is still large uncertainty in the estimates. For example, for mortality the univariate pooled OR 
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is 0.962 (95% CrI 0.594 to 1.780) and in the alternative bivariate meta-analysis model (5.2) 
this estimate is 0.947 (95% CrI 0.577 to 1.767). 
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𝝉� (95% CrI) 
Prob (Pooled 
OR<1) 
ρB�  (95% CrI) 
 Univariate ρB=ρWi=0 -0.284 0.213 0.753 (0.491 to 1.139) 0.257 (0.013 to 0.871) 0.922 - 
REINFARCTION 
Model (5.1) 
ρWi=0 -0.288 0.214 0.750 (0.491 to 1.144) 0.251 (0.012 to 0.883) 0.920 0.046 (-0.941 to 0.952) 
ρWi=0.2 -0.297 0.214 0.743 (0.486 to 1.133) 0.258 (0.012 to 0.891) 0.926 -0.025 (-0.949 to 0.941) 
ρWi=0.5 -0.316 0.226 0.729 (0.464 to 1.135) 0.318 (0.017 to 0.973) 0.930 -0.195 (-0.962 to 0.893) 
ρWi=0.9 -0.335 0.256 0.715 (0.424 to 1.180) 0.471 (0.042 to 1.157) 0.919 -0.453 (-0.976 to 0.653) 
ρWi~Unif(0,1) -0.286 0.223 0.751 (0.477 to 1.156) 0.299 (0.015 to 0.948) 0.914 -0.157 (-0.961 to 0.917) 
Model (5.2) ρO~Unif(-1,1) -0.294 0.220 0.745 (0.481 to 1.150) 0.279* (0.014 to 0.934) 0.919 0.059† (-0.501 to 0.575) 
 Univariate ρB=ρWi=0 -0.038 0.276 0.962 (0.594 to 1.780) 0.405 (0.022 to 1.201) 0.565 - 
MORTALITY 
Model (5.1) 
ρWi=0 -0.062 0.265 0.940 (0.585 to 1.689) 0.382 (0.020 to 1.164) 0.604 0.046 (-0.941 to 0.952) 
ρWi=0.2 -0.065 0.265 0.937 (0.583 to 1.684) 0.381 (0.020 to 1.171) 0.608 -0.025 (-0.949 to 0.941) 
ρWi=0.5 -0.057 0.283 0.945 (0.571 to 1.771) 0.462 (0.028 to 1.256) 0.590 -0.195 (-0.962 to 0.893) 
ρWi=0.9 -0.027 0.325 0.973 (0.538 to 1.975) 0.648 (0.080 to 1.474) 0.537 -0.453 (-0.976 to 0.653) 
ρWi~Unif(0,1) -0.080 0.273 0.923 (0.571 to 1.704) 0.402 (0.020 to 1.230) 0.630 -0.157 (-0.961 to 0.917) 
Model (5.2) ρO~Unif(-1,1) -0.055 0.279 0.947 (0.577 to 1.767) 0.431* (0.024 to 1.232) 0.587 0.059† (-0.501 to 0.575) 
ρWi is the within-study correlation in model (5.1); τ is the between-study standard deviation; * this is ψ�  - the additional variation in the alternative 
bivariate model (5.2); ρB is the between-study correlation in model (5.1); 




This chapter explored the use of multivariate meta-analysis in small phase II trials with 
multiple outcomes, which extends the univariate meta-analysis of phase II trials in Chapter 4. 
The key findings of the work are summarized in Figure 5.2, and it has raised a number of 
interesting questions, which are now discussed. 
Figure 5.2: Key findings. 
• The multivariate approach for meta-analysis of phase II trials can alter inferences for each 
outcome on their own by borrowing strength from the other outcome; this is especially 
apparent given missing outcomes in some trials. 
• The multivariate approach additionally allows us to estimate joint probabilities. When there is 
positive correlation between outcomes the joint probability estimates are larger compared to 
the product of the probabilities from the univariate analyses. 
• The value of the within-study correlations can have a large impact on multivariate model 
results, including pooled estimates, credible intervals, and posterior joint probabilities, 
especially when the within-study variances are large relative to the between-study variances. 
• Within-study correlations will often be unavailable, and so clinical guidance or external 
information (e.g. from a different but related setting) is needed to help specify a prior 
distribution for the missing ρWi. 
• The alternative model (5.2) is useful to estimate pooled effects when within-study correlations 
are unknown since it does not require within-study correlations to be specified; however the 
model does not allow predictions for true effects in new trials and is thus not especially useful 
for phase II meta-analysis. 
• The 95% credible interval from the posterior distribution of the between-study correlation will 




5.5.1 What are the additional benefits of multivariate meta-analysis of 
phase II trials in comparison to univariate methods? 
Multivariate meta-analysis methods have been promoted when there are multiple outcomes 
since the multivariate methods are statistically more efficient by accounting for correlation 
between the outcomes.213 Bayesian methods have also been promoted for multivariate meta-
analysis17,18 as existing information can be incorporated using prior distributions. The work in 
this chapter shows how Bayesian multivariate meta-analysis methods can be used in the 
setting of phase II trials, and identified the pros and cons. 
Firstly, the chapter showed that unknown within-study correlation estimates are an issue 
when no IPD are available. Multiple methods were considered to account for the unknown 
within-study correlations, such as using fixed values and a number of prior distributions, and 
an alternative model where the correlation is not partitioned into within-study and between-
study correlations. The pooled results were compared to assess the impact of these various 
choices. 
The primary analysis results show that the estimates and standard errors of the pooled log 
ORs, the between-study variance estimates and predicted probabilities can differ in the 
multivariate meta-analysis approach compared to the univariate approach. For example, for 
stroke, the univariate standard error of the pooled log OR is 0.515. For the bivariate model 
(5.1) the standard error is 0.414. For the same outcome in the bivariate analysis, assuming a 
uniform(0.02, 0.29) prior distribution for the within-study correlations, the estimate of τ is 
0.613 (95% CrI 0.036 to 1.625). This estimate is lower compared to univariate analysis 
where ?̂? is 0.704 (95% CrI 0.048 to 1.818). 
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The greatest advantage of the multivariate Bayesian approach for phase II trials is that it 
enables joint probability estimates, such as the probability that both pooled ORs are less 
than the value of no difference, or lower than some clinically relevant difference. For 
example, the joint probability estimate that both pooled ORs for stroke and mortality are less 
than one is 0.537, assuming a uniform(0.02,0.29) prior distribution for the within-study 
correlations. This probability is considerably higher than the joint probability from the 
univariate analysis, which is 0.468. This is because the bivariate model borrows strength by 
modelling the correlation between the outcomes, whereas the joint probability estimate from 
the univariate analysis is misleading because it does not account for the correlation between 
the outcomes. These joint probabilities from the multivariate analyses could be additionally 
useful in terms of clinical decision making. 
5.5.2 Is the multivariate approach appropriate in the setting of phase II 
trials? 
If there are multiple phase II trials with several correlated outcomes then multivariate meta-
analysis should be considered to inform phase III trial decisions, rather than using separate 
univariate meta-analyses, because the multivariate approach utilises the correlation and thus 
more information Clearly, those making decisions about phase III trials want to use all the 
information available, and so it seems inappropriate to ignore the correlation and only 
perform univariate analyses, thereby disgarding useful information. Therefore, in order to use 
a multivariate approach it would be advantageous to have the IPD available to enable 
multinomial modelling or, if the general multivariate normal approach to bivariate analysis is 




However, without IPD it is difficult to specify the within-study correlations. In this situation, 
bivariate model (5.1) is recommended because it can be implemented with prior distributions 
specified for the within-study correlations, which allow for uncertainty, instead of simply using 
fixed values. Previous evidence could be used to inform this prior distribution, such as the 
uniform(0.02,0.29) prior distribution that was explored in the example in acute myocardial 
infarction in this chapter. Or, there may be clinical guidance that could restrict the within-
study correlation to a range of values, such as a uniform(0,1) prior that was also used in this 
chapter because stroke and death are likely to be positively correlated. 
Bivariate model (5.1) is also more appropriate than the alternative model (5.2) because 
model (5.1) can derive prediction intervals for the true treatment effects in a new trial, 
whereas the alternative model cannot do this due to an inappropriate hierarchical structure. 
5.5.3 Limitations and further work 
This chapter has illustrated the use of multivariate meta-analysis, but there are limitations to 
the work. In particular, the findings are specific to outcomes from one dataset. Further 
evaluation in other phase II datasets are needed. An advantage of the multivariate approach 
compared to the univariate method is when there is missing data since information can be 
borrowed from the other outcomes.213 However, in the example in AMI, there is missing data 
for stroke in just one trial and there is complete data for reinfarction and mortality. Therefore, 
the benefit in the multivariate approach for phase II trials with missing data was not fully 
explored, although this could be done in further research by artificially removing some of the 
data. 
This chapter only explored the use of the methods for the multivariate meta-analysis of two 
correlated outcomes, although there may be more than two correlated outcomes in a 
different setting. There may be additional difficulties when synthesising more than two 
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outcomes. For more than two outcomes there would need to be further specification of prior 
distributions for within-study correlations and there would be multiple between-study 
correlations (rather than just one in bivariate meta-analysis). Additionally, the model 
specification becomes more difficult in terms of separating the parameters in the variance-
covariance matrices. 
A uniform(-1,1) prior distribution was used for the between-study correlation for all model 
(5.1) analyses in this chapter. All prior distributions must be chosen with caution21,29 but the 
impact of this uniform(-1,1) prior distribution on the estimates of the other parameters was 
not evaluated. This will be explored formally in the next chapter through a simulation study. 
If there was IPD it would be possible to estimate the pooled treatment effects with a 
multinomial regression model.217 A logistic regression model was used in Chapter 4 as well 
as models that assumed normality of treatment effect estimates. In Chapter 4, the logistic 
regression model was considered to be more appropriate due to the modelling of the 
binomial distribution of the data and the low event rates. However, this chapter could not 
explore the potential benefits of the extension to this model. 
5.6 Conclusion and recommendations 
Multivariate meta-analysis of phase II trials can be used when there are multiple outcomes 
instead of the more commonly used univariate meta-analysis approach for each outcome 
separately. The example in this chapter showed that the utilisation of correlation in a 
Bayesian framework has the potential to produce added information from a meta-analysis of 
phase II trials. In particular, joint probability estimates can be derived, which could further 
inform phase III trial decisions, and information about missing outcomes can be gathered 
using the known information from other correlated outcomes that are available, which may 
change inferences. However, there are several challenges involved in using multivariate 
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meta-analysis, such as lack of IPD forcing a general multivariate normal framework rather 
than multinomial modelling. This is only an approximation and is also challenging in terms of 
specifying unknown within-study correlations. The issue of unknown within-study correlations 
is further complicated in the phase II trial setting because the effect of incorrectly specifying 
the within-study correlations is worsened when the within-study variance is relatively large, 
and this tends to be the case in phase II trials due to the small sample sizes. The bivariate 
model (5.1) is perhaps more appropriate than the alternative bivariate model (5.2), because 
this allows joint predictions for true effects in new trials and allows for uncertainty in unknown 
within-study correlations by specifying prior distributions, which can be informed by previous 
evidence. Previous work has also advocated the use of prior distributions for unknown within-
study correlations, such as a multivariate meta-analysis of mixed outcomes by Bujkiewicz et 
al., which used IPD from external studies to derive informative prior distributions.17 Nam et al. 
conducted a sensitivity analysis for the prior distributions for the within-study and between-
study correlations in a multivariate meta-analysis due to the lack of external evidence to 
derive informative prior distibutions.226 In a slightly different context, Abrams et al. also 
considered the use of plausible prior distributions for missing within-subject correlation 
between baseline and follow-up measurements in a meta-analysis of randomised controlled 
trials.227 
In conclusion, the recommendations for future meta-analysis of phase II trials with multiple 
correlated outcomes are given in Figure 5.3. 
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Figure 5.3: Key recommendations. 
• Where possible, multivariate meta-analysis of phase II trials should be considered to inform 
phase III decisions as it utilises more of the evidence compared to univariate meta-analysis. 
• Researchers should provide IPD to facilitate multivariate meta-analysis approaches, such as 
multinomial modelling or to derive within-study correlations for a multivariate normal approach. 
• When IPD is not available, a Bayesian approach with prior distributions for the missing within-
study correlations is the preferred approach, for example, based on external evidence or 
clinical rationale. 
• Further research is needed to assess the impact of the prior distributions for between-study 








CHAPTER 6:  A SIMULATION STUDY TO ASSESS THE 
CHOICE OF PRIOR DISTRIBUTION FOR THE BETWEEN-
STUDY CORRELATION IN A BAYESIAN BIVARIATE 
META-ANALYSIS 
6.1 Introduction and aims 
Chapters 4 and 5 have illustrated several advantages and methodological issues of a 
Bayesian framework for meta-analysis of small trials. The Bayesian approach is a natural 
way to account for all parameter uncertainty, to make predictions regarding the possible 
treatment effect estimate in a new trial, and to derive joint probability estimates in multivariate 
meta-analysis. Chapter 4 explored the impact of the prior distribution for the between-study 
variance in a univariate Bayesian meta-analysis and agreed with those from a previous 
simulation study by Lambert et al.29: the pooled treatment effect estimates can be particularly 
sensitive to the choice of this prior distribution. In Chapter 5, the Bayesian framework was 
extended to a bivariate meta-analysis with two correlated outcomes. However, an 
unanswered question remains: what is the impact of the choice of prior distribution for the 
between-study correlation parameter? This question motivates the research in this chapter. 
In a Bayesian multivariate meta-analysis, a conjugate prior for the entire between-study 
covariance matrix is the inverse-Wishart prior distribution. For example, Riley et al.228 and 
Zwinderman and Bossuyt229 use an inverse-Wishart prior for the between-study covariance 
matrix in a bivariate meta-analysis of test accuracy studies. However, Wei and Higgins 
suggest it is preferable to place separate priors on each component of the between-study 
covariance matrix,18,230,231 because the Wishart prior can be very influential toward the 
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posterior estimates of the between-study variances; the Wishart prior is a generalisation of 
the gamma prior for some parameters, which Lambert et al.29 shows is influential in 
univariate meta-analysis when the true between-study variances are close to zero. 
Separation of the between-study covariance matrix also allows more flexibility in the choice 
of priors for each component, and is thus the approach considered here. Thus in a bivariate 
meta-analysis, prior distributions will be required for the between-study variances and the 
between-study correlation. 
There are many different prior distributions that could be chosen for the between-study 
correlation, depending on whether external evidence is available or not. In this chapter, the 
focus is mainly on situations where there is no prior information and so vague prior 
distributions are desired. Often, in this situation, researchers use a uniform(-1,1) prior 
distribution for the between-study correlation. This gives equal weight to all possible values 
of the between-study correlation, and thus may be perceived to be suitable when there is no 
previous evidence about the correlation’s magnitude. However, as discussed, meta-analysis 
results are known to be sensitive to seemingly vague priors for the between-study variance29 
– thus it seems plausible that results also be sensitive to this seemingly vague uniform(-1,1) 
prior for the correlation. Despite this, many researchers do not conduct sensitivity analyses to 
check whether their prior distribution for the between-study correlation is appropriate. For 
example, Nam et al.226 use a uniform(-1,1) prior distribution for the between-study correlation 
in a Bayesian bivariate meta-analysis that investigated the impact of passive smoking on two 
correlated outcomes of asthma and lower respiratory disease; no sensitivity analysis was 
undertaken for the choice of this prior. Another previous study18 of the choice of prior 
distribution for the between-study covariance matrix in a Bayesian multivariate meta-analysis 
explored various separation strategies that allow prior distributions to be placed on different 
components of the matrix, including the between-study correlation. They also selected a 
uniform(-1,1) prior distribution for the between-study correlation but did not explore other 
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choices of prior for this parameter.18 Riley et al.213 investigated the influence of ignoring 
within-study correlation in a Bayesian meta-analysis with correlated outcomes and also 
focussed only on a uniform(-1,1) prior distribution for the between-study correlation. 
Thus, it seems that the choice of prior distribution for the between-study correlation has been 
somewhat neglected in the multivariate meta-analysis literature. Therefore, in this chapter an 
extensive simulation study will be performed to assess the choice of a range of vague prior 
distributions for the between-study correlation in a bivariate random-effects meta-analysis 
model. In particular, this will explore the impact of the prior distribution on the posterior 
pooled treatment effects, both for complete and missing outcome data, and on the posterior 
estimates of the between-study correlation itself. It will also examine if the priors for the 
between-study variance impact on the posterior between-study correlation estimates (and 
vice-versa), since variance and correlation parameters are not independent. 
The remainder of the chapter is structured as follows. Section 6.2 introduces the bivariate 
random-effects meta-analysis model and the prior distributions for the between-study 
correlation that will be used throughout this chapter. Section 6.3 details two motivating 
example meta-analysis datasets and results for the various prior distributions for the 
between-study correlation. The findings from the motivating examples are used to inform the 
selection of scenarios in section 6.4, which is a simulation study that is used to determine 
whether the results can be generalised. This chapter concludes with discussion of the 
findings. 
6.2 Bivariate random-effects meta-analysis model 
As mentioned, the focus here is on the prior distributions in a bivariate normal random-effects 
meta-analysis model. The extension to more than two outcomes will be discussed briefly in 
the Discussion. To ensure clarity, the bivariate model (previously given as model (5.1)) is 
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given again in (6.1) below. For two outcomes, the treatment effect estimates, Yi1 and Yi2, in 
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The pooled treatment effects for outcomes, j=1,2, are denoted by β1 and β2, which are the 
average effects of treatment across all studies. The within-study covariance matrix, Si, 
contains within-study variances for each trial, i, for outcome j=1,2, si12  and si22  (assumed 
known and estimated by the trial data), and within-study covariances, ρWisi1si2,, where ρWi 
represents the within-study correlation (also assumed known). The between-study 
covariance matrix, D contains the unknown between-study standard deviations, τj, and 
between-study correlation, which is represented by ρB. A vague normal prior distribution, 
centred on zero with variance 1000, is used throughout this chapter for the pooled treatment 
effects, βj. 
6.2.1 Prior distributions for between-study correlation 
In this chapter, a range of prior distributions are considered to account for varying levels of 
hypothetical prior knowledge that may inform the prior distribution for the between-study 
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correlation. Below are five possible “vague” priors in which priors 1 to 3 allow the between-
study correlation to be positive or negative, and priors 4 and 5 only allow the between-study 
correlation to be positive. The five prior distributions are shown in Figure 6.1. 
Prior 1 
ρB~Uniform(-1,1) 
This prior distribution gives equal weight to all possible positive and negative values of 
correlation. This distribution is often considered appropriate when there is no prior 
information regarding the true value of the between-study correlation. As mentioned, it is 
commonly used in Bayesian multivariate meta-analysis applications, such as Nam et al.226 









This prior distribution is referred to as a Fisher prior17 and it is similar to prior 1 with the same 
mean and allows both positive and negative values. However, there is more weight around 
the mean and less weight at the extremes, and it has a 95% prior CrI for ρB of -0.655 to 
0.655. This prior distribution could be applied if there is external evidence suggesting that the 
correlation is unlikely to be either very highly negative or positive, so values between -0.6 to 
+0.6 are most plausible (but the direction of the correlation is not known). It could also be 
useful if the prior belief was that the between-study correlation is zero. Riley et al.218 show 
that the between-study correlations are often poorly estimated at +1 or -1 when there is little 
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data to estimate them, and so this prior distribution would potentially restrain this issue by 





Similar to priors 1 and 2, the Beta prior distribution 3 also allows for positive and negative 
values of the between-study correlation. It is similar to prior 1 in that it is relatively flat across 
the range of values, with the exception that values at the extreme ends of the distribution are 
considered extremely unlikely. This prior distribution could be considered practical when 
there is very little external information to inform the true value of the between-study 
correlation; however, it may be clinically sensible to suggest that values close to -1 and +1 
are implausible. The scale and shape parameter values of 1.5 are chosen here to ensure a 
prior that is noticeably different to both priors 1 and 2. It gives a 95% prior CrI for ρB of -0.878 
to 0.878, which is wider than prior 2 but narrower than prior 1. 
Prior 4 
ρB~Uniform(0,1) 
This prior distribution gives equal weight to all possible positive values of correlation. This 
distribution could be applied if there is external evidence to suggest a positive correlation but 
there is very little evidence to suggest the true positive value. An example is treatment 
effects for nested outcomes, such as disease free survival and overall survival, which by 
definition should be positively correlated but the magnitude is often unknown. This prior 





Similar to prior 4, this logit prior distribution allows only positive values, however, more 
weight is given around the mean and less weight is given in the tails of the distribution 
(Figure 6.1). Therefore, this prior is also centred on 0.5 but the 95% CrI is 0.173 to 0.827, 
which is narrower than for prior 4. This prior could be selected if there is prior evidence that 
the true value of the correlation is likely to be moderately high. 
Many other choices of prior distributions could, of course, be specified, but these five are 
chosen as they reflect a sufficient range of different and realistic prior distributions for 




Figure 6.1: Density plots for prior distributions for between-study correlation: 





� ~ N(0, sd=0.4) (Prior 2); 
(c) �ρB+1�2  ~ Beta(1.5,1.5) (Prior 3); (d) ρB ~ Uniform(0,1) (Prior 4); 
(e) logit(ρB) ~ N(0, sd=0.8) (Prior 5). 
 
6.3 Motivating examples 
Before the simulation study is conducted it is useful to obtain some preliminary findings from 
real-life examples. Therefore, this section will explore the prior distributions described above 
in two motivating example datasets from previous bivariate meta-analyses. The results of 
these analyses will give an initial idea of the impact of the choice of prior distribution on the 

















































analysis, prior distributions must also be specified for the between-study variances. Previous 
simulation studies revealed that the choice of prior distribution for the between-study 
variance is important and must be selected with caution.29 In these motivating examples, the 
amount of between-study variance is larger in example A compared to example B, therefore 
it is possible to explore the impact of the choice of prior distribution for the between-study 
correlation on this parameter itself, and also how the prior distributions for the between-study 
variances affect the estimate of the between-study correlation and the pooled results. 
6.3.1 Motivating example A 
The dataset for the first motivating example is from an individual participant data (IPD) meta-
analysis of hypertension trials by Wang et al.224, which investigated whether hypertension 
treatments reduce systolic blood pressure (SBP) and diastolic blood pressure (DBP) more 
than control. The summary results for the 10 trials are shown in Table 6.1 as taken from 
Riley et al.225 The within-study correlations were obtained via non-parametric bootstrapping. 
In a previous frequentist analysis of this data, using restricted maximum likelihood, the 
estimate of between-study correlation was 0.78, and estimates of the between-study 




Table 6.1: Summary results for the 10 trials in the meta-analysis by Wang et al.224 for 
systolic blood pressure and diastolic blood pressure. 
Trial 








correlations SBP & 
DBP (from bootstrap) 
ATMH 750 780 -6.66 (0.72) -2.99 (0.27) 0.79 
HEP 199 150 -14.17 (4.73) -7.87 (1.44) 0.50 
EWPHE 82 90 -12.88 (10.31) -6.01 (1.77) 0.59 
HDFP 2371 2427 -8.71 (0.30) -5.11 (0.10) 0.77 
MRC-1 3445 3546 -8.70 (0.14) -4.64 (0.05) 0.64 
MRC-2 1337 1314 -10.60 (0.58) -5.56 (0.18) 0.50 
SHEP 2371 2365 -11.36 (0.30) -3.98 (0.075) 0.48 
STOP 131 137 -17.93 (5.82) -6.54 (1.31) 0.59 
Sy-Chi 1139 1252 -6.55 (0.41) -2.08 (0.11) 0.45 
Sy-Eur 2297 2398 -10.26 (0.20) -3.49 (0.04) 0.48 
* Trial names are consistent with Wang et al.,224 where further details and trial publications can be 
found. 
Prior distribution for between-study variance 
The impact of the prior distribution for the between-study correlation must be viewed together 
with the choice of prior for the between-study variances, τj2. A previous simulation study of 
the impact of the prior distribution for between-study variance in univariate meta-analysis,29 
and the sensitivity analysis conducted in Chapter 4, both highlighted that the pooled results 
can be particularly sensitive to the choice of prior distribution for the between-study variance. 
This may be even more of a concern in bivariate meta-analysis because priors for the 
between-study variance might also affect the posterior estimate of the between-study 
correlation, which in turn will affect the pooled treatment effect estimates (especially if there 
is missing data for either outcome232) and their credibility intervals. Therefore, several prior 
distributions for the between-study variances are also investigated in these motivating 
examples, and also later in the simulation studies as follows: 
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Variance prior 1a 
τj~N(0,1)I(0,) 
This specifies a half normal distribution for τj, where I(0,) denotes the distribution is truncated 
at zero. The variance of this distribution is small so that the posterior estimate of between-
study variance is not unreasonably large. 
Variance prior 1b 
τj~N(0,2)I(0,) 
Given the frequentist estimates of between-study variance in the hypertension example, a 
slightly more conservative prior distribution is also considered. 




This is a common prior distribution used for a transformation of the variance.22,29 This 
distribution is approximately uniform for most of the range, but has a ‘spike’ of probability 
mass close to zero.29 






Prior distribution 2a allows very large values of τj, therefore, for a sensitivity analysis, the 
same prior distribution with shape and scale parameters of one is also explored. 
Variance prior 3 
τj~Uniform(0,2) 
This is a prior distribution for the between-study standard deviation, which contains plausible 
values of the between-study variance for these examples, rather than a wide vague prior 
distribution that will allow large estimates of the variance parameters. 
Variance prior 4 
log(τj2)~Uniform(-10,1.386) 
This prior distribution for the log of the variance is fairly informative since it bounds τj2 
between zero and four. The choice of the value of the upper bound is subjective here, 
however it may be considered implausible that the between-study variance could be larger 
than four.29 
Variance prior 5 
log(τj2)~t(-3.44,2.59
2,5) 
This is an empirical prior distribution for the log of the between-study variance predicted for a 
new meta-analysis of randomised trials with a continuous outcome, as derived empirically 
from previous meta-analyses of randomised trials with continuous outcomes by Rhodes et 
al.38 This student’s t-distribution was recommended by Rhodes et al. for use in a general 
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setting and has a median of 0.03 and a 95% range of 0.0002 to 5.14 on the untransformed 
scale (τj). 
6.3.2 Motivating example B 
The second example dataset is from the same IPD meta-analysis in motivating example A, 
but is concerned with whether smoking is a prognostic factor for stroke, where smoking is a 
binary variable by yes (current smoker) or no (not current smoker). There are two prognostic 
effects for smoking: a partially adjusted log hazard ratio (HR), which is adjusted for 
treatment, and a fully adjusted log HR, which is adjusted for treatment, age and BMI. The 
summary results are shown in Table 6.2. There is missing information for age and BMI in five 
out of 10 trials, and so only partially adjusted HR estimates are available in these. However, 
in the remaining five trials, there is information to estimate both fully and partially adjusted log 
HRs and these prognostic effect estimates are highly correlated with the within-study 
correlations (derived from bootstrapping) close to +1.225 
In addition to the priors described in Section 6.3.1, another prior distribution considered for 
the between-study variance in this example is an empirical prior distribution that was derived 
by Turner et al.36 
Variance prior 6: 
τj
2~lognormal(-2.89,1.912) 
Turner et al. derived predictive distributions for the between-study variance for future meta-
analyses with a binary outcome where there may be few studies to estimate this parameter 
within the model.36 This prior distribution is for non-pharmacological interventions with semi-
objective outcomes (an objective outcome that is not all-cause mortality). The median is 
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0.056 and a 95% prior interval is 0.001 to 2.35 for τj2. This prior distribution is not an exact 
match as these are prognostic effects rather than intervention effects, and the outcome is 
survival rather than binary. However, the event (stroke) is rare in this example and hazard 
ratios and odds ratios are often similar in this setting,233,234 therefore this empirical prior 
distribution is considered suitable for application in this example. 
Table 6.2: Summary results for the 10 trials in the meta-analysis by Riley et al.224 for 













ATMH 750 780 0.216 (0.752) 0.173 (0.754) 0.992 
HEP 199 150 1.238 (0.182) 1.477 (0.223) 0.893 
EWPHE 82 90 -1.038 (1.080) -0.667 (1.125) 0.988 
HDFP 2371 2427 0.884 (0.072) 0.894 (0.074) 0.985 
MRC-1 3445 3546 1.232 (0.119) 1.209 (0.120) 0.986 
MRC-2 1337 1314 0.379 (0.039) - - 
SHEP 2371 2365 0.399 (0.027) - - 
STOP 131 137 1.203 (1.256) - - 
Sy-Chi 1139 1252 0.633 (0.042) - - 
Sy-Eur 2297 2398 0.156 (0.100) - - 
* Trial names are consistent with Wang et al.,224 where further details and trial publications can be 
found. 
Examples A and B provide a helpful contrast. Example B relates to time-to-event outcomes, 
whilst example A relates to continuous outcomes. Example B represents a situation where 
bivariate meta-analysis results may differ considerably to those from a univariate meta-
analysis (ρWi=ρB=0 in model (6.1)). There are large within-study correlations, which are 
accounted for in the bivariate meta-analysis to borrow strength between partially and fully-
adjusted results,232,235 which is considerably important here as five studies do not provide the 
fully-adjusted result. By contrast, example A has complete data for both outcomes and so 
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univariate and bivariate results are likely to be similar.232 Example B also has smaller 
estimates of the between-study variances compared to example A (τ̂1 is 0.063 and τ̂2 is 0.033 
using REML in the original paper). Therefore, it is possible to examine the impact of prior 
distributions for the between-study correlation for different sizes of true between-study 
variation across the two examples. It is also likely that a prior distribution for the between-
study variance, which is appropriate for the data in example A, may not be appropriate for 
the data in example B. Hence examples A and B provide contrasting examples. 
The posterior estimates of the parameters in model (6.1) for each dataset are obtained using 
the Gibbs Sampler MCMC method, which is implemented in SAS 9.3 using the PROC 
MCMC procedure.236 The analyses are performed with 100000 iterations after allowing for a 
100000 iteration burn in and the samples are thinned by 10 to reduce concerns of 
autocorrelation. The convergence of parameters was checked using history and trace plots. 
6.3.3 Summary of key findings from motivating examples 
Table 6.3 shows the pooled results for example A using the various prior distributions for the 
between-study correlation, combined with the choices of prior distributions for between-study 
variance. Table 6.4 shows the corresponding results for example B. The key findings as 
observed in these examples are now discussed. 
Key finding (i): The choice of prior distribution for ρB influences the posterior 
estimates for ρB. 
As expected, in both these examples as the prior distribution for ρB is varied, the posterior 
mean of ρB and the 95% CrI change. In example B, with a N(0,2)I(0,) prior for τj, ρ�B is 0.074 
(95% CrI -0.608 to 0.700) using a Fisher prior distribution for transformation of ρB. This is 
much smaller than the estimate of ρB when a logit transformation prior distribution is used for 
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ρB, which is 0.531 (95% CrI 0.184 to 0.847). However, these large changes in the between-
study correlation estimates do not greatly affect the pooled treatment effect estimates, and 
the conclusions remain the same. For example, for the same two prior distributions for ρB, 
the pooled estimate of the partially-adjusted log HR is 0.586 (95% CrI 0.352 to 0.845) 
compared to 0.587 (95% CrI 0.346 to 0.866). The pooled estimate of the fully-adjusted log 
HR is 0.717 (95% CrI 0.373 to 1.121) (Fisher prior distribution) compared to 0.696 (95% CrI 
0.356 to 1.082) (logit prior distribution). Thus, it appears that the between-study correlation 
has little impact in example B in regard to the pooled estimates; this is also apparent in 
example A. 
Key finding (ii): The prior distribution for τj influences the posterior results for ρB. 
In both examples, as the estimates of the between-study variances increase, ρ�B also 
increases, even when the prior distribution for ρB remains the same. For example, in 
motivating example B, when ρB~uniform(-1,1), ρ�B is 0.226 (95% CrI -0.923 to 0.981) if a 
N(0,1)I(0,) prior distribution is applied for τj, and 0.842 (95% CrI -0.644 to 0.999) when a 
gamma(0.1,0.1) prior distribution is used for 1/τj2. This is because the posterior estimates of τj 
are larger if the prior distribution for τj is wider (τ̂1
2 is 0.092 and τ̂2
2  is 0.142 with a N(0,1)I(0,) 
prior distribution, compared to τ̂1
2, which is 4.508 and τ̂2
2 , which is 6.821 with a 
gamma(0.1,0.1) prior). Therefore, these examples illustrate that the choice of prior 
distribution for the between-study variances can impact considerably upon the posterior 
distribution for ρB. 
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Table 6.3: Motivating example A - summary results from bivariate meta-analysis for various prior distributions for ρB and τj. 
Prior for τ 
Prior for ρB 
Pooled mean 
difference in 




diastolic BP (95% 
CrI) 
τ̂1
2(95% CrI) τ̂22 (95% CrI) ρ�B (95% CrI) 
Prob(reduction 
in SBP>9 & 
reduction in 
DBP>4) 
τj~N(0,1)I(0,)       
ρB=ρWi=0 
-9.906 
(-11.491 to -8.523) 
-4.540 
(-5.580 to -3.593) 
4.033 
(1.984 to 8.890) 
2.068 





(-11.327 to -8.476) 
-4.448 
(-5.376 to -3.569) 
3.754 
(1.174 to 8.101) 
1.653 
(0.557 to 3.880) 
0.483 




(-11.291 to -8.520) 
-4.436 
(-5.367 to -3.579) 
3.509 
(1.108 to 7.809) 
1.577 
(0.520 to 3.729) 
0.349 




(-11.307 to -8.470) 
-4.443 
(-5.357 to -3.583) 
3.682 
(1.177 to 8.121) 
1.607 
(0.559 to 3.689) 
0.453 




(-11.324 to -8.491) 
-4.456 
(-5.410 to -3.596) 
3.744 
(1.199 to 8.082) 
1.637 
(0.567 to 3.838) 
0.515 




(-11.333 to -8.476) 
-4.450 
(-5.364 to -3.576) 
3.693 
(1.223 to 7.942) 
1.618 
(0.579 to 3.691) 
0.528 
(0.224 to 0.791) 
0.502 
τj~N(0,2)I(0,)       
ρB=ρWi=0 
-9.991 (-11.749 to -
8.421) 
-4.567 
(-5.702 to -3.531) 
5.502 
(1.556 to 13.085) 
2.473 




-9.894 (-11.564 to -
8.322) 
-4.476 
(-5.479 to -3.549) 
5.064 
(1.505 to 11.976) 
2.010 
(0.630 to 4.899) 
0.523 
(-0.073 to 0.872) 
0.497 
Fisher z~N(0,sd=0.4) 
-9.919 (-11.598 to -
8.430) 
-4.469 
(-5.492 to -3.528) 
4.718 
(1.397 to 11.177) 
1.911 
(0.604 to 4.896) 
0.365 




Prior for τ 
Prior for ρB 
Pooled mean 
difference in 




diastolic BP (95% 
CrI) 
τ̂1
2(95% CrI) τ̂22 (95% CrI) ρ�B (95% CrI) 
Prob(reduction 




-9.889 (-11.581 to -
8.393) 
-4.470 
(-5.473 to -3.555) 
5.037 
(1.493 to 11.823) 
1.972 
(0.624 to 4.877) 
0.483 
(-0.093 to 0.854) 
0.485 
ρB~Uniform(0,1) 
-9.916 (-11.611 to -
8.383) 
-4.478 
(-5.487 to -3.526) 
5.183 
(1.540 to 12.248) 
2.209 
(0.639 to 4.950) 
0.552 




(-11.637 to -8.432) 
-4.473 
(-5.458 to -3.540) 
4.978 
(1.538 to 11.505) 
1.932 
(0.629 to 4.569) 
0.547 
(0.234 to 0.808) 
0.505 
1/τj2~Gamma(1,1)       
ρB=ρWi=0 
-10.028 
(-11.970 to -8.374) 
-4.542 
(-5.657 to -3.569) 
6.409 
(1.440 to 19.304) 
2.251 





(-11.707 to -8.344) 
-4.467 
(-5.493 to -3.539) 
5.450 
(1.377 to 14.886) 
1.901 
(0.638 to 4.747) 
0.523 




(-11.683 to -8.420) 
-4.458 
(-5.402 to -3.586) 
4.857 
(1.249 to 13.802) 
1.704 
(0.588 to 4.259) 
0.367 




(-11.665 to -8.362) 
-4.468 
(-5.433 to -3.553) 
5.283 
(1.333 to 15.200) 
1.836 
(0.604 to 4.595) 
0.479 




(-11.690 to -8.328) 
-4.467 
(-5.459 to -3.540) 
5.393 
(1.383 to 14.769) 
1.891 
(0.617 to 4.995) 
0.545 




(-11.555 to -8.365) 
-4.463 
(-5.406 to -3.551) 
5.151 
(1.350 to 13.897) 
1.793 
(0.627 to 4.360) 
0.545 
(0.232 to 0.807) 
0.502 
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Prior for τ 
Prior for ρB 
Pooled mean 
difference in 




diastolic BP (95% 
CrI) 
τ̂1
2(95% CrI) τ̂22 (95% CrI) ρ�B (95% CrI) 
Prob(reduction 
in SBP>9 & 
reduction in 
DBP>4) 
1/τj2~Gamma(0.1,0.1)       
ρB=ρWi=0 
-10.298 
(-12.893 to -7.958) 
-4.657 
(-6.311 to -3.027) 
13.846 
(2.608 to 31.881) 
6.219 





(-12.766 to -7.551) 
-4.554 
(-6.152 to -2.981) 
16.352 
(4.508 to 47.418) 
6.089 
(2.152 to 16.434) 
0.712 




(-12.481 to -7.827) 
-4.569 
(-6.081 to -3.075) 
12.678 
(3.808 to 34.851) 
5.316 
(1.959 to 13.619) 
0.414 




(-12.718 to -7.545) 
-4.565 
(-6.120 to -2.997) 
15.037 
(4.397 to 40.828) 
5.701 
(2.045 to 14.301) 
0.652 




(-12.855 to -7.395) 
-4.567 
(-6.125 to -2.932) 
17.279 
(4.684 to 50.817) 
6.226 
(2.168 to 16.668) 
0.739 




(-12.629 to -7.725) 
-4.576 
(-6.087 to -3.067) 
13.486 
(4.068 to 36.220) 
5.300 
(1.986 to 13.069) 
0.630 
(0.269 to 0.881) 
0.482 
τj~Uniform(0,2)       
ρB=ρWi=0 
-9.815 
(-11.098 to -8.539) 
-4.566 
(-5.591 to -3.540) 
2.980 
(1.613 to 4.000) 
2.241 





(-11.125 to -8.562) 
-4.483 
(-5.442 to -3.588) 
2.985 
(1.430 to 3.960) 
1.808 
(0.618 to 3.648) 
0.482 




(-11.029 to -8.535) 
-4.430 
(-5.357 to -3.567) 
2.909 
(1.306 to 3.956) 
1.750 
(0.581 to 3.640) 
0.343 
(-0.165 to 0.721) 
0.462 
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Prior for τ 
Prior for ρB 
Pooled mean 
difference in 




diastolic BP (95% 
CrI) 
τ̂1
2(95% CrI) τ̂22 (95% CrI) ρ�B (95% CrI) 
Prob(reduction 





(-11.042 to -8.553) 
-4.461 
(-5.418 to -3.547) 
2.952 
(1.343 to 3.958) 
1.813 
(0.605 to 3.711) 
0.446 




(-11.101 to -8.566) 
-4.459 
(-5.413 to -3.564) 
2.981 
(1.439 to 3.961) 
1.808 
(0.611 to 3.646) 
0.506 




(-11.042 to -8.524) 
-4.452 
(-5.412 to -3.540) 
2.971 
(1.385 to 3.959) 
1.796 
(0.632 to 3.652) 
0.526 








(-11.101 to -8.567) 
-4.550 
(-5.574 to -3.591) 
2.874 
(1.470 to 3.999) 
2.031 





(-11.066 to -8.550) 
-4.451 
(-5.339 to -3.594) 
2.829 
(1.153 to 3.954) 
1.599 
(0.538 to 3.493) 
0.464 




(-11.006 to -8.502) 
-4.408 
(-5.322 to -3.581) 
2.755 
(1.143 to 3.942) 
1.552 
(0.500 to 3.485) 
0.335 




(-11.038 to -8.523) 
-4.428 
(-5.329 to -3.566) 
2.828 
(1.232 to 3.942) 
1.594 
(0.527 to 3.488) 
0.438 




(-11.045 to -8.501) 
-4.432 
(-5.334 to -3.555) 
2.852 
(1.228 to 3.951) 
1.609 
(0.552 to 3.483) 
0.491 




(-11.108 to -8.540) 
-4.433 
(-5.356 to -3.590) 
2.840 
(1.237 to 3.942) 
1.601 
(0.539 to 3.470) 
0.516 
(0.215 to 0.779) 
0.495 
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Prior for τ 
Prior for ρB 
Pooled mean 
difference in 




diastolic BP (95% 
CrI) 
τ̂1
2(95% CrI) τ̂22 (95% CrI) ρ�B (95% CrI) 
Prob(reduction 




2)~t(-3.44,2.592,5)       
ρB=ρWi=0 
-10.088 
(-12.187 to -8.366) 
-4.548 
(-5.686 to -3.570) 
7.147 
(1.491 to 22.128) 
2.311 





(-11.946 to -8.388) 
-4.492 
(-5.527 to -3.575) 
6.111 
(1.286 to 18.818) 
1.954 
(0.536 to 5.405) 
0.521 




(-11.638 to -8.320) 
-4.439 
(-5.388 to -3.569) 
5.208 
(1.184 to 15.481) 
1.671 
(0.485 to 4.474) 
0.359 




(-11.750 to -8.232) 
-4.451 
(-5.465 to -3.520) 
5.906 
(1.271 to 17.634) 
1.897 
(0.546 to 5.345) 
0.486 




(-11.765 to -8.263) 
-4.459 
(-5.455 to -3.511) 
6.041 
(1.338 to 18.137) 
1.956 
(0.532 to 5.567) 
0.550 




(-11.675 to -8.358) 
-4.457 
(-5.418 to -3.556) 
5.588 
(1.280 to 16.212) 
1.786 
(0.537 to 4.809) 
0.544 
(0.227 to 0.814) 
0.508 
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Table 6.4: Motivating example B - summary results from bivariate meta-analysis for various prior distributions for ρB and τj. 
Prior for τ 
Prior for ρB 
Pooled partially-
adjusted log HR 
(95% CrI) 
Pooled fully-
adjusted log HR 
(95% CrI) 
τ̂1






τj~N(0,1)I(0,)       
ρB=ρWi=0 
0.587 
(0.281 to 0.910) 
0.928 
(0.162 to 1.536) 
0.112 
(0.000 to 0.549) 
0.311 





(0.345 to 0.863) 
0.708 
(0.379 to 1.100) 
0.092 
(0.000 to 0.298) 
0.142 
(0.000 to 0.410) 
0.226 




(0.356 to 0.833) 
0.710 
(0.389 to 1.099) 
0.047 
(0.000 to 0.232) 
0.060 
(0.000 to 0.398) 
0.071 




(0.349 to 0.854) 
0.708 
(0.383 to 1.093) 
0.055 
(0.000 to 0.272) 
0.064 
(0.000 to 0.391) 
0.161 




(0.337 to 0.871) 
0.695 
(0.353 to 1.063) 
0.073 
(0.000 to 0.338) 
0.078 
(0.000 to 0.460) 
0.585 




(0.337 to 0.865) 
0.700 
(0.368 to 1.077) 
0.066 
(0.000 to 0.299) 
0.069 
(0.000 to 0.415) 
0.529 
(0.188 to 0.848) 
0.740 
τj~N(0,2)I(0,)       
ρB=ρWi=0 
0.591 
(0.289 to 0.935) 
0.924 
(0.071 to 1.616) 
0.124 
(0.000 to 0.607) 
0.447 





(0.342 to 0.857) 
0.707 
(0.372 to 1.102) 
0.065 
(0.000 to 0.331) 
0.076 
(0.000 to 0.520) 
0.221 




Prior for τ 
Prior for ρB 
Pooled partially-
adjusted log HR 
(95% CrI) 
Pooled fully-
adjusted log HR 
(95% CrI) 
τ̂1








(0.352 to 0.845) 
0.717 
(0.373 to 1.121) 
0.053 
(0.000 to 0.254) 
0.071 
(0.000 to 0.467) 
0.074 




(0.353 to 0.857) 
0.717 
(0.383 to 1.104) 
0.060 
(0.000 to 0.297) 
0.070 
(0.000 to 0.451) 
0.166 




(0.335 to 0.888) 
0.698 
(0.351 to 1.095) 
0.079 
(0.000 to 0.378) 
0.088 
(0.000 to 0.528) 
0.589 




(0.346 to 0.866) 
0.696 
(0.356 to 1.082) 
0.063 
(0.000 to 0.289) 
0.079 
(0.000 to 0.477) 
0.531 
(0.184 to 0.847) 
0.716 
1/τj2~Gamma(1,1)       
ρB=ρWi=0 
0.599 
(0.091 to 1.102) 
0.835 
(-0.224 to 1.813) 
0.474 
(0.160 to 1.245) 
0.938 





(0.080 to 1.126) 
0.724 
(0.072 to 1.415) 
0.480 
(0.170 to 1.180) 
0.586 
(0.179 to 1.730) 
0.723 




(0.128 to 1.098) 
0.823 
(0.021 to 1.622) 
0.411 
(0.149 to 1.028) 
0.647 
(0.174 to 2.057) 
0.242 




(0.117 to 1.114) 
0.763 
(0.037 to 1.532) 
0.452 
(0.162 to 1.118) 
0.617 
(0.177 to 1.880) 
0.569 




(0.083 to 1.123) 
0.710 
(0.068 to 1.333) 
0.489 
(0.169 to 1.215) 
0.583 
(0.187 to 1.654) 
0.813 
(0.163 to 0.998) 
0.558 
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Prior for τ 
Prior for ρB 
Pooled partially-
adjusted log HR 
(95% CrI) 
Pooled fully-
adjusted log HR 
(95% CrI) 
τ̂1








(0.124 to 1.094) 
0.749 
(0.040 to 1.449) 
0.424 
(0.152 to 1.043) 
0.616 
(0.178 to 1.905) 
0.606 
(0.234 to 0.895) 
0.520 
1/τj2~Gamma(0.1,0.1)       
ρB=ρWi=0 
0.553 
(-0.667 to 1.779) 
0.645 
(-2.409 to 3.588) 
3.512 
(1.262 to 9.138) 
10.999 





(-0.811 to 1.938) 
0.674 
(-1.146 to 2.434) 
4.508 
(1.570 to 11.341) 
6.821 
(1.924 to 22.742) 
0.842 




(-0.658 to 1.819) 
0.741 
(-2.061 to 3.507) 
3.475 
(1.266 to 8.940) 
10.201 
(1.929 to 42.271) 
0.143 




(-0.750 to 1.885) 
0.676 
(-1.493 to 2.902) 
3.963 
(1.391 to 10.333) 
8.083 
(1.883 to 31.501) 
0.629 




(-0.818 to 2.006) 
0.666 
(-1.044 to 2.396) 
4.642 
(1.598 to 11.856) 
6.423 
(1.884 to 21.295) 
0.932 




(-0.672 to 1.770) 
0.666 
(-1.768 to 3.082) 
3.488 
(1.297 to 8.919) 
8.955 
(1.922 to 34.985) 
0.622 
(0.234 to 0.908) 
0.401 
τj~Uniform(0,2)       
ρB=ρWi=0 
0.582 
(0.297 to 0.899) 
0.871 
(-0.036 to 1.586) 
0.102 
(0.000 to 0.570) 
0.435 





(0.336 to 0.864) 
0.705 
(0.353 to 1.117) 
0.067 
(0.000 to 0.343) 
0.090 
(0.000 to 0.607) 
0.256 
(-0.893 to 0.982) 
0.774 
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Prior for τ 
Prior for ρB 
Pooled partially-
adjusted log HR 
(95% CrI) 
Pooled fully-
adjusted log HR 
(95% CrI) 
τ̂1








(0.351 to 0.855) 
0.717 
(0.387 to 1.131) 
0.055 
(0.000 to 0.265) 
0.083 
(0.000 to 0.594) 
0.083 




(0.357 to 0.864) 
0.723 
(0.376 to 1.135) 
0.061 
(0.000 to 0.308) 
0.081 
(0.000 to 0.551) 
0.166 




(0.329 to 0.883) 
0.693 
(0.335 to 1.086) 
0.081 
(0.000 to 0.395) 
0.098 
(0.000 to 0.594) 
0.591 




(0.322 to 0.876) 
0.696 
(0.306 to 1.081) 
0.069 
(0.000 to 0.321) 
0.095 
(0.000 to 0.596) 
0.530 








(0.367 to 0.801) 
0.967 
(0.462 to 1.398) 
0.035 
(5.8E-5 to 0.256) 
0.089 





(0.378 to 0.773) 
0.638 
(0.395 to 0.947) 
0.016 
(0.000 to 0.105) 
0.013 
(0.000 to 0.105) 
0.041 




(0.369 to 0.769) 
0.634 
(0.393 to 0.935) 
0.014 
(0.000 to 0.097) 
0.011 
(0.000 to 0.086) 
0.020 




(0.383 to 0.777) 
0.641 
(0.417 to 0.935) 
0.015 
(0.000 to 0.099) 
0.013 
(0.000 to 0.091) 
0.028 




(0.375 to 0.783) 
0.635 
(0.400 to 0.934) 
0.017 
(0.000 to 0.112) 
0.015 
(0.000 to 0.113) 
0.515 
(0.026 to 0.977) 
0.897 
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Prior for τ 
Prior for ρB 
Pooled partially-
adjusted log HR 
(95% CrI) 
Pooled fully-
adjusted log HR 
(95% CrI) 
τ̂1








(0.372 to 0.790) 
0.640 
(0.396 to 0.947) 
0.017 
(0.000 to 0.116) 
0.013 
(0.000 to 0.102) 
0.505 









(0.335 to 0.852) 
0.978 
(0.447 to 1.449) 
0.057 
(0.000 to 0.272) 
0.120 





(0.362 to 0.821) 
0.692 
(0.399 to 1.031) 
0.036 
(0.001 to 0.155) 
0.035 
(0.001 to 0.200) 
0.199 




(0.367 to 0.812) 
0.701 
(0.410 to 1.037) 
0.033 
(0.001 to 0.143) 
0.031 
(0.001 to 0.161) 
0.069 




(0.364 to 0.817) 
0.696 
(0.410 to 1.027) 
0.036 
(0.001 to 0.160) 
0.036 
(0.001 to 0.160) 
0.029 




(0.359 to 0.826) 
0.681 
(0.404 to 0.995) 
0.042 
(0.001 to 0.177) 
0.037 
(0.001 to 0.187) 
0.561 




(0.360 to 0.821) 
0.682 
(0.400 to 1.001) 
0.038 
(0.001 to 0.149) 
0.035 
(0.001 to 0.177) 
0.522 
(0.183 to 0.841) 
0.772 
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Key finding (iii): Bivariate meta-analysis impacts upon the pooled estimates more 
when there are missing data. 
The pooled results from the univariate meta-analysis (where ρWi=ρB=0 in model (6.1)) for 
both examples are also shown in Table 6.3 and Table 6.4. In example A, the pooled 
treatment effects are very similar regardless of using bivariate or univariate meta-analysis. 
Riley et al.232 identify this is due to complete data in all studies (i.e. both treatment effects are 
known in all 10 studies). However, in example B, the univariate pooled estimate of the fully-
adjusted log HR is vastly different to the bivariate pooled estimate due to additional 
borrowing of strength in those five studies where the fully-adjusted result was missing. For 
example, the univariate meta-analysis has a pooled fully-adjusted log HR of 0.928 (95% CrI 
0.162 to 1.536) using a prior of τj~N(0,1)I(0,). In the bivariate meta-analysis with the same 
prior distribution for τj, and ρB~uniform(-1,1), the pooled log HR is 0.708 (95% CrI 0.379 to 
1.100). Although the conclusions based on these two pooled estimates would be the same, 
the pooled effect is much smaller with a narrower credible interval in the bivariate meta-
analysis due to the borrowing of strength across outcomes. 
Also, the joint probability estimates are affected in the bivariate model compared to the 
univariate model. For example, in the univariate analysis where τj~N(0,1)I(0,) the joint 
probability that partially adjusted log HR>0.405 and fully adjusted log HR>0.405 is 0.656. 
This probability is higher for the bivariate meta-analysis model for all prior distributions for ρB. 
In particular, when ρB~uniform(-1,1), this joint probability is 0.754. 
Key finding (iv): Bivariate meta-analysis also impacts upon the posterior results for τj. 
The estimates of the between-study variances are also different between the univariate and 
bivariate meta-analyses. This is especially evident in example B. For example, in the 
univariate analysis using a prior of τj~N(0,1)I(0,), τ̂1
2 is 0.112 (95% CrI 0.000 to 0.549); 
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however, in the bivariate analysis using priors of ρB~uniform(-1,1) and τj~N(0,1)I(0,), τ̂1
2 is 
0.092 (95% CrI 0.000 to 0.298). Similarly, τ̂2
2  is 0.311 (95% CrI 0.000 to 1.859) in the 
univariate analysis, compared to 0.142 (95% CrI 0.000 to 0.410) in the bivariate analysis. 
Key finding (v): The prior distribution for ρB also influences the posterior estimates for 
τj. 
The prior distribution for ρB can alter the posterior estimates of the between-study variance 
for the same choice of prior distribution for τj. For example, in example B when using priors of 
1/τj2~gamma(0.1,0.1) and ρB~uniform(-1,1) the posterior estimate of τ12 is 4.508 (95% CrI 
1.570 to 11.341) and for τ22 is 6.821 (95% CrI 1.924 to 22.742). In this analysis, the posterior 
estimate of ρB is 0.842 (95% CrI: -0.644 to 0.999) However, when the Fisher transformation 
prior is used for ρB the posterior estimate of τ12 is 3.475 (95% CrI 1.266 to 8.940) and the 
posterior estimate of τ22 is 10.201 (95% CrI 1.929 to 42.271). In this analysis, the posterior 
estimate of ρB is 0.143 (95% CrI: -0.647 to 0.804). 
Key finding (vi): The gamma prior distribution for 1/τj2 appears inappropriate. 
The gamma prior distribution for the between-study variance appears particularly 
inappropriate because the posterior estimates of τj2 are much larger than other prior 
distributions, and this increases the posterior estimate of ρB, which affects the joint probability 
estimates. For example, in motivating example B with a uniform(-1,1) prior for ρB the 
posterior estimates of τ12 and τ22 are 4.508 (95% CrI 1.570 to 11.341) and 6.821 (95% CrI 
1.924 to 22.742), respectively when using a gamma(0.1,0.1) prior distribution for the 
between-study variance parameters. The posterior estimate of ρB is 0.842 (95% CrI -0.644 to 
0.999) and the joint probability of interest is 0.446. In contrast, the corresponding estimates, 
with perhaps a more realistically vague N(0,2)I(0,) prior for τj, are 0.065 (95% CrI 0.000 to 
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0.331) for τ12 and 0.076 (95% CrI 0.000 to 0.520) for τ22. The posterior estimate of ρB is 0.221 
(95% CrI -0.923 to 0.979) and the joint probability of interest is 0.729, both dramatically 
different to when the gamma prior was used. This finding agrees with those already 
determined by Lambert et al.29 and Wei et al.237 about the influential impact of a gamma 
(Wishart) prior on the between-study variances; in addition, the above results reveal it is also 
influential toward the between-study correlation and joint inferences. 
Summary 
In summary, the two motivating examples highlight six key findings. Clearly, the choice of 
prior distributions for the between-study correlation and between-study variances are 
important. These can all influence posterior results and joint inferences, sometimes 
dramatically so when the chosen priors are inappropriate. This is especially important when 
there is large borrowing of strength in a bivariate meta-analysis as in example B. Thus, the 
examples indicate that all prior distributions must be specified with due consideration in a 
bivariate meta-analysis and that seemingly vague priors may actually be influential. Of 
course, these are merely two examples that motivate further inquiry, and thus a simulation 
study will now be conducted to explore whether these results are found more generally. 
6.4 Methods of the simulation study 
This section introduces a simulation study of the impact of prior distributions for the between-
study correlation in a Bayesian estimation of bivariate meta-analysis model (6.1). The 
simulation focuses mainly on N=10 studies per meta-analysis, as this represents a fairly 
typical size of meta-analysis.238 Section 6.7 will briefly consider alternative N. Both complete 
data (both outcomes are available in all studies) and missing data (some studies only provide 
one outcome) are considered. 
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Given below is an outline of the procedure used to simulate the data. The description of the 
procedure is brief because this data was generated for a previous simulation study by Riley 
et al.,218 where the aim was to evaluate the benefits of model (6.1) in comparison to 
univariate meta-analysis models (in a frequentist framework). Riley et al. generated meta-
analysis data for N=50 studies per meta-analysis dataset, which consisted of an estimate for 
each outcome (Yi1 and Yi2) in each study, and their variances (si12  and si22 ) and a chosen 
within-study correlation. Complete data were generated for both outcomes and the full 
dataset contained 1000 simulated meta-analyses. 
6.4.1 How Riley et al. generated bivariate meta-analysis data for 50 
studies 
To obtain the data, Riley et al.225 generated data at summary level rather than for the 
individual patient level, for 50 studies as follows. Two true mean (pooled) treatment effects 
were chosen to reflect contrasting effects, so β1=0 (e.g. no difference in blood pressure) to 
reflect no clinical benefit, and β2=2 (e.g. 2 mmHg difference in blood pressure) to reflect 
potentially useful clinical benefit. The 50 within-study variances (i.e.si12  and si22  from model 
(6.1)) were sampled from the following distribution: �
ln(si12 )
ln(si22 )
�  ~ N��0.250.25�  , �
0.25 0
0 0.25��, 
and were assumed known and kept the same across all the 1000 simulated meta-analysis 
datasets. Using the known 50 si12  and 50 si22 , and letting τ1=0.5 and τ2=0.5, 50 Yi1 and 50 Yi2 
were generated 1000 times for each of the four following settings. 
1. ρWi=0; ρB=0; β1=0; β2=2, τ1=0.5, τ2=0.5 and 50 si12  and 50 si22  
2. ρWi=0; ρB=0.8; β1=0; β2=2, τ1=0.5, τ2=0.5 and 50 si12  and 50 si22  
3. ρWi=0.8; ρB=0; β1=0; β2=2, τ1=0.5, τ2=0.5 and 50 si12  and 50 si22  
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4. ρWi=0.8; ρB=0.8; β1=0; β2=2, τ1=0.5, τ2=0.5 and 50 si12  and 50 si22  
These four settings vary according to the magnitude of within-study and between-study 
correlations. Only non-negative within-study and between-study correlations are considered, 
as bivariate meta-analyses are similar regardless of whether positive or negative correlations 
are considered218 in terms of their impact on pooled treatment effect estimates. 
For each of the four settings, 50 θi1 and 50 θi2 were randomly generated 1000 times from the 
corresponding bivariate distribution at the study-level. Using setting 1 as an example, where 
there is no between-study correlation between the treatment effects, the 50 θi1 and 50 θi2 





�  ~ N��
β1
β2




For settings 2 and 4, equation (6.2) was changed so that the covariance in D was 0.2, to 
ensure the 50 θi1 and θi2 were generated according to a between-study correlation of 0.8. 
Then, the next step was to generate the Yi1 and Yi2. In each setting separately, and for each 
set of the 50 θi1 and 50 θi2, obtained, 50 Yi1 and 50 Yi2 were generated using the 50 θi1 and 
50 θi2 together with the 50 si12  and 50 si22 . Using setting 1 as an example, where there is no 






�  ~ N ��θi1θi2








In settings 3 and 4, the covariance in equation (6.3) was changed to ensure the within-study 
correlation was 0.8. In this way, for each of the 1000 simulations in each setting, 50 Yi1 and 
50 Yi2 were generated. 
6.4.2 Step-by-step guide to new simulation study 
The simulation procedure used in this chapter is now described. 
Step 1: Data set-up 
The data generated by Riley et al. was used in this new simulation study to evaluate the 
impact of prior distributions in each of settings 1 to 4. As described, 50 study estimates were 
available per outcome in each meta-analysis dataset, but only a proportion of these are used 
here. For example, if there are 10 studies per meta-analysis, the first 10 studies are selected 
and the rest are discarded. 
Step 2: Analysis 
In each setting and for each number of studies per meta-analysis, to each of the 1000 meta-
analysis datasets a bivariate meta-analysis model (6.1) was fitted with a particular set of 
chosen prior distributions. This was then repeated for each different set of prior distributions 
of interest. The posterior estimates of the parameters in model (6.1) for each dataset were 
obtained using the Gibbs Sampler Markov chain Monte Carlo (MCMC) method, which was 
implemented in SAS 9.3 using the PROC MCMC procedure.236 For each dataset, the 
analyses were performed with 300000 iterations after allowing for a 200000 iteration burn in 
and the samples were thinned by 100 to reduce concerns of autocorrelation (see Appendix 
D1 for SAS code). The convergence of parameters was checked using history and trace 
plots. The mean, median, standard deviation, and 95% credible interval from the posterior 
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distribution for each of the parameters in model (6.1), and the individual and joint 
probabilities were stored from the results of each of the 1000 datasets. 
Step 3: Comparison of results 
To compare the choice of prior distribution for the between-study correlation, the following 
were calculated from the set of 1000, for each combination of priors: 
• The average posterior mean estimate of pooled treatment effects (β�j) across all 
simulations, the average (mean/median) posterior between-study standard deviation 
estimates (τj�) across all simulations; and the average (mean/median) posterior 
between-study correlation estimate (ρ�B) across all simulations (to check for bias), 
• The mean and median standard error of the posterior pooled treatment effects, β�1 and 
β�2 across simulations, 
• The mean-squared error (MSE) of the pooled treatment effects, calculated by the 
average squared deviation from the true value across the 1000 simulated datasets, 
• The coverage performance of the 95% credible intervals for the pooled treatment 
effects, calculated by the percentage of the 95% credible intervals that contain the 
true treatment effect, 
• The average marginal probabilities that θi1new>0 and θi2new>2, and the average joint 
probability that θi1new>0 and θi2new>2. 
Recall that, based on bivariate model (6.1), the predictive distribution of treatment effects in a 












When drawing θi1new and θi2new samples from this distribution during the MCMC process, the 
uncertainty in the pooled average treatment effects, β1 and β2, and the uncertainty in the 
between-study covariance matrix, D, will also be accounted for. In settings 1 and 3, where 
ρB=0, the true marginal probabilities are 0.5 for both treatment effects, and the true joint 
probability that θi1new>0 and θi2new>2 is 0.25. When ρB=0.8 in settings 2 and 4, the true joint 
probability is 0.4. 
These simulation results (e.g. bias, MSE, coverage) are essentially a frequentist evaluation 
of a Bayesian analysis, which some may argue may not be appropriate. In particular, Senn239 
previously suggested that it is perhaps philosophically incorrect to conduct a simulation study 
to assess the performance of Bayesian prior distributions because it is “irrelevant to any 
Bayesian who truly believed what the prior distribution represented”. However, the rationale 
for a simulation study to assess the various prior distributions here is similar to that of 
Lambert et al. in their response to this article. They say that, “if a statistician desires to have 
a model with good bias and coverage properties, but needs/wants to use Bayesian methods, 
then we believe that simulation is a very good way of establishing this.”240 
6.4.3 Choice of prior distribution for between-study correlation 
The prior distributions for the between-study correlation considered in the simulation study 
were the same as those used in motivating Examples A and B described in section 6.3. The 
distributions are repeated below: 
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• Prior 1: ρB~uniform(-1,1), 





• Prior 3: �ρB+1�
2
~Beta(1.5,1.5), 
• Prior 4: ρB~uniform(0,1), 
• Prior 5: logit(ρB)~N(0,sd=0.8). 
6.4.4 Choice of prior distribution for between-study variance 
The motivating examples in section 6.3 highlight that the choice of prior distribution for the 
between-study variance does affect the between-study correlation and the pooled results. 
Rather than observing the effect of the prior distribution for the correlation parameter, any 
potential observations of this choice of prior may be mistaken for those that actually arise 
from the choice of prior distribution for the between-study variances. Alternatively, it may be 
that the prior distribution for the between-study correlation may be inappropriate due to the 
choice of prior distribution for the between-study variance since these parameters are not 
independent.17 Thus, it is important to initially determine an appropriate prior distribution for 
the between-study variance parameters, τj2, to use in the simulation study. To do this, a 
univariate meta-analysis approach was applied first to the simulated datasets, where 
ρWi=ρB=0 in model (6.1), in order to determine an appropriate prior distribution for τj. The 
following prior distributions for the between-study variance as introduced in section 6.3 were 
evaluated. No empirical prior distributions are used in this simulation study. 
• τj~N(0,1)I(0,) and τj~N(0,2)I(0,), 
• 1/τj2~gamma(1,1) and 1/τj2~gamma(0.1,0.1), 
• τj~uniform(0,2), 
• log(τj2)~uniform(-10, 1.386). 
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The results are shown in Appendix D2 and indicate that, for this simulation study where the 
true between-study standard deviations are 0.5, the τj~N(0,2)I(0,) prior distribution was most 
suitable giving appropriate posterior estimates and coverage for all parameters, including the 
between-study standard deviations, which had posterior means close to the true value of 
τj=0.5. The gamma priors for 1/τj2 were by far the poorest. Thus, in the bivariate simulations 
that follow, the simulations are repeated for both the N(0,2)I(0,) prior distribution (a good 
prior) and, for contrast, a gamma(0.1,0.1) prior distribution (a poor prior). 
6.4.5 Summary of all the settings and prior distributions to be evaluated 
in the simulation study of bivariate meta-analysis 
To summarise, the four following settings are assessed in this simulation study: 
1. ρWi=0; ρB=0; β1=0; β2=2, τ1=0.5, τ2=0.5 and 50 si12  and 50 si22  
2. ρWi=0; ρB=0.8; β1=0; β2=2, τ1=0.5, τ2=0.5 and 50 si12  and 50 si22  
3. ρWi=0.8; ρB=0; β1=0; β2=2, τ1=0.5, τ2=0.5 and 50 si12  and 50 si22  
4. ρWi=0.8; ρB=0.8; β1=0; β2=2, τ1=0.5, τ2=0.5 and 50 si12  and 50 si22  
Within each setting, all 10 different combinations of the chosen prior distributions shown 
below in Table 6.5 for the between-study correlation and the between-study variance 
parameters are evaluated. 
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Table 6.5: All combinations of prior distributions for between-study correlation and 
between-study variance. 
Combination Prior distribution for ρB Prior distribution for τj 














(iv) ρB~uniform(0,1) τj~N(0,2)I(0,) 
(v) logit(ρB)~N(0,sd=0.8) τj~N(0,2)I(0,) 
















(ix) ρB~uniform(0,1) 1/τj2~gamma(0.1,0.1) 
(x) logit(ρB)~N(0,sd=0.8) 1/τj2~gamma(0.1,0.1) 
 
6.5 Results of the bivariate simulation study with complete data 
6.5.1 Results when using prior distribution for between-study variance 
of τj~N(0,2)I(0,) 
The results of the simulation study are now described, focussing firstly on a meta-analysis of 
10 studies with complete data (i.e. both outcomes available in all studies). Table 6.6 displays 
the simulation results for setting 1 for the various prior distributions for the between-study 
correlation, where the prior distribution for τj is always N(0,2)I(0,). The equivalent results for 
settings 2, 3, and 4 are presented in Table 6.7, Table 6.8, and Table 6.9, respectively. The 
key findings are now discussed. 
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Table 6.6: Simulation results for 10 studies with complete data (setting 1). The within-study correlation, ρWi was zero and the 
same for each study. The prior distribution for τj is N(0,2)I(0,) and for βj is N(0,10002). 















































































































































































MSE is mean-square error; CrI is credible interval; s.e. is standard error; the means and medians represent the posterior means and medians from the 
distribution of summary estimates from the 1000 datasets. 
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Table 6.7: Simulation results for 10 studies with complete data (setting 2). The within-study correlation, ρWi was zero and the 
same for each study. The prior distribution for τj is N(0,2)I(0,) and for βj is N(0,10002). 















































































































































































MSE is mean-square error; CrI is credible interval; s.e. is standard error; the means and medians represent the posterior means and medians from the 
distribution of summary estimates from the 1000 datasets. 
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Table 6.8: Simulation results for 10 studies with complete data (setting 3). The within-study correlation, ρWi was 0.8 and the same 
for each study. The prior distribution for τj is N(0,2)I(0,) and for βj is N(0,10002). 















































































































































































MSE is mean-square error; CrI is credible interval; s.e. is standard error; the means and medians represent the posterior means and medians from the 
distribution of summary estimates from the 1000 datasets. 
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Table 6.9: Simulation results for 10 studies with complete data (setting 4). The within-study correlation, ρWi was 0.8 and the same 
for each study. The prior distribution for τj is N(0,2)I(0,) and for βj is N(0,10002). 
















































































































































































MSE is mean-square error; CrI is credible interval; s.e. is standard error; the means and medians represent the posterior means and medians from the 
distribution of summary estimates from the 1000 datasets. 
238 
 
Impact of prior distribution for ρB on the posterior estimates for ρB 
In all settings the prior distribution for ρB is informative of the posterior estimate of ρB, which 
is consistent with the finding in the motivating examples in section 6.3.3. For the prior 
distributions for ρB that are centred on zero, in all settings the average estimate of ρB across 
simulations is close to zero, regardless of the true value of ρB. However, when the prior 
distribution is centred on a different value (in this case, those priors centred on 0.5), the 
average posterior mean of ρB is close to 0.5. This is expected since there are only 10 studies 
per meta-analysis, which means there is little data to estimate this parameter and thus the 
posterior mean is similar to the prior mean. For example, in setting 1 (where ρWi=ρB=0) where 
ρB~uniform(-1,1), the posterior mean of ρB across simulations is 0.007. When 
ρB~uniform(0,1), the posterior mean of ρB across simulations is 0.412. A similar result is 
observed in settings 2-4. In setting 2 and setting 4, the true ρB is 0.8, however, none of the 
selected priors led to estimates of this parameter close to its true value. For example, in 
setting 4 (ρWi=ρB=0.8) where ρB~uniform(0,1), the posterior mean of ρB is only 0.646. 
Impact of prior distribution for ρB on marginal and joint inferences about treatment 
effect 
The average marginal probability estimates are close to the true value of 0.5 for both 
treatment effects for all settings. However, the prior distribution for ρB has an impact on the 
joint probability estimates of interest. The average joint probabilities are slightly higher for the 
positive prior distributions for ρB even when the true between-study correlation is zero. In 
setting 1, where the true joint probability of interest is 0.25, the average estimate of this 
probability is 0.296 when ρB~uniform(0,1). When ρB~uniform(-1,1), the average estimate of 
this joint probability is 0.248. Also, since no prior distribution leads to estimates of the true 
between-study correlation close to 0.8 in settings 2 and 4, the joint probability is lower than 
the true value of 0.4. In setting 4 (Table 6.9), where ρB~uniform(-1,1), the posterior average 
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joint probability is 0.328 compared to the true value of 0.4. With a uniform(0,1) prior 
distribution for ρB, the average joint probability is closest to 0.4 compared to the other prior 
distribution analyses with an estimate of 0.346. Given that the joint probability is 
underestimated this will be investigated further for larger numbers of studies per meta-
analysis in Section 6.7. 
Impact of prior distribution for ρB on pooled treatment effect estimates 
Although the prior distribution for ρB affects the estimate of ρB, the posterior means of β1 and 
β2 across all simulations are very close to the true values. For example, in setting 1 (Table 
6.6) when ρB~uniform(-1,1), the mean β1 is -0.002 compared to β1=0, and the mean β2 is 
2.001 compared to the true β2=2. The performance of the 95% credible intervals is also close 
to 95% for the pooled estimates. 
Impact of prior distribution for ρB on between-study standard deviations 
The average between-study standard deviation across simulations is estimated close to the 
true value for all settings (τj=0.5). The estimates of between-study variability tend to be 
slightly larger when the estimate of between-study correlation is larger. For example, in 
setting 3 (Table 6.8), the posterior mean τ1 across simulations is 0.584 when 
logit(ρB)~N(0,sd=0.8), and the posterior mean of ρB is 0.456. However, the posterior mean τ1 
is 0.532 when ρB~uniform(-1,1) and the posterior mean of ρB is lower (-0.035). 
6.5.2 Results when prior distribution for between-study variance is 
1/τj2~gamma(0.1,0.1) 
Table 6.10 displays the simulation results for setting 1 for the various prior distributions for 
the between-study correlation, where the prior distribution for 1/τj2 is gamma(0.1,0.1). The 
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equivalent results for settings 2, 3, and 4 are presented in Table 6.11, Table 6.12, and Table 
6.13, respectively. The key findings for these scenarios are now discussed. 
The mean pooled treatment effect estimates remain unbiased for all prior distributions for ρB 
for settings 1 to 4. However, as observed in the univariate meta-analysis simulation study in 
section 6.4.4 and Appendix D2, the gamma prior distribution leads to estimates of between-
study variance that are much larger than the true value for both outcomes. Therefore, the 
average standard errors of the pooled treatment effect estimates are much larger than those 
when τj~N(0,2)I(0,). Thus, the credible intervals for the pooled effect estimates are much 
wider, which means the number of credible intervals that contain the true value is 100% for 
all prior distributions in all settings. 
The motivating examples highlighted that if the between-study variance is larger, this is likely 
to increase the estimate of ρB. This is evident again as the mean estimates of ρB are larger 
than in the corresponding analyses where the prior distribution of τj~N(0,2)I(0,) was used. For 
example, where 1/τj2~gamma(0.1,0.1) and ρB~uniform(-1,1) in setting 4 (Table 6.13, 
ρWi=ρB=0.8), the posterior mean ρB across simulations is 0.809. However, the posterior mean 
ρB is only 0.516 with the same prior for ρB, but where τj~N(0,2)I(0,) (Table 6.9). This is 
because the average estimates of τj are much higher with the gamma prior (posterior mean 
τ1=1.954, posterior mean τ2=2.126) compared to the normal prior (posterior mean τ1=0.513, 




Table 6.10: Simulation results for 10 studies with complete data (setting 1). The within-study correlation, ρWi was zero and the 
same for each study. The prior distribution for 1/τj2 is gamma(0.1,0.1) and for βj is N(0,10002). 















































































































































































MSE is mean-square error; CrI is credible interval; s.e. is standard error; the means and medians represent the posterior means and medians from the 
distribution of summary estimates from the 1000 datasets. 
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Table 6.11: Simulation results for 10 studies with complete data (setting 2). The within-study correlation, ρWi was zero and the 
same for each study. The prior distribution for 1/τj2 is gamma(0.1,0.1) and for βj is N(0,10002). 















































































































































































MSE is mean-square error; CrI is credible interval; s.e. is standard error; the means and medians represent the posterior means and medians from the 
distribution of summary estimates from the 1000 datasets. 
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Table 6.12: Simulation results for 10 studies with complete data (setting 3). The within-study correlation, ρWi was 0.8 and the 
same for each study. The prior distribution for 1/τj2 is gamma(0.1,0.1) and for βj is N(0,10002). 















































































































































































MSE is mean-square error; CrI is credible interval; s.e. is standard error; the means and medians represent the posterior means and medians from the 
distribution of summary estimates from the 1000 datasets. 
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Table 6.13: Simulation results for 10 studies with complete data (setting 4). The within-study correlation, ρWi was 0.8 and the 
same for each study. The prior distribution for 1/τj2 is gamma(0.1,0.1) and for βj is N(0,10002). 















































































































































































MSE is mean-square error; CrI is credible interval; s.e. is standard error; the means and medians represent the posterior means and medians from the 
distribution of summary estimates from the 1000 datasets. 
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Also, when the gamma prior distribution is used for the between-study variance parameters, 
and thus the between-study variance is overestimated, there can be a huge upward bias in 
the posterior estimate of the between-study correlation even if the uniform(-1,1) prior 
distribution is selected for ρB. For example, in Table 6.13 (setting 3: ρWi=0.8, ρB=0) and 
ρB~uniform(-1,1) the mean posterior ρB is 0.605. This highlights the need to conduct 
sensitivity analyses for the prior distributions on both between-study variance and between-
study correlation, especially where robust external information is unavailable a priori for 
these parameters. 
The marginal probability estimates for θi1new and θi2new are close to the true values of 0.5 for 
all settings with the gamma prior. However, as expected, the joint probability(θ� i1new>0 & 
θ� i2new>2) is influenced by the estimate of correlation between the outcomes (the true joint 
probability is 0.4 if ρB=0.8, and the true joint probability is 0.25 if ρB=0). For example, in 
setting 4 (ρB=0.8, Table 6.13), the joint probability estimate is 0.273 for the analysis with a 
Fisher prior distribution for ρB, whereas this probability is 0.387 when ρB~uniform(-1,1). 
These probabilities are also different to those estimated with variance prior τj~N(0,2)I(0,) in 
which the mean joint probability with the Fisher prior distribution for ρB is 0.292 and this joint 
probability estimate is 0.328 when ρB~uniform(-1,1). These examples highlight that if the prior 
distribution is incorrectly specified for the between-study variances and between-study 
correlation, this can lead to incorrect joint inferences. 
6.6 Impact of prior distribution for ρB when there is missing 
outcome data 
The simulation studies in this chapter so far have assessed the various prior distributions for 
unknown parameters when the data is complete for both outcomes. One important finding is 
that although the prior for the between-study correlation is informative toward the between-
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study correlation estimates, it has little impact on the pooled results of interest. However, 
these findings may be different if there is missing data for one outcome because the role of 
the between-study correlation becomes more important. In particular, a multivariate meta-
analysis should reduce the MSE in the pooled estimate for the outcome with missing data 
compared to a univariate meta-analysis.17,200,213,215,225,232 But, an incorrect choice of prior for 
the between-study correlation may alter this. In order to explore this, a dataset with missing 
data (missing not at random) was generated by selectively removing the treatment effect 
estimate for outcome 1 (Yi1) if it is larger than the unweighted mean of Yi1 within each set of 
10 trials, i.e.: 







On average, this will remove half of the treatment effect estimates and their standard errors 
for outcome 1 in each simulated dataset. Thus, it is of particular interest whether the prior 
distributions affect the outcome 1 results in this setting. The intention to selectively remove 
the data for outcome 1 in this way is to represent a situation similar to selective outcome 
reporting bias and to explore the impact of the choice of prior distribution in this setting. Both 
the N(0,2)I(0,) prior distribution for τj and the gamma(0.1,0.1) prior distribution for 1/τj2 are 
used but only for settings 3 and 4 where there is within-study correlation of 0.8. 
6.6.1 Results with missing data when prior distribution for τj is N(0,2)I(0,) 
The simulation results for this missing data scenario are shown in Table 6.14 for setting 3 
(β1=0, β2=2, τ1=τ2=0.5, ρWi=0.8, ρB=0) and in Table 6.15 for setting 4 (β1=0, β2=2, τ1=τ2=0.5, 
ρWi=ρB=0.8). As expected, due to the selective missingness, the average pooled treatment 
effect estimate for β1 is consistently lower than the true value for all prior distributions, and in 
all settings. For example, in setting 4 (Table 6.15), the posterior mean β1 is -0.432 (s.e. is 
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0.250) where ρB~uniform(-1,1). However, if the posterior mean ρB is higher, the bias in the 
pooled posterior estimate of β1 is lower. For example, in the same set of results, if 
ρB~uniform(0,1) then the posterior mean ρB is 0.545 and the mean β1 is -0.390. The estimate 
of treatment effect for outcome two remains unbiased across all settings as there is complete 
data for this outcome. 
The posterior mean pooled β1 across simulations is closer to the true value for all prior 
distributions for ρB compared to the univariate model. For example, in Table 6.15 
(ρwi=ρB=0.8) where ρB~uniform(-1,1), the posterior mean β1 is -0.436 (s.e. is 0.258) whereas 
this estimate from the univariate analysis is -0.483 (s.e. is 0.251). The MSE of β1 is lower in 
the bivariate model compared to the univariate model, for all prior distributions for ρB. In the 
same scenario, the MSE of β1 is 0.249 when ρB~uniform(-1,1) and the equivalent statistic for 
the univariate analysis is higher with an estimate of 0.296. Further, if a more appropriate prior 
distribution is used for ρB, the MSE is reduced compared to the other prior distributions. For 
example, in the same setting, where ρB~uniform(0,1) (posterior mean ρB is 0.545), the MSE 
of β1 is 0.210. This is smaller than when ρB~uniform(-1,1) above, and it is also considerably 
lower than that from the univariate analysis. The more appropriate prior distributions for ρB 
also lead to increased numbers of 95% CrIs that contain the true value. Where 
ρB~uniform(0,1), the number of 95% CrIs that contain β1 is 73.5%, compared to 67.2% when 




Table 6.14: Simulation results for 10 studies with missing data for outcome 1 (setting 3). The within-study correlation, ρWi was 
0.8 and the same for each study. The prior distribution for τj is N(0,2)I(0,) and for βj is N(0,10002). 





































































































































































































MSE is mean-square error; CrI is credible interval; s.e. is standard error; the means and medians represent the posterior means and medians from the 
distribution of summary estimates from the 1000 datasets. 
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Table 6.15: Simulation results for 10 studies with missing data for outcome 1 (setting 4). The within-study correlation, ρWi was 
0.8 and the same for each study. The prior distribution for τj is N(0,2)I(0,) and for βj is N(0,10002). 





































































































































































































MSE is mean-square error; CrI is credible interval; s.e. is standard error; the means and medians represent the posterior means and medians from the 
distribution of summary estimates from the 1000 datasets. 
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Although there are reductions in the standard errors and MSE of the average treatment 
effects with the bivariate meta-analysis model compared to the univariate model, the prior 
distribution for the between-study correlation is even more influential on its posterior 
distribution compared to the complete case simulation study. This is due to fewer studies that 
provide both outcomes. Therefore, in these simulation settings all prior distributions lead to 
underestimated between-study correlation. In Table 6.15, where the true ρB is 0.8, and for 
ρB~uniform(-1,1), the mean ρ�B is 0.155. This has an impact on the joint probability estimates. 
For example, for the same scenario, the joint probability estimate that θ� i1new>0 and θ� i2new>2 
is 0.113 (true joint probability is 0.4). For ρB~uniform(0,1), the posterior mean ρB across 
simulations is 0.545 and, as a result, the joint probability is slightly higher with an estimate of 
0.145. 
6.6.2 Results with missing data when prior distribution for 1/τj2 is 
gamma(0.1,0.1) 
The results of the missing data scenario when the prior distribution for 1/τj2 is gamma(0.1,0.1) 
are shown in Table 6.16 (ρWi=0.8, ρB=0) and Table 6.17 (ρWi=ρB=0.8). The results here are 
similar to those from the complete data simulation study with this prior distribution for the 
between-study variances. The posterior estimates of τj are hugely overestimated, which 
means that the posterior mean estimates of ρB are higher for all prior distributions for ρB 
(compared to the N(0,2)I(0,) prior for τj). This increases the average standard deviation of the 
posterior distribution for β1 for the bivariate analyses compared to the univariate analysis and 
thus the number of 95% CrIs that contain the true β1 is 100%. For example, in Table 6.17 
(ρWi=ρB=0.8) where ρB~uniform(-1,1) the posterior mean of τ1 is 2.585 (τ1=0.5) and the mean 




Table 6.16: Simulation results for 10 studies with missing data for outcome 1 (setting 3). The within-study correlation, ρWi was 
0.8 and the same for each study. The prior distribution for1/τj2 is gamma(0.1,0.1) and for βj is N(0,10002). 





































































































































































































MSE is mean-square error; CrI is credible interval; s.e. is standard error; the means and medians represent the posterior means and medians from the 
distribution of summary estimates from the 1000 datasets. 
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Table 6.17: Simulation results for 10 studies with missing data for outcome 1 (setting 4). The within-study correlation, ρWi was 
0.8 and the same for each study. The prior distribution for1/τj2 is gamma(0.1,0.1) and for βj is N(0,10002). 





































































































































































































MSE is mean-square error; CrI is credible interval; s.e. is standard error; the means and medians represent the posterior means and medians from the 
distribution of summary estimates from the 1000 datasets. 
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6.7 The number of trials per meta-analysis and the influence of 
the prior distribution for the between-study correlation on its 
posterior distribution 
The results from the simulations so far illustrate that the prior distribution for the between-
study correlation is highly informative towards its posterior distribution and this is largely 
because there are only 10 studies per meta-analysis to estimate this parameter (or five 
studies per meta-analysis in the missing data scenarios). In settings 2 and 4, where there is 
strong true between-study correlation (ρB=0.8), most of the prior distributions for ρB result in 
this parameter being underestimated. This is a problem because the estimate of between-
study correlation affects the joint inferences, such as joint probability estimates and therefore 
it is important to estimate this parameter accurately. Thus, the following section investigates 
the number of studies per meta-analysis that result in a more accurate estimate of the 
between-study correlation. This simulation study is only investigated for complete case data 
in setting 4, where β1=0, β2=2, τ1=τ2=0.5, ρWi=0.8 and ρB=0.8, and a N(0,2)I(0,) prior 
distribution is selected again for τj. The numbers of studies per meta-analysis which are 




Table 6.18: Simulation results for 25 studies with complete data (setting 4). The within-study correlation, ρWi was 0.8 and the 
same for each study. The prior distribution for τj is N(0,2)I(0,) and for βj is N(0,10002). 





































































































































































































MSE is mean-square error; CrI is credible interval; s.e. is standard error; the means and medians represent the posterior means and medians from the 
distribution of summary estimates from the 1000 datasets. 
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Table 6.19: Simulation results for 50 studies with complete data (setting 4). The within-study correlation, ρWi was 0.8 and the 
same for each study. The prior distribution for τj is N(0,2)I(0,) and for βj is N(0,10002). 





































































































































































































MSE is mean-square error; CrI is credible interval; s.e. is standard error; the means and medians represent the posterior means and medians from the 
distribution of summary estimates from the 1000 datasets. 
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As expected, as the number of studies per meta-analysis increases, the posterior mean of ρB 
is closer to the true value. For example, when there are 10 studies (Table 6.9) and 
ρB~uniform(-1,1), the posterior mean ρB across simulations is 0.516, compared to an 
estimate of 0.734 when there are 50 studies. Interestingly, the average posterior estimate of 
ρB is still not especially close to the true value of 0.8 for any of the priors for ρB. Therefore, 
the choice of prior distribution for this parameter is very important because it is still influential 
on the posterior estimate of ρB even when there are 50 studies. Also, this improvement in the 
estimate of ρB has an effect on the joint probability estimates, but they are still lower than the 
true value of 0.4 for all prior distributions for ρB even when N=50. 
Also, as the number of studies per meta-analysis increases, the MSE and average standard 
errors for the two pooled treatment effect estimates reduce. For example, when there are 50 
studies and ρB~uniform(-1,1), the MSE of β1 is 0.008, compared to 0.038 when there are 10 
studies. Also, the mean standard error of the posterior distribution of β1 is 0.095 with 50 
studies compared to 0.219 with 10 studies. 
6.8 What if the between-study correlation is known? 
There is still a downward bias in the joint probability estimates even with large numbers of 
studies. This is, in part, due to the estimate of the between-study correlation, which is still not 
estimated particularly well even when there are 50 studies. However, it is not clear whether 
there may be another influence on the joint probability estimates. Therefore, setting 4 was 
repeated for a number of scenarios where the true between-study correlation is assumed 
known and equal to 0.8, but the other parameters are either fixed or assumed unknown (with 
complete data and 10 studies). Therefore, the following scenarios are investigated:  
1. ρB=0.8, τj~N(0,2)I(0,), βj~N(0,10002) 
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2. ρB=0.8, τj=0.5, βj~N(0,10002) 
3. ρB=0.8, τj~N(0,2)I(0,), β1=0, β2=2 
4. ρB=0.8, τj=0.5, β1=0, β2=2. 
The results are shown in Table 6.20. For scenario 1, the joint probability is still 
underestimated with an average estimate across simulations of 0.372 compared to 0.4. 
Given that the between-study correlation is fixed at the true value, it appears that the 
uncertainty in the parameter estimates has an effect on the joint inferences. This is confirmed 
in scenario 4 where the mean posterior joint probability estimate is 0.397. Therefore, it would 
seem that it is not just the downward bias of the between-study correlation that has been 
affecting the downward bias in the joint probability inferences throughout the simulations in 
this chapter. In other words, unless the meta-analysis has a very large number of studies, the 
uncertainty in the estimates of the pooled treatment effects, the between-study variances and 
the between-study correlation, all lead to joint probabilistic inferences that are lower than 
expected if these parameters were known. 
This finding can perhaps be considered comparable to the use of the t-distribution for the 
derivation of prediction intervals for θinew by Higgins et al. in a frequentist framework.190 Here, 
the t-distribution is used instead of the normal distribution to account for the uncertainty in the 
between-study variance. This can be extended to a bivariate setting. If 2,000,000 samples of 
x and y are drawn from a bivariate t-distribution (with 8 degrees of freedom since the number 
of trials is 10) with means zero and two, respectively, variances equal to 0.25, and correlation 
equal to 0.8, then the joint probability that x>0 and y>2 is just 0.366. This is similar to the 
estimate of 0.372 for scenario 1 in Table 6.20. The joint probability is only equal to 0.4 when 
the bivariate normal distribution is assumed. If 2,000,000 x and y are sampled from the 
bivariate normal distribution, with the same parameter values as those used above, then the 
resulting probability is very close to 0.4. 
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Table 6.20: Simulation results for fixed values of parameters with 10 studies with complete data (setting 4). The within-study 












































































0.8/ 0.8 0.3715 

















0.4993 0.5/ 0.5 0.5/0.5 0.8/0.8 0.3820 
3. ρB=0.8, β1=0, 
β2=2, τj~N(0,2)I(0,) 






4. ρB=0.8, β1=0, 
β2=2, τj=0.5 
0 0 0 1000 0.4999 2 0 0 1000 0.4994 0.5/0.5 0.5/0.5 0.8/0.8 0.3972 
MSE is mean-square error; CrI is credible interval; s.e. is standard error; the means and medians represent the posterior means and medians from the 




This chapter explored the choice of prior distribution for the between-study correlation 
parameter in a bivariate random-effects meta-analysis model within a simulation study. This 
extends the univariate and multivariate meta-analysis of phase II trials in Chapter 4 and 
Chapter 5. The key findings of the work are summarized in Figure 6.2, which are now 
discussed. 
6.9.1 Overview of key findings 
The prior distribution for the between-study correlation is informative of its posterior 
distribution. 
As expected, the prior distribution for the between-study correlation is informative of its 
posterior distribution, especially when there are few studies in the meta-analysis, or missing 
outcome data. Even with large numbers of studies, such as 50 studies in Table 6.19, the 
prior distribution still influences the posterior estimates. In this scenario, if a uniform(-1,1) 
prior distribution is used, the mean posterior estimate of ρB is 0.734, whereas this estimate is 
0.554 with a Fisher transformation prior for ρB (true value is 0.8 in this scenario). Therefore, 
the prior distribution for the correlation must be selected carefully. 
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Figure 6.2: Key findings. 
• The prior distribution for the between-study correlation is informative of the posterior 
distribution of this parameter, in particular when there are few studies in a meta-analysis. 
• If the data is complete, the prior distribution for between-study correlation has a minimal 
impact on the pooled treatment effect estimates. However, if the posterior estimate of the 
between-study correlation is incorrect, this can lead to incorrect joint inferences, such as the 
joint probability estimates. 
• If there is missing data, the choice of the prior distribution for the between-study correlation 
has more influence on its posterior distribution as the number of studies with both outcomes is 
reduced. In particular, if the true between-study correlation is large and there are few studies, 
several vague prior distributions underestimate this parameter. 
• The choice of prior distribution for the between-study variance impacts the posterior 
distribution of the between-study correlation. Further, if the between-study variance posterior 
estimate is upwardly biased this increases the estimate of the between-study correlation. 
• If there is selectively missing data for outcome j, a Bayesian bivariate meta-analysis reduces 
the bias in the posterior mean estimate of βj and increases the number of 95% CrIs that 
contain the true parameter value, compared to a univariate meta-analysis, for all prior 
distributions for the between-study correlation. What’s more, a narrower prior distribution that 
is centred closer to the true value for the correlation parameter further reduces the bias in the 
posterior mean estimate of βj and further increases the number of 95% CrIs that contain the 
true value. 
• Even when the true between-study correlation is zero, inappropriate prior distributions (e.g. 
gamma) for between-study variances lead to dramatically upwardly biased posterior estimates 
of between-study correlation, and thus a potentially misleading impact of between-study 
correlation. 
• Even if the between-study correlation is estimated perfectly, the joint probabilities are still 
affected by the uncertainty in the other parameters. In the scenarios in this simulation study, 
the joint predictions are downwardly biased. This is akin to joint probabilities being lower from 




There is minimal impact of the between-study correlation on the estimates of pooled 
treatment effects with complete data. 
A key finding from all the analyses is that, if the data is complete and an appropriate prior 
distribution is chosen for the between-study variance, the choice of prior distribution for the 
between-study correlation, from a range of various vague prior distributions, has little impact 
on the pooled treatment effect estimates and their standard errors. This result remains true 
even when the posterior distribution for the between-study correlation is centred far from the 
true value of the correlation. The scenario in Table 6.7 is used for illustration here where 
there is complete data and the true values for the correlation parameters are ρWi=0, ρB=0.8, 
and τj~N(0,2)I(0,). If ρB~uniform(-1,1), the posterior mean ρB across simulations is 0.467, the 
mean β1 across simulations is -0.005 (s.e. of mean 0.197) (true β1 is zero) and the posterior 
mean estimate of β2 is 1.993 (s.e. of mean 0.230) (true β2 is two). In contrast, if 
ρB~uniform(0,1), the mean estimate of ρB is much higher (and closer to the true value of 0.8) 
at 0.620, but the mean treatment effect estimates are almost unchanged with the posterior 
mean β1 equal to -0.006 (s.e. of mean 0.197) and the mean β2 equal to 1.995 (s.e. of mean 
0.220). Therefore, in the setting with complete case data there is very little impact of any of 
the prior distributions for the between-study correlation (used in this chapter) on the pooled 
treatment effect estimates, and therefore there is only minimal impact on any decision-
making on the basis of these results. 
The choice of prior distribution for the between-study correlation is more important if 
there is missing data. 
If there is missing data, the prior distribution for the between-study correlation must be 
selected more carefully. The prior distribution is more informative of the posterior distribution 
for this parameter since there is less data to estimate the between-study correlation with less 
trials reporting both outcomes. Also, a prior distribution that is centred closer to the true value 
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of the correlation will reduce the average standard error and the MSE of the pooled treatment 
effect estimate for the outcome with missing data compared to other prior distributions. For 
example, observe the missing data scenario given in Table 6.15, where the true parameter 
values are β1=0, β2=2, ρWi=0.8, ρB=0.8, τ1=τ2=0.5 and outcome one is selectively missing for 
half the studies (Yij is missing if it is greater than the un-weighted mean of the Yij within the 
meta-analysis). If ρB~uniform(0,1), the posterior mean ρB is 0.545 and the mean standard 
error of β1 is 0.237 and the MSE of β1 is 0.210. However, if ρB~uniform(-1,1), which is centred 
on zero, the mean ρB is 0.155 and so the mean standard error of β1 is larger (0.250) and the 
MSE of β1 is larger (0.249). 
The difference in the posterior estimate of the between-study correlation by the choice of 
prior distribution also affects the joint probability estimates since the mean joint probability 
across simulations is 0.113 with a uniform(-1,1) prior distribution for ρB, but this is higher with 
a uniform(0,1) prior since the mean joint probability estimate is 0.145. 
Additionally, if the prior distribution for the between-study variance parameters is 
inappropriate within a missing data scenario, the posterior estimate of ρB across simulations 
can be hugely overestimated when the posterior estimates of τj are overestimated. As a 
result, the mean standard error of βj is much greater, which increases the width of the 95% 
CrIs from the posterior distributions of βj and the performance of the 95% CrI becomes 
100%. For example, in Table 6.16 (ρB=0) when 1/τj2~gamma(0.1,0.1) and ρB~uniform(-1,1), 
the mean τ1 across simulations is 2.570, the mean ρB is greater than zero with an estimate of 
0.314 and as a result, the mean standard error of β1 is 1.411 and so the number of 95% CrI 
that contain the true β1 is 100%. 
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The choice of prior distribution for τj impacts the posterior distribution of ρB. 
The choice of prior distribution for the between-study correlation and the between-study 
variance are not independent, and therefore wise choices must be made for both parameters 
in the bivariate meta-analysis model. Where Chapter 4 illustrates how important the prior 
distribution is for the between-study variance in a univariate meta-analysis, the simulation 
studies in this chapter reveal this is perhaps even truer for a bivariate meta-analysis. If an 
inappropriate prior distribution is selected for the between-study variance, this not only has 
an impact on the posterior estimates of the between-study variances themselves, but also on 
the posterior estimate of between-study correlation and the standard error of the pooled 
treatment effect estimates. 
For illustration, the scenario in Table 6.12 is used where the data is complete, the true 
ρWi=0.8, ρB=0, and the prior distribution for the between-study variation is 
1/τj2~gamma(0.1,0.1), which overestimates the true τj=0.5. In this scenario, if ρB~uniform(-
1,1), the mean estimates of between-study standard deviation are too large since the 
posterior mean τ1 is 1.926, the mean τ2 is 2.157, and as a result, the mean posterior estimate 
of between-study correlation across simulations is 0.605 (true ρB=0). The average standard 
errors of the pooled treatment effect estimates are larger with the gamma prior for the 
between-study variance compared to those in the corresponding analyses where 
τj~N(0,2)I(0,), and this increases the width of the 95% credible intervals around the pooled 
treatment effect estimates. In the same scenario with the gamma prior, the mean standard 
error of β1 is 0.681 and the mean standard error of β2 is 0.794. In the corresponding scenario 
with a normal prior for τj, the mean standard error of β1 is 0.221 and the mean standard error 
of β2 is 0.260. However, even though all these parameters are poorly estimated with a 
gamma prior for the between-study heterogeneity, the mean pooled treatment effect 
estimates across simulations are unbiased with complete data. In the same scenario in Table 
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6.12 with a gamma prior for the between-study variance parameters, the posterior mean of β1 
is 0.0024 (s.e. of mean 0.200) and the posterior mean of β2 is 1.992 (s.e. of mean 0.241). 
The joint probability is affected by the uncertainty in the other parameters as well as 
the estimate of the between-study correlation. 
The results from all scenarios show that the posterior estimate of the between-study 
correlation affects the estimate of the joint probability. However, in addition, the uncertainty in 
the other parameters also affects the joint probability, which is observed when the between-
study correlation is fixed at 0.8. For the analysis that estimates ρB perfectly (Scenario 1 in 
Table 6.20), the average posterior estimate of the between-study correlation is only 0.372, 
compared to the true value of 0.4. If all parameters are fixed at their true values, the average 
joint probability is very close to the true value (0.398). This can be considered akin to the 
probability being lower from a bivariate t-distribution compared to a bivariate normal 
distribution. The t-distribution is used to estimate prediction intervals in a frequentist meta-
analysis to account for uncertainty in the between-study variance estimates. 
6.9.2 Recommendations for the choice of prior distributions in future 
bivariate meta-analyses 
The key findings have led to the derivation of a number of recommendations for future 
Bayesian bivariate meta-analyses, which are shown in Figure 6.3 and are now discussed. 
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Figure 6.3: Key recommendations. 
When adopting a Bayesian approach for multivariate meta-analysis, researchers should consider the 
following: 
• The prior distributions for between-study variances need to be chosen sensibly as they impact 
on parameter estimates including the between-study correlation. For this purpose, empirical 
prior distributions may be useful, such as those by Turner et al.36 and Rhodes et al.38 
• The prior distribution for between-study correlation(s) also need to be chosen sensibly. A 
uniform(-1,1) prior distribution for ρB is not always vague and thus should not be routinely used 
without due thought, especially when the number of studies is small. 
• Further research should establish empirical prior distributions for between-study correlations, if 
possible, for particular pairs of outcomes across a range of disease fields. 
• Without empirical evidence, clinical or biological rationale might provide external evidence to 
inform the prior distribution for between-study correlations (for example, a uniform(0,1) prior 
distribution could be specified if only positive values are plausible). 
• Sensitivity analysis for the choice of prior distributions is needed, especially when external 
evidence to inform the prior distributions is not available. 
 
If possible, previous evidence should be considered to derive prior distributions for between-
study variances, such as those previously derived by Turner et al.,36 and Rhodes et al.,38 due 
to the dependency of the between-study variance-covariance parameters. Additionally, the 
prior distribution for the between-study correlation needs to be chosen sensibly. Some of the 
scenarios considered in this simulation study revealed that the uniform(-1,1) prior distribution 
for ρB is not as “vague” as it is sometimes considered. This is largely due to the dependency 
of ρB and τj on each other and the need for an appropriate prior distribution for τj. Therefore, 
the uniform(-1,1) prior distribution for ρB should not be used without careful thought, in 
particular if there are small numbers of studies. 
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It would be useful to derive empirical prior distributions for the between-study correlation for 
future studies. However, this is likely to be difficult until multivariate meta-analysis becomes 
routine practice for the meta-analysis of multiple outcomes and the practicalities of this 
challenge are discussed further in Chapter 7. Until empirical prior distributions have been 
derived, clinical guidance should be sought to develop plausible prior distributions, such as a 
uniform(0,1) prior distribution that only allows positive values. If there is no previous evidence 
to inform the prior distribution then the uniform(-1,1) prior distribution is recommended, but a 
sensitivity analysis for this choice is important, especially when there are few studies. 
6.9.3 Limitations 
This chapter presents several important findings of the impact of the choice of the prior 
distribution for the between-study correlation. However, the findings may only apply to the 
specific settings in which the simulation studies have been conducted. Whilst there are some 
key findings that have been described above, there are, of course, numerous other prior 
distributions for the between-study correlation that could be used in a bivariate random-
effects meta-analysis, but were not considered in this chapter; in particular prior distributions 
with a very narrow range of possible values. 
Also, the simulation is specifically for bivariate meta-analysis, but of course there may be 
more than two correlated outcomes. In this case, there are several between-study correlation 
parameters that require prior distributions. 
Importantly, this simulation study only considered one set of true values for the between-
study standard deviations (τj=0.5). For these true values, the normal(0,2)I(0,) prior 
distribution was most appropriate out of those considered. However, this would not 
necessarily be the case for different values of the between-study standard deviations. Also, 
the relative size of the within-study and between-study variances alters the impact of the 
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between-study variances and therefore different relationships of these variances need to be 
explored. 
6.10 Conclusion 
The motivating examples and the simulation study in this chapter reveal that the choice of 
prior distribution for the between-study correlation in a Bayesian bivariate random-effects 
meta-analysis is important and must be chosen with caution, and in conjunction with the 
choice of prior distribution for the between-study variance. The prior distribution for the 
between-study correlation is highly informative for the posterior estimate of this parameter 
when there are few studies per meta-analysis, and impacts upon inferences about the 
treatment effects for each outcome, in particular when there is missing outcome data for 
some of the studies. In conclusion, empirical studies are recommended to identify suitable 
prior distributions for the between-study correlation for particular pairs of outcomes across a 
range of disease fields that can be used for future bivariate (and multivariate) meta-analyses 






CHAPTER 7:  DISCUSSION 
7.1 Overview of thesis 
Randomised clinical trials are the best method to obtain evidence about the effect of an 
intervention, and to thereby update current knowledge and to support health care decision 
making. The key aims of a clinical trial are to explore whether a treatment, device or strategy 
is safe and effective in a population of interest, and a crucial part of the evaluation of a 
clinical trial is the statistical design and analysis, and then synthesis with results of other 
trials. Traditionally, the analysis and synthesis of clinical trials has been undertaken using a 
frequentist framework. However, this thesis has explored the use of Bayesian methods and 
compared these with a frequentist approach in several settings to determine key differences, 
advantages and limitations. 
In Chapter 2, the literature review of Bayesian methods in randomised trials in general 
medical journals in 2012 suggested that Bayesian methods may be advantageous in clinical 
trials where the sample size is small because the Bayesian approach can formally 
incorporate external evidence via the prior distributions. Therefore, the Bayesian framework 
was investigated in Chapter 3 in a randomised trial that failed to recruit its target sample size 
(PLUTO). In this trial, for the condition of interest there was elicited prior information derived 
from specialist clinicians and this was formally incorporated into the analysis of the trial. The 
findings suggested that there was evidence that the intervention may be beneficial, and the 
additional probability estimates from the Bayesian analyses could be used to inform guideline 




Chapter 2 also identified that very few randomised phase III trials (8% of articles reviews in 
the Lancet in 2012) used results from previous or related phase II trials to inform their design 
in terms of sample size. Hence the use of meta-analysis of phase II trials was explored in 
Chapters 4 and 5 to explore the issues relating to meta-analysis of small trials and how to 
incorporate informative prior distributions within a Bayesian framework. Firstly, the methods 
were considered in the context of univariate meta-analysis of phase II trials (Chapter 4) 
where the purpose was to obtain an estimate of treatment effect from all available evidence 
to inform whether further research in a large-scale phase III trial should be recommended. 
Several Bayesian and frequentist methods were applied and compared in an existing 
published meta-analysis in acute myocardial infarction for illustration. The Bayesian 
approach was shown to easily account for all parameter uncertainty, which could be 
quantified by prediction intervals for the estimated treatment effect in a new phase III trial. 
Another possible advantage of the Bayesian approach, which was seen in an article in the 
literature review in Chapter 2, was that direct probability estimates were useful for decision 
making. This was useful in meta-analysis of phase II trials where probability estimates 
regarding the pooled or predicted treatment effect could be derived. However, a limitation of 
the Bayesian approach was the need to specify an appropriate prior distribution for the 
between-study variance parameter and thus empirical prior distributions must be sought, or a 
sensitivity analysis for this prior distribution is important. 
Previous work highlighted the benefits of a multivariate meta-analysis if there are several 
correlated outcomes; in particular this approach has advantages over separate univariate 
meta-analyses if there is missing outcome data.200,213 Bayesian methods were therefore 
explored in this setting (Chapter 5) in the context of synthesising phase II trials with multiple 
correlated outcomes. The Bayesian approach was shown to help reduce the common issue 
of unknown within-study correlations through the use of prior distributions for this parameter. 
Also, the Bayesian framework allowed joint predictive probabilities to be derived, which are 
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potentially useful for clinical guidance that makes joint decisions in the context of multiple 
possible outcomes. The same example dataset in acute myocardial infarction was used for 
illustration in this chapter and showed that the within-study correlations can impact on the 
model estimates. Therefore, external information from a related setting can be useful for the 
prior distributions for the within-study correlations. 
Throughout this thesis, an important message is that an appropriate choice of prior 
distributions is key to any Bayesian analysis, especially when sample sizes are small within a 
trial (or when there are small numbers of studies within a meta-analysis), and therefore 
sensitivity to the choice of prior distributions was routinely conducted. In particular, Chapter 3 
showed that the findings of the Bayesian analysis of the under-recruited trial were heavily 
influenced by the choice of prior distribution for the treatment effect. Chapter 4 also showed 
that sensitivity to the choice of prior distribution for the between-study variance parameter in 
a random-effects univariate meta-analysis was important because it is difficult to select a 
non-informative prior distribution.29 In Chapter 6, the impact of prior distributions was 
explored in the context of a bivariate meta-analysis, with an extensive simulation study 
undertaken to assess the impact of various prior distributions for the between-study 
correlation and variance parameters. This explored several different scenarios including 
complete and missing outcome data, and identified a number of novel findings. In particular, 
an inappropriate choice of prior distribution for the between-study variance can adversely 
impact the posterior influences about the between-study correlation. Further, the routine use 
of a uniform(-1,1) prior distribution for the between-study correlation should be avoided, 
where possible, as they are not necessarily vague; rather, a more informative prior 
distribution should be incorporated, for example restricting values to be either positive or 
negative as indicated by clinical or prior knowledge. 
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In the remainder of this final chapter, the main advantages and limitations of Bayesian 
methods for clinical trial analysis and synthesis are discussed in light of the findings in this 
thesis. Overarching recommendations are made, and suggestions for further research are 
presented to tackle the remaining challenges left unaddressed by the research. 
7.2 Key findings and recommendations 
In this section the key findings from all chapters are discussed alongside the pivotal 
recommendations, which are displayed in Figure 7.1. 
7.2.1 The use of Bayesian methods for the analysis of randomised 
clinical trials was rare in general medical journal articles 
There have been vast developments of Bayesian methods for the analysis of clinical trials, 
which have been promoted in various settings; in particular for interim monitoring of large 
randomised trials241 and adaptive trials,241,242 because the Bayesian approach has several 
potential advantages compared to the frequentist approach. First, the Bayesian can estimate 
direct probabilities of interest such as the probability that treatment A is better than treatment 
B. In contrast, the frequentist can only interpret the p-value as the probability of observing the 
estimate of effect or one more extreme, if the null hypothesis of no difference is true. 
Secondly, the Bayesian can formally incorporate external, related information in the prior 
distribution, whereas the frequentist can only make inferences from the data. This advantage 
is also the Bayesian’s downfall because the derivation of prior distributions can be extremely 
difficult, and thus – even where vague prior distributions are desired - sensitivity to the prior 
distribution should always be advocated. The Bayesian approach can also be more flexible 
than the frequentist in terms of updating the inferences based on accumulating data, which is 
why the methods are so useful for interim monitoring.142 However, in 2012 in seven general 
medical journals, only 3 out of 314 published randomised trials adopted a Bayesian approach 
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for the analysis of all, or even part, of their trial (Chapter 2). Evidently, although there are 
these potential advantages of the Bayesian framework, they are still not being widely used in 
research that is deemed important by general medical journals for their readers. 
7.2.2 Clinical implications were identified in some specific Bayesian 
analyses 
Though much of the thesis concentrated on methodology development, a number of real 
applications were made that have important clinical value. Bayesian methods were explored 
in Chapter 3 for the analysis of the PLUTO trial, which investigated a rare disease. In this 
setting, several elicited prior distributions had already been derived from specialist clinicians 
with the hope that there would be increased precision in the conclusions of the trial if the 
prior distributions were combined with the data, and, in turn, this would help the decision 
process. The frequentist analyses were inconclusive; yet, Bayesian posterior probability 
estimates highlighted the high probability of a benefit of the intervention in the PLUTO trial. 
However, there were consistently low probabilities of a clinically important treatment effect 
(as defined by a HR estimate lower than 0.646), which helped to inform the updated 
guidelines of clinical practice in the future. The recommendations were that there may be 
some benefit of the intervention in some settings, but that the mother must be advised as to 
the risk of the procedure to the unborn baby, and that long-term outcomes had not yet been 
assessed. 
Chapters 4 and 5 investigated univariate and multivariate meta-analysis using a previously 
published meta-analysis of phase II trials in acute myocardial infarction for illustration. The 
authors of the original meta-analysis raised concerns that the results from the phase II meta-
analysis were contradictory to the results from a meta-analysis of the subsequent phase III 
trials.169 They also suggested that this was due to publication bias of the phase II trials. 
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However, when a Bayesian approach was used within a random-effects meta-analysis 
model, and prediction intervals for the true treatment effect in a new trial were derived, the 
meta-analysis results showed that the subsequent phase III trial results were entirely 
plausible based on the phase II evidence, and that publication bias was not necessarily an 
issue. The wide prediction intervals for the true treatment effect in a new phase III trial 
highlighted the large uncertainty upon which the decision to conduct the phase III trials was 
actually based. It also highlighted that the causes of heterogeneity in treatment effects 
should ideally be identified to ensure that phase III trials can be better targeted to those 
populations where the treatment effect is likely to be higher. 
7.2.3 Bayesian methods were identified as important in the meta-
analysis of phase II trials to inform phase III trial decisions 
The decision to proceed to a phase III trial should be based on all existing evidence, 
including results of earlier phase II trials, alongside their potential cost and feasibility. If there 
are multiple phase II trials then a meta-analysis of these results should be conducted to help 
inform phase III decisions. However, due to the small numbers of phase II trials, and the 
likely small sample sizes within these trials, there are several methodological issues that 
arise, as follows. 
It is difficult to examine and quantify the heterogeneity in a phase II meta-analysis. 
The small sample sizes within phase II trials can cause low power and large within-study 
variation, which make it difficult to assess the amount of between-study heterogeneity. It has 
previously been argued that the I2 statistic or tests for heterogeneity should not be used to 
determine whether to use a fixed-effect or random-effects model to pool treatment effects,199 
however they are still often used in practice.207-212 In the phase II meta-analysis example in 
acute myocardial infarction in Chapter 4, where there were small studies combined with rare 
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event rates, the I2 statistic often suggested little or no evidence of heterogeneity, whereas 
direct estimates of this parameter, particularly in a Bayesian framework, suggested that 
heterogeneity was present. In the frequentist framework, this is a general issue for 
hypothesis testing when the result of a significance test is used to make the assumption that 
no evidence of an effect is the same as evidence of no effect, which is not appropriate. 
Therefore, a key recommendation is to not rely on the I2 statistic for making modelling 
decisions in a meta-analysis of phase II trials. It is likely that heterogeneity will exist in a 
meta-analysis of phase II trials and therefore researchers are better off deciding, a priori, that 
a random-effects model is more appropriate. 
The derivation of prediction intervals for the true treatment effect in a new trial is 
important for the phase III decision. 
When informing the phase III decision it is crucial that decision-makers understand the 
statistical uncertainty in the phase II trial result before making the decision to proceed. Often 
the decision is based on the average pooled effect estimates,39 as done in the meta-analysis 
by Eikelboom et al.,169 however it is perhaps more important to derive prediction intervals for 
the true intervention effect (or the estimated treatment effect with a given sample size) in a 
new trial because this may be different to the average effect. Prediction intervals derived 
from the posterior distribution of true (or estimated) treatment effects in new studies will, in 
the Bayesian framework, naturally account for all parameter uncertainty, and thus allow for 
more appropriate dissemination of the uncertainty of evidence for those making phase III 
decisions (section 4.6). This is important because researchers need to decide to progress to 
phase III for interventions with potential clinical benefit, but they also need to design the 
phase III trial appropriately in terms of its sample size. The number of phase III trials that 
achieve statistical significance can be low in certain health-care areas; in particular a report 
in 2012 reviewed 235 recently published phase III randomised clinical trials in oncology, and 
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only 38% achieved results with statistical significance.243 This is often considered to be due 
to an incorrect sample size calculation, which has been designed with an overly optimistic 
estimate of treatment effect.244 
Bayesian meta-analysis methods also lead naturally to direct probability statements 
regarding the treatment’s potential effectiveness in a new trial and this can be estimated for 
varying sample sizes of a potential new trial to further aid decisions regarding the design of 
the phase III trial (section 4.6.3). Additionally, the researcher can incorporate an analysis with 
a sceptical or cautious prior distribution for the pooled treatment effect if there is reason to 
believe that there may be optimism in the results (section 4.10, for example, as a result of 
publication bias). 
The choice of prior distribution for the between-study variances is important. 
The choice of prior distribution for the between-study variance parameter in a Bayesian 
meta-analysis can influence the results, and an inappropriately selected prior distribution for 
this parameter can be highly informative towards the posterior distribution of the pooled 
treatment effect estimates and the prediction intervals29 (section 4.11). Therefore, empirical 
prior distributions for the between-study variance should be used where possible in 
practice.36,38 The empirical prior distributions that have been derived by Turner et al.35 and 
Rhodes et al.40 for binary and continuous outcomes are particularly useful for a future 
Bayesian random-effects meta-analysis because the number of studies in the meta-analysis 
is often low and therefore there is little data to estimate this parameter well. However, 
empirical prior distributions have not been derived specifically for meta-analyses of small 
phase II trials and therefore, until these are available, a sensitivity analysis for the prior 
distribution for the between-study variance should always be conducted. 
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It is beneficial to use a Bayesian multivariate meta-analysis model when within-study 
correlations are unknown. 
Where possible, phase II multivariate meta-analysis for multiple correlated outcomes should 
be considered to inform phase III trial decisions as the approach utilises more of the 
available evidence compared to univariate meta-analysis.200,215,218,225,232 The multivariate 
approach accounts for the correlation amongst outcomes, and thereby can ‘borrow strength’ 
to gain more information toward the meta-analysis results, especially when some outcomes 
are missing in some trials. Although multivariate meta-analysis has been growing in 
importance, they had not been previously considered for synthesis of phase II trials. This 
application identified an important issue: within-study correlations are often unknown and 
cannot be derived without individual participant data (IPD) (Chapter 5). Researchers should 
provide IPD to facilitate multivariate approaches, such as multinomial modelling, or to derive 
within-study correlation estimates for a multivariate normal approach. 
If IPD are not available, one option to deal with this is to use the alternative Riley model, 
which does not require the user to specify the unknown within-study correlations.215 In a 
meta-analysis of phase III trials where the focus is often on the pooled result, this may be 
adequate; however, Chapter 4 showed that a crucial element of meta-analysis of phase II 
trials is the derivation of prediction intervals to account for all parameter uncertainty, and to 
estimate the true treatment effect in a new trial. Such prediction intervals cannot be derived 
from the alternative model by Riley et al.,215 as it does not correctly model the between-study 
variance. Therefore, in Chapter 5 the Bayesian approach to multivariate meta-analysis was 
proposed in order to specify a range of possible values for within-study correlations using 
prior distributions. In particular, upon application to meta-analysis of phase II trials in acute 
myocardial infarction, a prior distribution was derived for missing within-study correlations 
based on external evidence from trials and outcomes in a related context, where such 
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correlations had been reported. The Bayesian approach was also shown to easily estimate 
joint posterior probabilities for the true treatment effects in a new trial, which are useful to 
inform whether to proceed to a phase III trial based on the evidence for multiple outcomes, 
rather than single outcomes (section 5.3.7). But, further work is required to develop prior 
distributions for the within-study correlations of pairs of outcomes in future multivariate meta-
analyses. 
The prior distributions for between-study covariance parameters in a bivariate meta-
analysis must be chosen carefully. 
Previous methodological and applied articles that used Bayesian methods for multivariate 
meta-analysis revealed that there does not appear to be a consensus for the choice of prior 
distribution for the between-study correlation parameter in a Bayesian bivariate random-
effects meta-analysis. Often the uniform(-1,1) prior distribution is selected without a 
sensitivity analysis. Bujkiewicz et al. also demonstrate that if prior distributions are specified 
for the individual components of the between-study covariance matrix (rather than for the 
matrix itself) then caution must be taken to ensure that all prior distributions are appropriate, 
since these parameters are not independent.17 A simulation study of the choice of prior 
distributions for the between-study covariance parameters in Chapter 6 revealed that when 
adopting a Bayesian approach for multivariate meta-analysis, researchers need to ensure 
that the prior distribution for the between-study correlation is chosen sensibly. This is 
because the prior distribution for the between-study correlation is informative of its posterior 
distribution, in particular when there are few studies in the meta-analysis. This has little 
impact on the pooled treatment effect estimates if the data is complete, however it does alter 
the joint inferences, such as the joint probability estimates, which are a key benefit of the 
Bayesian approach for decision-making. Therefore, even in this setting, the choice of prior 
distribution for the between-study correlation is important. More importantly, if there is 
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missing outcome data, the choice of prior distribution for the between-study correlation might 
even alter the pooled treatment effect estimates, and so the choice of prior distribution is 
even more important in this situation (section 6.6). Importantly, a uniform(-1,1) prior 
distribution is not always vague and should not be used routinely without careful 
consideration, especially when the number of studies is small. Therefore, if possible, a key 
recommendation is to use a more informative prior distribution that is based on prior clinical 
or external information. For example, if the outcomes were disease-free and overall survival, 
or systolic and diastolic blood pressure then a uniform(0,1) prior distribution may be 
considered appropriate for the between-study correlation. If the between-study correlation is 
considered to be negative then a uniform(-1,0) prior distribution may be appropriate, for 
example for the meta-analysis of sensitivity and specificity from test-accuracy studies. 
Interestingly, even if the between-study correlation is estimated perfectly, the joint 
probabilities are still affected by the uncertainty in the other parameters (section 6.8). In the 
scenarios in this simulation study, the joint predictions are downwardly biased (that is, under 
a frequentist long-run perspective, the joint probabilities on average are lower than the true 
joint probability). This merely reflects that uncertainty in parameter estimates makes it hard to 
make joint inferences appropriately. This is akin to joint probabilities being lower from a 
bivariate t-distribution compared to a bivariate normal distribution, unless the degrees of 
freedom are considerably large. 
Also, it has already been discussed in detail throughout this thesis that the pooled results can 
be sensitive to the choice of prior distribution for between-study variance parameters.29 
However, in a bivariate meta-analysis setting, the variance parameters additionally affect the 
posterior distribution of the between-study correlation. If the posterior estimates of the 
between-study variances are upwardly biased this increases the estimates of the between-
study correlation, which in turn alters the pooled estimates if there is missing data, and 
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changes the joint inferences. Further research should be considered to establish empirical 
prior distributions for between-study correlations for particular pairs of outcomes across a 
range of disease fields. If there is a lack of empirical evidence, clinical guidance should be 
used where possible to inform the prior distribution for between-study correlations. In all 
meta-analyses with a Bayesian approach, sensitivity analysis for the choice of prior 
distribution should be considered, especially when external evidence to inform the prior 
distributions is not available. 
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Figure 7.1: Key methodological recommendations. 
• In trials with small patient numbers, either by design or due to failure to recruit, frequentist 
analyses will invariably be underpowered, or the results will likely be inconclusive. An 
alternative Bayesian analysis should be considered that can generate probabilistic statements, 
which may aid decision-making. 
• Meta-analysis of phase II trials should be conducted to inform the phase III trial decision. 
• The decision to use a fixed-effect or random-effects univariate meta-analysis model should not 
be based on the I2 statistic or tests for heterogeneity, especially in trials with small sample 
sizes (for example, phase II trials). 
• Prediction intervals for the true treatment effect in a new phase III trial should be derived 
following a meta-analysis of phase II trials, ideally in a Bayesian framework, to account for all 
parameter uncertainty. 
• In a Bayesian univariate or multivariate meta-analysis model, empirical prior distributions for 
between-study variances based on previous evidence should be implemented. 
• Where possible, phase II multivariate meta-analysis for multiple correlated outcomes should 
be considered to gain more information toward phase III trial decisions, and enable inferences 
based on multiple outcomes jointly. 
• Researchers should provide IPD to facilitate multivariate meta-analysis in order to use a 
multinomial model for correlated binary outcomes, or to derive within-study correlation 
estimates for an approximate multivariate normal approach. 
• If IPD are not available for multivariate meta-analysis, a Bayesian approach with prior 
distributions for the unknown within-study correlations should be used, ideally based on 
external evidence. 
• The prior distribution for between-study correlations in a Bayesian multivariate meta-analysis 
model must be chosen sensibly. A uniform(-1,1) prior distribution should not be used without 
clinical guidance because it is not always vague. 
• In all Bayesian meta-analyses, sensitivity analysis for the choice of prior distribution should be 




7.3 Bayesian methods in the context of current clinical research: 
should they be used? 
7.3.1 Where is the Bayesian approach most justifiable? 
An overarching question that remains is whether there is a rationale for the use of Bayesian 
methods for the design, analysis or synthesis of clinical trials, instead of an approach within a 
frequentist framework? It is acknowledged that there is a lack of Bayesian methods in clinical 
trials, despite the methodological advances, ethical advantages, and alternative designs for 
randomised clinical trials.142 However, based on the findings of this thesis, there are key 
reasons why Bayesian methods are specifically advocated: 
Incorporation of external evidence 
Bayesian methods are especially encouraged when one wishes to formally incorporate 
external evidence via the prior distributions. In particular, in Chapter 3 there were elicited 
prior distributions derived from specialist clinicians that could be combined with the small 
data from a trial that failed to recruit its target sample size within a rare disease setting. It 
was useful to see whether there would be different, or even stronger, conclusions with the 
addition of this previous clinical evidence, as conclusions based solely on the data were not 
strong. 
In univariate random-effects meta-analysis, which was explored in detail in Chapter 4, it was 
shown that prior distributions were useful for the unknown between-study variance because 
very often there is little information to estimate this parameter well from the data alone. It is 
also difficult to specify truly vague prior distributions for variance parameters29 therefore, 




Another setting where informative prior distributions were useful was for unknown within-
study correlations within bivariate meta-analysis. Chapter 5 discussed the benefits of using 
multivariate meta-analysis when there are correlated outcomes of interest.17,18,200,213,214,218,226 
A common issue with this approach is that the within-study correlations must be specified but 
they are unknown. Prior distributions for the unknown within-study correlations enable the 
meta-analyst to define a range of values and account for the uncertainty in these 
parameters.17 This approach is more beneficial if there is external evidence to inform the 
likely range of values, for example if it is known clinically that the correlation is positive. 
Accounting for all parameter uncertainty 
The Bayesian approach can easily account for all parameter uncertainty, which is important 
for clinical decision making. In particular, this is important when decision-makers decide 
whether to conduct a phase III trial based on the results of a meta-analysis of phase II trials. 
In a random-effects meta-analysis, the Bayesian approach can easily estimate the 
uncertainty in the between-study variance parameter, which is important when there are few 
studies per meta-analysis because the between-study variance parameter is often poorly 
estimated245 (section 4.6.2). In terms of making decisions about further research, a Bayesian 
value-of-information analysis could then be used to formally incorporate other information, 
such as costs and adverse events, as well as information on treatment effect. These 
methods consider the value of additional information that could be collected against the costs 
of uncertainty surrounding a clinical decision.246 The “expected costs of uncertainty are 
determined by the probability that a treatment decision based on existing (prior) information 
will be wrong and by the consequences if the wrong decision is made (loss function).”246 
Value-of-information modelling may be used to predict the potential impact of studies that are 
being considered in terms of reduced uncertainty in parameters, such as treatment effect, 
and prioritise where additional investment may have maximal benefit. 
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Making direct probability statements 
The Bayesian approach is also advocated for the benefit of being able to make direct 
probability statements. For example, in Chapter 3 in the analysis of the PLUTO trial, it was 
useful to estimate the probability of a benefit of the intervention, and also to estimate the 
probability that the intervention was clinically important. This highlighted that there was a 
high probability that the intervention improved survival compared to the standard care, 
however, the probability of a clinically meaningful difference in survival rates was low. The 
use of Bayesian methods in trials with rare diseases has previously been suggested as “a 
way out of a conundrum” because small trials “are expected to provide useful information, 
even when a definitive answer is unlikely in prospect.”148 However, the Bayesian approach 
can give probability estimates that the clinical effect lies within a range of values. Probability 
estimates were also estimated for pooled and predicted treatment effects in meta-analysis of 
phase II trials. In particular, in multivariate meta-analysis (Chapter 5), joint probability 
estimates were derived, which incorporated the correlation between outcomes. 
7.3.2 Will there be acceptance of Bayesian results if they depend on the 
choice of prior distributions? 
A counter argument to the advantage of using informative prior distributions is whether the 
research community will ever truly accept results that depend on the choice of prior 
distributions. It would perhaps be more difficult to find acceptance of results that combine 
data with subjective prior distributions. In the PLUTO trial in Chapter 3, several of the prior 
distributions were subjective. The results from these analyses were largely in agreement with 
the frequentist results and therefore additional strength can perhaps be gained from the 
Bayesian approach in general, such as probability estimates. However, if the results using 
the subjective prior distributions were contradictory, either to each other, or to the frequentist 
results, it is unlikely that decisions would be made based purely on these subjective prior 
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analyses. Perhaps in this scenario more weight would be given to those conclusions using a 
frequentist approach, or a Bayesian analysis with vague prior distributions. 
In random-effects meta-analysis (univariate or multivariate) empirical prior distributions for 
variance parameters appear useful.36,38 But, it is difficult to know how similar the current 
meta-analysis is to the meta-analyses from which the empirical prior distribution was derived. 
The variance parameters are highly influential in the estimation of pooled effects and 
subsequent prediction intervals and it is very difficult to know whether the selected prior 
distributions are appropriate. Therefore, the results of such an analysis may not be accepted 
by some parts of the medical community if they disagree with the meta-analysts reasons for 
adopting a particular set of prior distributions. 
When there is uncertainty in the choice of prior distributions, and thus ‘vague’ prior 
distributions are desired, a sensitivity analysis is often advocated, especially for the between-
study variance parameters. As a consequence, there will be several results to inform one 
decision, and this makes the decision process more difficult. This is even more difficult if 
there is no evidence to inform the prior distributions because the results could be more 
diverse. In Chapter 4, a sensitivity analysis for the prior distribution for the between-study 
variance highlighted the difference between the prediction intervals for the true treatment 
effect in a new trial, depending on the choice of this prior distribution. This begs the question 
as to whether a Bayesian approach should be adopted at all if there is no evidence to inform 
the prior distributions that, as a consequence, can be very informative to the results. 
7.3.3 What if a Bayesian approach is not chosen? 
If the arguments above convince researchers not to use Bayesian methods then instead a 
frequentist approach will be adopted. In a clinical trial setting where there is a large dataset, 
for example a large-scale phase III trial, which is powered to detect clinically meaningful 
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differences, there may be no additional benefits from using a Bayesian approach that 
outweigh the difficulties in using the Bayesian framework, such as specifying prior 
distributions. Perhaps this is the reason why there is very low prevalence of Bayesian 
methods in randomised trials in the general medical journal literature in 2012 (see Chapter 
2), because these journals are more likely to publish the results from larger trials, rather than 
the more challenging trial settings, such as rare diseases. Or perhaps researchers are not 
recognising that external evidence exists and that there may be benefits from incorporating 
this into a Bayesian analysis as an alternative to using a frequentist framework. 
There are several settings in this thesis that have demonstrated where the frequentist 
approach struggles in comparison to the Bayesian, and perhaps where a Bayesian approach 
could more commonly be adopted. For example, the data may not be sufficient to answer the 
clinical question, such as the small dataset in the PLUTO trial (Chapter 3). All frequentist 
analyses were statistically non-significant, and it is difficult to make decisions about clinical 
practice based on results such as these. Whereas the Bayesian can additionally quantify 
their uncertainty with direct probability estimates, such as the probability that the new 
treatment is clinically significantly different to standard care. 
The frequentist approach also struggles to estimate certain parameters, such as the 
between-study variances in both univariate and multivariate random-effects meta-analysis, 
because there are often few studies. But, as already mentioned, this parameter is highly 
influential to pooled results and subsequent predictions, and so it needs to be estimated well. 
Also, in multivariate meta-analysis, sometimes the frequentist cannot estimate between-
study correlation; in particular, if there are few studies, or if the within-study variance is 
relatively large compared to the between-study variance, the maximum likelihood estimator 
routinely estimates the between-study correlation as -1 or +1.218 Further, the frequentist 
approach cannot estimate pooled estimates from a multivariate meta-analysis without 
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specifying the within-study correlations, which are often unknown. Thus, the frequentist could 
either fix the within-study correlations and these may not be reliable, or they could use the 
alternative Riley model,215 which cannot be used to make predictions. 
An alternative proposal for the statistical approach could be to use a frequentist analysis but 
interpret the results as if they were obtained from a Bayesian analysis with vague prior 
distributions. Therefore, confidence intervals would be interpreted as Bayesian credible 
intervals. For example, the results from the PLUTO trial were very similar for the frequentist 
analyses compared to those with a vague prior distribution for the unknown treatment effect. 
However, this would only be acceptable if the prior distributions were truly vague and as 
discussed earlier, it is not easy to specify a vague prior distribution for variance-covariance 
parameters. The concept of using a frequentist analysis followed by a Bayesian interpretation 
is what led to the recommendation to use a t-distribution for the prediction interval of the true 
treatment effect in a new trial following a meta-analysis.39,190 However, this t-distribution is an 
approximation of the unknown underlying distribution, but a Bayesian analysis using MCMC 
does not need to make this assumption because it can sample from the posterior distribution 
of true effects even when it does not know its true form. Therefore, it may still be better to 
use a Bayesian approach in this setting. 
7.4 Future research needs 
This thesis has made important contributions to the Bayesian analysis of clinical trials, 
however there are several research needs that remain unaddressed and these are listed in 
Figure 7.2. Firstly, in Chapter 2, the literature review obtained an overview of the prevalence 
of Bayesian methods in randomised trials, and what methods have recently been adopted in 
practice. As previously mentioned it would be beneficial to know what the prevalence is in 
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specialised journals (e.g. in cancer) that may be more willing to publish alternative statistical 
methodology in order to see whether the prevalence is the same in these settings. 
In Chapter 5, it was suggested that the best method of conducting a multivariate meta-
analysis of two or more binary outcomes is to use a multinomial model because this method 
avoids the need to specify within-study correlations, which are often unknown. However, this 
model could not be explored for the example in acute myocardial infarction because there 
was no available IPD. Therefore, Bayesian methods for the multinomial model need to be 
explored and compared to the (approximate) multivariate normal model. 
Figure 7.2: Key future research needs. 
• The prevalence of Bayesian methods in randomised controlled trials in specialised medical 
journals needs to be reviewed, for example, in cancer. 
• The use of a multinomial model for the meta-analysis of two or more binary outcomes in 
phase II trials needs to be explored and compared to the approximate multivariate normal 
model. 
• Further research should establish empirical prior distributions for between-study variances in 
meta-analysis of phase II trials, and for between-study correlations for particular pairs of 
outcomes across a range of health-care settings. 
• The multivariate meta-analysis methods of Chapters 5 and 6 needs to be extended to the 
synthesis of more than two outcomes. 
• Additional scenarios need to be considered to fully assess the impact of prior distributions in a 
bivariate meta-analysis. In particular, prior distributions for between-study variance-covariance 
parameters need to be assessed for different sizes and ratios of within and between-study 
variances. 
 
Empirical prior distributions need to be derived, if possible, for between-study variances for 
meta-analysis of phase II trials and between-study correlations for a range of different 
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disease areas, rather than using vague prior distributions for these parameters, which result 
in the need for several sensitivity analyses. Empirical prior distributions have previously been 
derived for between-study variances for several health-care settings, for both continuous38 
and binary outcomes.36 These are particularly useful because they provide realistic prior 
distributions for a future meta-analysis without the need to specify a vague prior distribution 
and a sensitivity analysis for this choice. However, it is unclear whether these are applicable 
to the setting of meta-analysis of phase II trials since there are often less phase II trials and 
they may be more heterogeneous than phase III trials. If empirical prior distributions are not 
available, it may be possible to elicit subjective beliefs. The methods involved for the 
elicitation of subjective prior beliefs have been presented previously by O’Hagan.26,247 The 
elicitation of subjective beliefs to form probability distributions remains a difficult task 
because there may be a wide range of research findings that inform an expert’s opinion, and 
this makes it difficult to ensure that the expert’s judgement has been captured accurately and 
reliably.26 
The recommendation to derive empirical priors for between-study correlations is, in theory, a 
necessary development. However, it is important to consider what this would involve 
practically and whether this is realistic at this stage. The methods to derive empirical priors 
would likely be similar to those of Turner et al.36 and Rhodes et al.38 In their development of 
empirical prior distributions they collected thousands of meta-analyses and used hierarchical 
models to analyse the data, while investigating the effects of meta-analysis characteristics on 
the level of between-study heterogeneity.36,38 Thus, for the empirical prior distributions for 
between-study correlations to be valid for future meta-analyses there would need to be a 
substantial number of applied multivariate meta-analyses from which to derive them. In 
theory, the use of multivariate meta-analysis has been advocated;17,200,213,218,221 however, the 
application in practice still seems to be limited. There is certainly a greater uptake of 
multivariate meta-analysis for sensitivity and specificity than other settings;248 but there 
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needs to be application of the methods in all disease areas, for various outcomes, and 
different types of interventions, before empirical prior distributions for between-study 
correlations can be derived that would be applicable to a wide range of future multivariate 
meta-analyses. Thus, for now, it is unlikely that empirical prior distributions can be derived for 
between-study correlations. 
The use of a Bayesian framework for multivariate meta-analysis within Chapters 5 and 6 
looked specifically at bivariate meta-analysis. Of course, it may be clinically important to 
investigate the joint synthesis of more than two outcomes and this has not been explored in 
either of these chapters, but there may be additional difficulties when synthesising more than 
two outcomes. For more than two outcomes there would need to be further specification of 
prior distributions for within-study correlations and there would be multiple between-study 
correlations (rather than just one in bivariate meta-analysis). Additionally, the model 
specification becomes more difficult in terms of separating the parameters in the variance-
covariance matrices. 
The simulation study in Chapter 6 did not assess all possible scenarios for bivariate meta-
analysis. Importantly, this only focussed on five prior distributions for the between-study 
correlation but there are numerous other possible choices that could have been explored. 
Also, for all simulations, the true between-study variance was 0.5 for both outcomes, which is 
fairly comparable to the within-study variances. However, it is likely that the impact of the 
prior distribution for the between-study correlation would differ in alternative settings. Large 
and small between-study variances relative to the within-study variances, and between-study 
variances that are different to each other, should be assessed in future research. 
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7.5 Final conclusions 
In conclusion, there are clearly many arguments for and against the use of Bayesian 
methods for the analysis and synthesis of clinical trials. This debate has existed for a long 
time and despite the important methodological findings made, the work in this thesis is 
perhaps only a small step toward more use of Bayesian methods in applied research. 
Perhaps in clinical research, Bayesian methods will always remain those that are adopted as 
a consequence of difficulties faced by the frequentist approach, and as a result, maybe the 
prevalence of Bayesian methods will always remain low. However, in certain applications, 
such as random-effects (multivariate) meta-analysis that requires estimation of between-
study variance-covariance parameters, the Bayesian approach has the potential for much 
benefit compared to a frequentist approach, especially if empirical prior distributions are 
deemed sensible for use. Also, for a long time, the Bayesian approach was not adopted 
because it was too computationally complex to implement. However, this is no longer the 
case and, in fact, simulation methods such as MCMC allow highly complex analyses, which 
make the Bayesian approach more attractive.249 But, perhaps there is still some way to go 
before Bayesian methods will be accepted by the wider research community as the default 
method in any setting. Breslow previously stated “it seems clear that Bayesian and 
frequentist approaches each will have a role to play in biostatistical applications in the years 
to come.”250 It has been suggested that possibly the first step in introducing Bayesian 
methods more commonly into randomised trials is to compliment a frequentist analysis with a 
Bayesian analysis251, like that of the PLUTO trial. But, despite the current challenges for the 
application of Bayesian methods in trials, this thesis has shown that the Bayesian approach 
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Appendix B1: WinBUGS code for univariate random-effects meta-
analysis using a logistic regression model. 
Model { 
for( i in 1:Nstud ) { 
rinf[i] ~ dbin(pinf[i], ninf[i]) 
rbol[i] ~ dbin(pbol[i], nbol[i]) 
logit(pinf[i]) <- mu[i] 
logit(pbol[i]) <- mu[i] + delta[i] 
mu[i] ~ dnorm(0.0,1.0E-6) 
delta[i] ~ dnorm(d, prec) 
} 
OR <- exp(d) 




d.new ~ dnorm(d, prec) 
OR.new <-exp(d.new) 
prob1 <- step(1-OR) 




Appendix B2: History and trace plots to display convergence of 
parameters from a univariate random-effects logistic regression model. 
In these plots, d is the pooled treatment effect, d.new is the true treatment effect in a new 







Appendix B3: Publication in Trials arising from the univariate meta-
analysis of phase II trials that was explored in Chapter 4. 
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Meta-analysis of randomized phase II trials to 
inform subsequent phase Ill decisions 
Danielle L Burke'' ,Lucinda J Billingham1.2, Alan J Grlng 1 and Richard D Rile/ 
Abstract 
Background: t multiple Phase II randomi2ed trials exist then meta-ana¥is is favorable to increase statistiGll power 
and summarize the existing ·evidence about an interventon's effect in order to help inform Phase II decisions. We 
consider some statistical issues for meta-ana~is of Phase II trials for this purpose, as motivated by a real example 
involving nine Phase I trials of bolus thrombolytic therapy in acute myocardial infarction with binary outcomes. 
Methods: We propose that .1 Bayesian random effects logistic regression model is most suitable as it models the 
binomial distributon of the data, helps avoid continuity corrections, accounts for between-trial heterogeneity, and 
incorporates parameter uncertainty when making inferences. The model also allows predictions that inform Phase 
Ill decisions, and we show how to derive: (Q the probability that the intervention will be truly beneficial in a new 
trial, and iji) the probability that. in a new trial with a given sample size, the 95% credible interval for the odds ratio 
wil be entirely in favor of the interventoo. As Phase II trials are potentially optimistic due to bias in design and 
repating, we allo discuss ho.v skepli:.ll prior distributions can reduce this oplimilm to make more realisti:: prediaon~ 
Results: In the example, the model identifies heterogeneity in intervention effect missed by an !-squared of 016. 
Prediction intervals accounting for this heterogeneity are shown to supp011 subsequent Phase II trial~ The probabiity 
of success in Phase Ill trials increases as the sample size increases, up to 0.82 for intracr .1nial hemorrhage and 0.79 
for reinfarction outcomes. 
Conclusions: The choice of meta-analysis methods can inftuence the decision about whether a trial should 
proceed to Phase Ill and thus need to be clearly documented and investigated whenever a Phase II meta-analysis 
is performed. 
Keywords: Meta-analysis, Phase II and Ill, Prediction, Heterogeneity, Bayesian 
Background 
Phase III trials are rigorous .evaluations of an interven .. 
tion (such as a new drug or surgical technique). and are 
rypicaUy protocol-driven with large patient numbers, ap-
propriate statistical power, and a suitable trial design and 
analysis plan. However, the decision to initiate a Phase III 
trial for a particular intervention is no< straightforward 
and depends on many factors. sum as costs, risks (to the 
trial funders and patients), and practicalities such as pa-
tient recruitment [1). Perhaps the most pivoo:al factor is 
the intervention's likely effeaiveness. Clearly, the more 
likely an intervention is to succeed, the more tikely 
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FIAiloltof aJt:ha inbrmation i~awlatE at the end d the amde 
funders will risk investment in a Phase lii trial. To this 
end, before initiation of a Phase lii trial funders will con· 
sider the existing evidence about an intervention's poten .. 
tial benefit, for example from eartier Phase trials. 
The initial estimate of the intervention effect often 
arises from a Phase II randomized trial These typically 
contain small patient numbers or events, and give an 
imprecise intervention effect estimate with a wide 95% 
confidence interval However, sometimes multiple Phase 
II trials are conducted, for example in stightly different 
patient groups or by different (or competing) researchers 
(or companies) working on the same or similar interven .. 
tions. In this situation, a rneta .. analysis is useful to in .. 
crease statistical power [21 by combining the statistical 
estimates (such as odds ratios (ORs)) from the multiple 
trials and thereby summarizing the intervention effect 
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Appendix C1: WinBUGS code for bivariate random-effects normal meta-
analysis model (5.1). 
model { 
for (i in 1:N) { 
ws_covmat[i,1,1] <- sigmasq1[i]+tausq[1] 
ws_covmat[i,2,2] <- sigmasq2[i]+tausq[2] 
ws_covmat[i,1,2] <- ws_cov[i] + (rhob*sqrt(tausq[1]*tausq[2])) 
ws_covmat[i,2,1] <- ws_covmat[i,1,2] 
ws_cov[i]<-rhow[i]*sqrt(sigmasq1[i])*sqrt(sigmasq2[i]) 
rhow[i]~dunif(0,1) 
ws_prec[i,1:2,1:2] <- inverse(ws_covmat[i, , ]) 































Appendix C2: WinBUGS code for bivariate random-effects normal meta-
analysis model (5.2). 
model { 
for (i in 1:N) { 
covmat[i,1,1] <- sigmasq1[i]+psisq[1] 
covmat[i,2,2] <- sigmasq2[i]+psisq[2] 
covmat[i,1,2] <- rho*sqrt((psisq[1]+sigmasq1[i])*(psisq[2]+sigmasq2[i])) 
covmat[i,2,1] <- covmat[i,1,2] 
prec[i,1:2,1:2] <- inverse(covmat[i, , ]) 
































Appendix C3: Results for secondary bivariate meta-analysis of 
reinfarction and mortality. 
Table C1: 95% prediction intervals and posterior probability estimates for reinfarction 
and mortality for model (5.1). 
 Assumption 95% prediction interval OR Prob(new trial OR<1) 
Reinfarction 
ρB=ρWi=0 0.300 to 1.879 0.814 
ρWi=0 0.299 to 1.875 0.815 
ρWi=0.2 0.291 to 1.874 0.819 
ρWi=0.5 0.255 to 2.044 0.807 
ρWi=0.9 0.188 to 2.634 0.762 
ρWi~Unif(0,1) 0.268 to 2.026 0.795 
Mortality 
ρB=ρWi=0 0.290 to 3.889 0.554 
ρWi=0 0.286 to 3.566 0.579 
ρWi=0.2 0.285 to 3.587 0.583 
ρWi=0.5 0.250 to 4.139 0.567 
ρWi=0.9 0.181 to 5.926 0.530 
ρWi~Unif(0,1) 0.268 to 3.802 0.597 
 







correlation (95% CrI) 
Model (5.1) 
(ρB=ρWi=0) 0.521 0.451 - 
ρWi=0 0.557 0.476 0.046 (-0.941 to 0.952) 
ρWi=0.2 0.569 0.481 -0.025 (-0.949 to 0.941) 
ρWi=0.5 0.559 0.454 -0.195 (-0.962 to 0.893) 
ρWi=0.9 0.504 0.373 -0.453 (-0.976 to 0.653) 
ρWi~Unif(0,1) 0.589 0.476 -0.157 (-0.961 to 0.917) 








Appendix D1: SAS code to fit Bayesian bivariate random-effects meta-
analysis on 1000 simulated datasets using MCMC 
PROC MCMC data=sim.N10wc08bc08t105t205b10b22 nbi=200000 
nmc=300000 ntu=1000 thin=100 stats=all simreport=10 seed=100 
diagnostics=none monitor=(beta_A beta_B sdtau_A sdtau_B tau_A tau_B rhoB 
cov_AB prob_thetanewA prob_thetanewB prob_thetanewjoint); 
 
title 'Bayesian bivariate random-effects model 




ods select Postsummaries PostIntervals ; 
 




/* declarations and initializations */ 
array theta[2] theta_A theta_B; /* includes study-specific random effects 
*/ 
array beta[2] beta_A beta_B; 
array omega[2,2] tau_A cov_AB cov_AB2 tau_B; /* Between-study covariance 
matrix */ 
array Sigma[2,2] s_A wscov_AB wscov_AB2 s_B; /* Within-study covariance 
matrix */ 
array y[2] y_A y_B; 













parms rhoB ; 
parms beta: ; 
parms sdtau_A sdtau_B; 
 
prior beta: ~ normal(0,var=1000); 
prior sdtau: ~ normal(0,var=2,lower=0); /*truncated normal distribution*/ 
prior rhoB ~ uniform(0,1); 
 
random theta ~ mvn(beta, omega) subject=id; 
model y ~ mvn(theta, Sigma); 




prob_thetanewA = (thetanew_A>0); 
prob_thetanewB = (thetanew_B>2); 




/* create different data set to run analyses from */  
data bivsim.buse_ws08bs08tN02rhou01_pool; 
 set bivsim.b_ws08bs08tN02rhou01_pool; 
run; 
 
/* sort dataset by parameter */ 
proc sort data=bivsim.buse_ws08bs08tN02rhou01_pool; 
 by parameter; 
run; 
 
/* estimate mean pooled estimate, stderr pooled estimate, average variance 
*/ 
proc means data=bivsim.buse_ws08bs08tN02rhou01_pool n mean std min max 
median stderr; 
 ods listing; 
 var mean StdDev P50; 
 by parameter; 
run; 
 
/* compute bias-squared in each simulated dataset */ 
data bivsim.buse_ws08bs08tN02rhou01_pool; 
 set bivsim.buse_ws08bs08tN02rhou01_pool; 
 MSE_A=(mean-0)**2; /* bias squared for outcome 1 */ 
 MSE_B=(mean-2)**2; /* bias squared for outcome 2 */ 
run; 
 
/* estimate MSE of pooled estimate for outcome 1 */ 
proc means data=bivsim.buse_ws08bs08tN02rhou01_pool n mean std min max 
median stderr ; 
 ods listing; 
 var MSE_A; 
 by parameter; 
 where parameter='beta_A'; 
run; 
 
/* estimate MSE of pooled estimate for outcome 2 */ 
proc means data=bivsim.buse_ws08bs08tN02rhou01_pool n mean std min max 
median stderr ; 
 ods listing; 
 var MSE_B; 
 by parameter; 




 set bivsim.b_ws08bs08tN02rhou01_cred; 
run; 
 
proc sort data=bivsim.buse_ws08bs08tN02rhou01_cred; 





/* Performance of Credible intervals */ 
data bivsim.cri_ws08bs08tN02rhou01; 
 set bivsim.buse_ws08bs08tN02rhou01_cred; 
 if CredibleLower >0 then b1high=1; 
 else b1high=0; 
 if CredibleUpper <0 then b1low=1; 
 else b1low=0; 
 if CredibleLower >2 then b2high=1; 
 else b2high=0; 
 if CredibleUpper <2 then b2low=1; 
 else b2low=0; 
run; 
 
/* Performance of Credible intervals for beta1 */ 
proc freq data=bivsim.cri_ws08bs08tN02rhou01; 
 by parameter; 
 where parameter='beta_A'; 
run; 
 
/* Performance of Credible intervals for beta2 */ 
proc freq data=bivsim.cri_ws08bs08tN02rhou01; 
 by parameter; 





Appendix D2: Results of simulation study with various prior distributions for between-study variance in 
univariate meta-analysis model 
Table D1: Univariate simulation study results for various prior distributions for between-study variance, τj. 
Prior for τj 
Mean of 








































































































































Additional detail for the findings in the univariate simulation study 
The mean pooled treatment effect estimates across the 1000 simulated datasets are very 
similar for each prior distribution, and they are close to the true values of the pooled 
treatment effects. For example, for between-study variance prior distribution 1a, the mean β�1 
is -0.002 compared to β1=0 (s.e of the mean 0.195), and the mean β�2 is 2.000 compared to 
β2=2 (s.e of mean 0.218). However, as expected, the average between-study standard 
deviations, τ̂1 and τ̂2, vary depending on the prior distribution for these parameters. Since we 
know that the true values of τ1 and τ2 are 0.5, the most appropriate prior distribution for τj in 
this example is N(0,2)I(0,). For this prior, the posterior mean and median τ1 are 0.493 and 
0.495, respectively, and the posterior mean and median τ2 are 0.525 and 0.523, respectively. 
Therefore, this prior distribution is chosen for the bivariate meta-analysis simulation study. 
For this prior distribution the number of 95% CrIs that contain the true treatment effects is 
good with 95.4% for β1 and 96.5% for β2. The number of credible intervals that contain the 
true parameter value is slightly higher for β2 due to a slightly larger estimate of τ2. The 
average probability that θ�1 is greater than zero is 0.497, which is close to the true value of 
0.5. The same finding is true for θ2. 
The results from this simulation study reveal that some of the prior distributions for τj estimate 
the variances particularly poorly. For example, the gamma(0.1,0.1) prior distribution for 1/τj2 
hugely overestimates the true between-study variances. The posterior mean and median τ1 
are 1.682 and 1.674, respectively, compared to τ1=0.5. Similarly, the posterior mean and 
median τ2 are 1.835 and 1.819, respectively. This highlights the potential dangers of selecting 
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